[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_3507":3508,"_3509":297},"routes/conference",{"_9":10},"data",{"_11":12,"_13":14,"_15":-5,"_16":-5,"_17":-5,"_18":19,"_20":-5,"_21":22,"_23":-5,"_24":25,"_26":27,"_28":29,"_30":-5,"_31":32,"_33":34,"_35":36,"_37":38,"_39":38,"_40":-5,"_41":42},"conference",{"_3496":3497,"_3498":276,"_3499":3472,"_3500":3476,"_3501":3502,"_3503":3504,"_3505":3506},"tracks",[3477,3478,3479,3480],"final","daySummary","track","days",[3472,3473,3474,3475,3476],"q","view","topics","day","topic","tag:#healthcare","topicProbe",{"_240":3467,"_242":25,"_244":288,"_246":3468,"_248":3469,"_250":3470,"_251":3470,"_252":3469,"_254":3469,"_255":3471,"_257":-5,"_258":-5,"_259":-5,"_261":38},"directions",[],"hot","probes",[43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239],"posts",[],"items",[],"page",1,"pageCount","nextCursor","generatedAt","2026-10-25T08:23:44.937Z",{"_240":3448,"_242":3449,"_244":245,"_246":3450,"_248":3451,"_250":3452,"_251":3453,"_252":3454,"_254":3455,"_255":3456,"_257":375,"_258":3457,"_259":3458,"_261":403},{"_240":3426,"_242":3427,"_244":245,"_246":3428,"_248":3429,"_250":3430,"_251":3431,"_252":3432,"_254":3433,"_255":3434,"_257":375,"_258":3435,"_259":3436,"_261":403},{"_240":3405,"_242":3406,"_244":245,"_246":3407,"_248":3408,"_250":3385,"_251":3409,"_252":3410,"_254":3411,"_255":3412,"_257":375,"_258":3413,"_259":3414,"_261":403},{"_240":3380,"_242":3381,"_244":615,"_246":3382,"_248":3383,"_250":3384,"_251":3385,"_252":3386,"_254":3387,"_255":3388,"_257":-5,"_258":-5,"_259":3389,"_261":403},{"_240":3355,"_242":3356,"_244":589,"_246":3357,"_248":3358,"_250":3339,"_251":3359,"_252":3360,"_254":3361,"_255":3362,"_257":-5,"_258":-5,"_259":3363,"_261":403},{"_240":3335,"_242":3336,"_244":245,"_246":3337,"_248":3338,"_250":3339,"_251":3340,"_252":3341,"_254":3342,"_255":3343,"_257":375,"_258":3344,"_259":3345,"_261":403},{"_240":3318,"_242":3319,"_244":245,"_246":3320,"_248":3321,"_250":3322,"_251":3323,"_252":2255,"_254":3324,"_255":3325,"_257":375,"_258":-5,"_259":3326,"_261":403},{"_240":3295,"_242":3296,"_244":615,"_246":3297,"_248":3298,"_250":3283,"_251":3299,"_252":3300,"_254":3301,"_255":3302,"_257":375,"_258":-5,"_259":3303,"_261":403},{"_240":3279,"_242":3280,"_244":615,"_246":3281,"_248":3282,"_250":3283,"_251":3284,"_252":2117,"_254":3285,"_255":3286,"_257":375,"_258":-5,"_259":3287,"_261":403},{"_240":3263,"_242":3264,"_244":245,"_246":3265,"_248":3266,"_250":2517,"_251":2965,"_252":3267,"_254":3268,"_255":3269,"_257":-5,"_258":-5,"_259":3270,"_261":403},{"_240":3245,"_242":3246,"_244":245,"_246":3247,"_248":3248,"_250":2517,"_251":2518,"_252":3249,"_254":3250,"_255":3251,"_257":-5,"_258":-5,"_259":3252,"_261":403},{"_240":3220,"_242":3221,"_244":615,"_246":3222,"_248":3223,"_250":3176,"_251":3224,"_252":1436,"_254":3225,"_255":3226,"_257":375,"_258":-5,"_259":3227,"_261":403},{"_240":3206,"_242":3207,"_244":245,"_246":3208,"_248":3209,"_250":3176,"_251":2517,"_252":3210,"_254":3211,"_255":3212,"_257":-5,"_258":-5,"_259":3213,"_261":403},{"_240":3188,"_242":3189,"_244":245,"_246":3190,"_248":3191,"_250":3176,"_251":2517,"_252":3192,"_254":3193,"_255":3194,"_257":375,"_258":3195,"_259":3196,"_261":403},{"_240":3172,"_242":3173,"_244":245,"_246":3174,"_248":3175,"_250":2451,"_251":3176,"_252":3177,"_254":3178,"_255":3179,"_257":-5,"_258":3180,"_259":3181,"_261":403},{"_240":3153,"_242":3154,"_244":245,"_246":3155,"_248":3156,"_250":3141,"_251":2485,"_252":3157,"_254":3158,"_255":3159,"_257":-5,"_258":-5,"_259":3160,"_261":403},{"_240":3137,"_242":3138,"_244":245,"_246":3139,"_248":3140,"_250":3141,"_251":2451,"_252":3142,"_254":3143,"_255":3144,"_257":375,"_258":-5,"_259":3145,"_261":403},{"_240":3116,"_242":3117,"_244":615,"_246":3118,"_248":3119,"_250":2413,"_251":2451,"_252":3120,"_254":3121,"_255":3122,"_257":375,"_258":-5,"_259":3123,"_261":403},{"_240":3100,"_242":3101,"_244":245,"_246":3102,"_248":3103,"_250":2437,"_251":3104,"_252":3105,"_254":3106,"_255":3107,"_257":375,"_258":-5,"_259":3108,"_261":403},{"_240":3085,"_242":3086,"_244":245,"_246":3087,"_248":3088,"_250":2437,"_251":2437,"_252":3089,"_254":3090,"_255":3091,"_257":375,"_258":-5,"_259":3092,"_261":403},{"_240":3073,"_242":3074,"_244":288,"_246":3075,"_248":3076,"_250":2356,"_251":2451,"_252":3077,"_254":3078,"_255":3079,"_257":-5,"_258":-5,"_259":3080,"_261":403},{"_240":3052,"_242":3053,"_244":589,"_246":3054,"_248":3055,"_250":2356,"_251":2437,"_252":3056,"_254":3057,"_255":3058,"_257":-5,"_258":-5,"_259":3059,"_261":403},{"_240":3030,"_242":3031,"_244":589,"_246":3032,"_248":3033,"_250":2980,"_251":2413,"_252":3034,"_254":3035,"_255":3036,"_257":-5,"_258":-5,"_259":3037,"_261":403},{"_240":3010,"_242":3011,"_244":589,"_246":3012,"_248":3013,"_250":2980,"_251":2437,"_252":3014,"_254":3015,"_255":3016,"_257":-5,"_258":-5,"_259":3017,"_261":403},{"_240":2996,"_242":2997,"_244":245,"_246":2998,"_248":2999,"_250":2980,"_251":2378,"_252":3000,"_254":280,"_255":3001,"_257":375,"_258":-5,"_259":3002,"_261":403},{"_240":2976,"_242":2977,"_244":245,"_246":2978,"_248":2979,"_250":2980,"_251":2980,"_252":2981,"_254":2982,"_255":2983,"_257":-5,"_258":2984,"_259":2985,"_261":403},{"_240":2961,"_242":2962,"_244":288,"_246":2963,"_248":2964,"_250":2165,"_251":2965,"_252":2966,"_254":2967,"_255":2968,"_257":-5,"_258":-5,"_259":2969,"_261":403},{"_240":2942,"_242":2943,"_244":245,"_246":2944,"_248":2945,"_250":2165,"_251":2356,"_252":2946,"_254":2947,"_255":2948,"_257":-5,"_258":-5,"_259":2949,"_261":403},{"_240":2919,"_242":2920,"_244":245,"_246":2921,"_248":2922,"_250":2304,"_251":2378,"_252":2923,"_254":2924,"_255":2925,"_257":-5,"_258":2926,"_259":2927,"_261":403},{"_240":2905,"_242":2906,"_244":615,"_246":2907,"_248":2908,"_250":2254,"_251":2165,"_252":1608,"_254":2909,"_255":2910,"_257":-5,"_258":-5,"_259":2911,"_261":403},{"_240":2890,"_242":2891,"_244":245,"_246":2892,"_248":2893,"_250":2012,"_251":2012,"_252":2894,"_254":2895,"_255":2896,"_257":-5,"_258":-5,"_259":2897,"_261":403},{"_240":2875,"_242":2876,"_244":615,"_246":2877,"_248":2878,"_250":2012,"_251":2012,"_252":2879,"_254":2880,"_255":2881,"_257":375,"_258":-5,"_259":2882,"_261":403},{"_240":2862,"_242":2863,"_244":245,"_246":2864,"_248":2865,"_250":472,"_251":2012,"_252":2866,"_254":2867,"_255":2868,"_257":-5,"_258":-5,"_259":2869,"_261":403},{"_240":2847,"_242":2848,"_244":245,"_246":2849,"_248":2850,"_250":472,"_251":2012,"_252":2851,"_254":2852,"_255":2853,"_257":-5,"_258":-5,"_259":2854,"_261":403},{"_240":2834,"_242":2835,"_244":245,"_246":2836,"_248":2837,"_250":1760,"_251":1760,"_252":2838,"_254":2839,"_255":2840,"_257":-5,"_258":-5,"_259":2841,"_261":403},{"_240":2820,"_242":2821,"_244":615,"_246":2822,"_248":2823,"_250":1760,"_251":1760,"_252":2824,"_254":2825,"_255":2826,"_257":-5,"_258":-5,"_259":2827,"_261":403},{"_240":2803,"_242":2804,"_244":245,"_246":2805,"_248":2806,"_250":1760,"_251":1760,"_252":2807,"_254":2808,"_255":2809,"_257":-5,"_258":-5,"_259":2810,"_261":403},{"_240":2790,"_242":2791,"_244":615,"_246":2792,"_248":2793,"_250":444,"_251":1760,"_252":2794,"_254":2795,"_255":2796,"_257":-5,"_258":-5,"_259":2797,"_261":403},{"_240":2776,"_242":2777,"_244":245,"_246":2778,"_248":2779,"_250":444,"_251":444,"_252":2780,"_254":2781,"_255":2782,"_257":-5,"_258":-5,"_259":2783,"_261":403},{"_240":2760,"_242":2761,"_244":245,"_246":2762,"_248":2763,"_250":444,"_251":444,"_252":2764,"_254":2765,"_255":2766,"_257":-5,"_258":2767,"_259":2768,"_261":403},{"_240":2734,"_242":2735,"_244":245,"_246":2736,"_248":2737,"_250":444,"_251":444,"_252":2738,"_254":2739,"_255":2740,"_257":-5,"_258":2741,"_259":2742,"_261":403},{"_240":2720,"_242":2721,"_244":245,"_246":2722,"_248":2723,"_250":403,"_251":403,"_252":2724,"_254":2725,"_255":2726,"_257":-5,"_258":-5,"_259":2727,"_261":403},{"_240":2706,"_242":2707,"_244":245,"_246":2708,"_248":2709,"_250":403,"_251":403,"_252":2710,"_254":2711,"_255":2712,"_257":-5,"_258":-5,"_259":2713,"_261":403},{"_240":2693,"_242":2694,"_244":245,"_246":2695,"_248":2696,"_250":403,"_251":403,"_252":2697,"_254":2698,"_255":2699,"_257":-5,"_258":-5,"_259":2700,"_261":403},{"_240":2680,"_242":2681,"_244":245,"_246":2682,"_248":2683,"_250":403,"_251":403,"_252":2684,"_254":2685,"_255":2686,"_257":-5,"_258":-5,"_259":2687,"_261":403},{"_240":2665,"_242":2666,"_244":245,"_246":2667,"_248":2668,"_250":403,"_251":403,"_252":2669,"_254":2670,"_255":2671,"_257":-5,"_258":-5,"_259":2672,"_261":403},{"_240":2653,"_242":2654,"_244":288,"_246":2655,"_248":2656,"_250":291,"_251":403,"_252":2657,"_254":2658,"_255":2659,"_257":-5,"_258":-5,"_259":2660,"_261":403},{"_240":2640,"_242":2641,"_244":245,"_246":2642,"_248":2643,"_250":291,"_251":403,"_252":2644,"_254":2645,"_255":2646,"_257":-5,"_258":-5,"_259":2647,"_261":403},{"_240":2617,"_242":2618,"_244":245,"_246":2619,"_248":2620,"_250":291,"_251":291,"_252":2621,"_254":2622,"_255":2623,"_257":375,"_258":-5,"_259":2624,"_261":403},{"_240":2598,"_242":2599,"_244":288,"_246":2600,"_248":2601,"_250":291,"_251":291,"_252":2602,"_254":2603,"_255":2604,"_257":375,"_258":-5,"_259":2605,"_261":403},{"_240":2584,"_242":2585,"_244":288,"_246":2586,"_248":2587,"_250":38,"_251":472,"_252":2588,"_254":2589,"_255":2590,"_257":-5,"_258":-5,"_259":2591,"_261":403},{"_240":2572,"_242":2573,"_244":389,"_246":2574,"_248":2575,"_250":38,"_251":291,"_252":865,"_254":2576,"_255":2577,"_257":-5,"_258":-5,"_259":2578,"_261":403},{"_240":2560,"_242":2561,"_244":288,"_246":2562,"_248":2563,"_250":38,"_251":291,"_252":2564,"_254":2565,"_255":2566,"_257":-5,"_258":-5,"_259":2567,"_261":403},{"_240":2539,"_242":2540,"_244":615,"_246":2541,"_248":2542,"_250":2517,"_251":2469,"_252":2543,"_254":2544,"_255":2545,"_257":375,"_258":-5,"_259":2546,"_261":291},{"_240":2513,"_242":2514,"_244":615,"_246":2515,"_248":2516,"_250":2517,"_251":2518,"_252":2519,"_254":2520,"_255":2521,"_257":375,"_258":-5,"_259":2522,"_261":291},{"_240":2496,"_242":2497,"_244":615,"_246":2498,"_248":2499,"_250":2500,"_251":2500,"_252":2501,"_254":2502,"_255":2503,"_257":-5,"_258":-5,"_259":2504,"_261":291},{"_240":2481,"_242":2482,"_244":288,"_246":2483,"_248":2484,"_250":2485,"_251":2486,"_252":2487,"_254":2488,"_255":2489,"_257":-5,"_258":-5,"_259":2490,"_261":291},{"_240":2465,"_242":2466,"_244":245,"_246":2467,"_248":2468,"_250":2451,"_251":2469,"_252":2470,"_254":2471,"_255":2472,"_257":375,"_258":-5,"_259":2473,"_261":291},{"_240":2447,"_242":2448,"_244":615,"_246":2449,"_248":2450,"_250":2451,"_251":2451,"_252":2452,"_254":2453,"_255":2454,"_257":375,"_258":-5,"_259":2455,"_261":291},{"_240":2433,"_242":2434,"_244":245,"_246":2435,"_248":2436,"_250":2437,"_251":2437,"_252":2438,"_254":2439,"_255":2440,"_257":-5,"_258":-5,"_259":2441,"_261":291},{"_240":2409,"_242":2410,"_244":615,"_246":2411,"_248":2412,"_250":2378,"_251":2413,"_252":2414,"_254":2415,"_255":2416,"_257":-5,"_258":-5,"_259":2417,"_261":291},{"_240":2391,"_242":2392,"_244":615,"_246":2393,"_248":2394,"_250":2378,"_251":2356,"_252":2395,"_254":2396,"_255":2397,"_257":375,"_258":-5,"_259":2398,"_261":291},{"_240":2374,"_242":2375,"_244":615,"_246":2376,"_248":2377,"_250":2378,"_251":2378,"_252":2379,"_254":2380,"_255":2381,"_257":375,"_258":-5,"_259":2382,"_261":291},{"_240":2352,"_242":2353,"_244":589,"_246":2354,"_248":2355,"_250":2165,"_251":2356,"_252":2357,"_254":2358,"_255":2359,"_257":-5,"_258":-5,"_259":2360,"_261":291},{"_240":2330,"_242":2331,"_244":615,"_246":2332,"_248":2333,"_250":2165,"_251":2165,"_252":1986,"_254":2334,"_255":2335,"_257":375,"_258":-5,"_259":2336,"_261":291},{"_240":2316,"_242":2317,"_244":288,"_246":2318,"_248":2319,"_250":2304,"_251":2304,"_252":2320,"_254":2321,"_255":2322,"_257":-5,"_258":-5,"_259":2323,"_261":291},{"_240":2300,"_242":2301,"_244":615,"_246":2302,"_248":2303,"_250":2254,"_251":2304,"_252":2305,"_254":2306,"_255":2307,"_257":375,"_258":-5,"_259":2308,"_261":291},{"_240":2284,"_242":2285,"_244":615,"_246":2286,"_248":2287,"_250":2254,"_251":2254,"_252":2288,"_254":2289,"_255":2290,"_257":-5,"_258":-5,"_259":2291,"_261":291},{"_240":2267,"_242":2268,"_244":245,"_246":2269,"_248":2270,"_250":2254,"_251":2254,"_252":2271,"_254":2272,"_255":2273,"_257":375,"_258":-5,"_259":2274,"_261":291},{"_240":2250,"_242":2251,"_244":615,"_246":2252,"_248":2253,"_250":2012,"_251":2254,"_252":2255,"_254":2256,"_255":2257,"_257":375,"_258":-5,"_259":2258,"_261":291},{"_240":2237,"_242":2238,"_244":615,"_246":2239,"_248":2240,"_250":2012,"_251":2012,"_252":2241,"_254":2242,"_255":2243,"_257":-5,"_258":-5,"_259":2244,"_261":291},{"_240":2199,"_242":2200,"_244":288,"_246":2201,"_248":2202,"_250":2012,"_251":2012,"_252":2203,"_254":2204,"_255":2205,"_257":375,"_258":-5,"_259":2206,"_261":291},{"_240":2187,"_242":2188,"_244":615,"_246":2189,"_248":2190,"_250":2012,"_251":2012,"_252":1608,"_254":2191,"_255":2192,"_257":375,"_258":-5,"_259":2193,"_261":291},{"_240":2174,"_242":2175,"_244":615,"_246":2176,"_248":2177,"_250":2012,"_251":2012,"_252":2178,"_254":2179,"_255":2180,"_257":-5,"_258":-5,"_259":2181,"_261":291},{"_240":2161,"_242":2162,"_244":288,"_246":2163,"_248":2164,"_250":472,"_251":2165,"_252":2166,"_254":2167,"_255":2168,"_257":-5,"_258":-5,"_259":2169,"_261":291},{"_240":2147,"_242":2148,"_244":245,"_246":2149,"_248":2150,"_250":472,"_251":2012,"_252":2151,"_254":2152,"_255":2153,"_257":-5,"_258":-5,"_259":2154,"_261":291},{"_240":2130,"_242":2131,"_244":615,"_246":2132,"_248":2133,"_250":472,"_251":472,"_252":2134,"_254":2135,"_255":2136,"_257":-5,"_258":-5,"_259":2137,"_261":291},{"_240":2113,"_242":2114,"_244":615,"_246":2115,"_248":2116,"_250":472,"_251":472,"_252":2117,"_254":2118,"_255":2119,"_257":-5,"_258":-5,"_259":2120,"_261":291},{"_240":2101,"_242":2102,"_244":245,"_246":2103,"_248":2104,"_250":472,"_251":472,"_252":2105,"_254":2106,"_255":2107,"_257":-5,"_258":-5,"_259":2108,"_261":291},{"_240":2079,"_242":2080,"_244":288,"_246":2081,"_248":2082,"_250":472,"_251":472,"_252":2083,"_254":2084,"_255":2085,"_257":-5,"_258":-5,"_259":2086,"_261":291},{"_240":2066,"_242":2067,"_244":615,"_246":2068,"_248":2069,"_250":472,"_251":472,"_252":2070,"_254":2071,"_255":2072,"_257":-5,"_258":-5,"_259":2073,"_261":291},{"_240":2039,"_242":2040,"_244":288,"_246":2041,"_248":2042,"_250":472,"_251":472,"_252":2043,"_254":2044,"_255":2045,"_257":-5,"_258":-5,"_259":2046,"_261":291},{"_240":2008,"_242":2009,"_244":615,"_246":2010,"_248":2011,"_250":1760,"_251":2012,"_252":2013,"_254":2014,"_255":2015,"_257":-5,"_258":-5,"_259":2016,"_261":291},{"_240":1996,"_242":1997,"_244":589,"_246":1998,"_248":1999,"_250":1760,"_251":1760,"_252":2000,"_254":2001,"_255":2002,"_257":-5,"_258":-5,"_259":2003,"_261":291},{"_240":1982,"_242":1983,"_244":245,"_246":1984,"_248":1985,"_250":1760,"_251":1760,"_252":1986,"_254":1987,"_255":1988,"_257":-5,"_258":-5,"_259":1989,"_261":291},{"_240":1969,"_242":1970,"_244":589,"_246":1971,"_248":1972,"_250":1760,"_251":1760,"_252":1973,"_254":1974,"_255":1975,"_257":-5,"_258":-5,"_259":1976,"_261":291},{"_240":1952,"_242":1953,"_244":589,"_246":1954,"_248":1955,"_250":1760,"_251":1760,"_252":1956,"_254":1957,"_255":1958,"_257":-5,"_258":-5,"_259":1959,"_261":291},{"_240":1937,"_242":1938,"_244":589,"_246":1939,"_248":1940,"_250":1760,"_251":1760,"_252":1941,"_254":1942,"_255":1943,"_257":-5,"_258":-5,"_259":1944,"_261":291},{"_240":1923,"_242":1924,"_244":288,"_246":1925,"_248":1926,"_250":444,"_251":1760,"_252":1927,"_254":1928,"_255":1929,"_257":-5,"_258":-5,"_259":1930,"_261":291},{"_240":1911,"_242":1912,"_244":288,"_246":1913,"_248":1914,"_250":444,"_251":1760,"_252":1915,"_254":1916,"_255":1917,"_257":-5,"_258":-5,"_259":1918,"_261":291},{"_240":1891,"_242":1892,"_244":615,"_246":1893,"_248":1894,"_250":444,"_251":444,"_252":1895,"_254":1896,"_255":1897,"_257":-5,"_258":-5,"_259":1898,"_261":291},{"_240":1878,"_242":1879,"_244":589,"_246":1880,"_248":1881,"_250":444,"_251":444,"_252":1882,"_254":1883,"_255":1884,"_257":-5,"_258":-5,"_259":1885,"_261":291},{"_240":1865,"_242":1866,"_244":245,"_246":1867,"_248":1868,"_250":444,"_251":444,"_252":1869,"_254":1870,"_255":1871,"_257":-5,"_258":-5,"_259":1872,"_261":291},{"_240":1841,"_242":1842,"_244":615,"_246":1843,"_248":1844,"_250":444,"_251":444,"_252":1845,"_254":1846,"_255":1847,"_257":-5,"_258":-5,"_259":1848,"_261":291},{"_240":1825,"_242":1826,"_244":615,"_246":1827,"_248":1828,"_250":444,"_251":444,"_252":1829,"_254":1830,"_255":1831,"_257":-5,"_258":-5,"_259":1832,"_261":291},{"_240":1812,"_242":1813,"_244":589,"_246":1814,"_248":1815,"_250":444,"_251":444,"_252":1816,"_254":1817,"_255":1818,"_257":-5,"_258":-5,"_259":1819,"_261":291},{"_240":1796,"_242":1797,"_244":615,"_246":1798,"_248":1799,"_250":444,"_251":444,"_252":1800,"_254":1801,"_255":1802,"_257":-5,"_258":-5,"_259":1803,"_261":291},{"_240":1784,"_242":1785,"_244":615,"_246":1786,"_248":1787,"_250":444,"_251":444,"_252":1788,"_254":1789,"_255":1790,"_257":-5,"_258":-5,"_259":1791,"_261":291},{"_240":1771,"_242":1772,"_244":288,"_246":1773,"_248":1774,"_250":403,"_251":472,"_252":1775,"_254":1776,"_255":1777,"_257":-5,"_258":-5,"_259":1778,"_261":291},{"_240":1756,"_242":1757,"_244":288,"_246":1758,"_248":1759,"_250":403,"_251":1760,"_252":1761,"_254":1762,"_255":1763,"_257":-5,"_258":-5,"_259":1764,"_261":291},{"_240":1738,"_242":1739,"_244":288,"_246":1740,"_248":1741,"_250":403,"_251":444,"_252":1742,"_254":1743,"_255":1744,"_257":-5,"_258":-5,"_259":1745,"_261":291},{"_240":1717,"_242":1718,"_244":615,"_246":1719,"_248":1720,"_250":403,"_251":444,"_252":1721,"_254":1722,"_255":1723,"_257":-5,"_258":-5,"_259":1724,"_261":291},{"_240":1704,"_242":1705,"_244":288,"_246":1706,"_248":1707,"_250":403,"_251":403,"_252":1708,"_254":1709,"_255":1710,"_257":-5,"_258":-5,"_259":1711,"_261":291},{"_240":1692,"_242":1693,"_244":245,"_246":1694,"_248":1695,"_250":403,"_251":403,"_252":1696,"_254":1697,"_255":1698,"_257":-5,"_258":-5,"_259":1699,"_261":291},{"_240":1679,"_242":1680,"_244":245,"_246":1681,"_248":1682,"_250":403,"_251":403,"_252":1683,"_254":1684,"_255":1685,"_257":-5,"_258":-5,"_259":1686,"_261":291},{"_240":1666,"_242":1667,"_244":615,"_246":1668,"_248":1669,"_250":403,"_251":403,"_252":1670,"_254":1671,"_255":1672,"_257":-5,"_258":-5,"_259":1673,"_261":291},{"_240":1653,"_242":1654,"_244":615,"_246":1655,"_248":1656,"_250":403,"_251":403,"_252":1657,"_254":1658,"_255":1659,"_257":-5,"_258":-5,"_259":1660,"_261":291},{"_240":1641,"_242":1642,"_244":615,"_246":1643,"_248":1644,"_250":403,"_251":403,"_252":1645,"_254":1646,"_255":1647,"_257":-5,"_258":-5,"_259":1648,"_261":291},{"_240":1604,"_242":1605,"_244":615,"_246":1606,"_248":1607,"_250":403,"_251":403,"_252":1608,"_254":1609,"_255":1610,"_257":375,"_258":-5,"_259":1611,"_261":291},{"_240":1588,"_242":1589,"_244":615,"_246":1590,"_248":1591,"_250":403,"_251":403,"_252":1592,"_254":1593,"_255":1594,"_257":-5,"_258":-5,"_259":1595,"_261":291},{"_240":1573,"_242":1574,"_244":615,"_246":1575,"_248":1576,"_250":403,"_251":403,"_252":1577,"_254":1578,"_255":1579,"_257":375,"_258":-5,"_259":1580,"_261":291},{"_240":1557,"_242":1558,"_244":615,"_246":1559,"_248":1560,"_250":403,"_251":403,"_252":1561,"_254":1562,"_255":1563,"_257":-5,"_258":-5,"_259":1564,"_261":291},{"_240":1544,"_242":1545,"_244":288,"_246":1546,"_248":1547,"_250":403,"_251":403,"_252":1548,"_254":1549,"_255":1550,"_257":-5,"_258":-5,"_259":1551,"_261":291},{"_240":1531,"_242":1532,"_244":288,"_246":1533,"_248":1534,"_250":403,"_251":403,"_252":1535,"_254":1536,"_255":1537,"_257":-5,"_258":-5,"_259":1538,"_261":291},{"_240":1519,"_242":1520,"_244":288,"_246":1521,"_248":1522,"_250":403,"_251":403,"_252":1523,"_254":1524,"_255":1525,"_257":-5,"_258":-5,"_259":1526,"_261":291},{"_240":1500,"_242":1501,"_244":288,"_246":1502,"_248":1503,"_250":291,"_251":444,"_252":1504,"_254":1505,"_255":1506,"_257":-5,"_258":-5,"_259":1507,"_261":291},{"_240":1487,"_242":1488,"_244":288,"_246":1489,"_248":1490,"_250":291,"_251":403,"_252":1491,"_254":1492,"_255":1493,"_257":-5,"_258":-5,"_259":1494,"_261":291},{"_240":1472,"_242":1473,"_244":615,"_246":1474,"_248":1475,"_250":291,"_251":403,"_252":1476,"_254":1477,"_255":1478,"_257":-5,"_258":-5,"_259":1479,"_261":291},{"_240":1459,"_242":1460,"_244":288,"_246":1461,"_248":1462,"_250":291,"_251":403,"_252":1463,"_254":1464,"_255":1465,"_257":-5,"_258":-5,"_259":1466,"_261":291},{"_240":1445,"_242":1446,"_244":245,"_246":1447,"_248":1448,"_250":291,"_251":403,"_252":1449,"_254":405,"_255":1450,"_257":-5,"_258":-5,"_259":1451,"_261":291},{"_240":1432,"_242":1433,"_244":389,"_246":1434,"_248":1435,"_250":291,"_251":403,"_252":1436,"_254":1437,"_255":1438,"_257":-5,"_258":-5,"_259":1439,"_261":291},{"_240":1419,"_242":1420,"_244":288,"_246":1421,"_248":1422,"_250":291,"_251":403,"_252":1423,"_254":1424,"_255":1425,"_257":-5,"_258":-5,"_259":1426,"_261":291},{"_240":1406,"_242":1407,"_244":245,"_246":1408,"_248":1409,"_250":291,"_251":403,"_252":1410,"_254":1411,"_255":1412,"_257":-5,"_258":-5,"_259":1413,"_261":291},{"_240":1393,"_242":1394,"_244":288,"_246":1395,"_248":1396,"_250":291,"_251":291,"_252":1397,"_254":1398,"_255":1399,"_257":-5,"_258":-5,"_259":1400,"_261":291},{"_240":1381,"_242":1382,"_244":245,"_246":1261,"_248":1383,"_250":291,"_251":291,"_252":1384,"_254":1385,"_255":1386,"_257":-5,"_258":-5,"_259":1387,"_261":291},{"_240":1368,"_242":1369,"_244":245,"_246":1370,"_248":1371,"_250":291,"_251":291,"_252":1372,"_254":1373,"_255":1374,"_257":-5,"_258":-5,"_259":1375,"_261":291},{"_240":1354,"_242":1355,"_244":245,"_246":1356,"_248":1357,"_250":291,"_251":291,"_252":1358,"_254":1359,"_255":1360,"_257":-5,"_258":-5,"_259":1361,"_261":291},{"_240":1339,"_242":1340,"_244":615,"_246":1341,"_248":1342,"_250":291,"_251":291,"_252":1343,"_254":1344,"_255":1345,"_257":-5,"_258":-5,"_259":1346,"_261":291},{"_240":1323,"_242":1324,"_244":615,"_246":1325,"_248":1326,"_250":291,"_251":291,"_252":1327,"_254":1328,"_255":1329,"_257":-5,"_258":-5,"_259":1330,"_261":291},{"_240":1304,"_242":1305,"_244":615,"_246":1306,"_248":1307,"_250":291,"_251":291,"_252":1308,"_254":1309,"_255":1310,"_257":-5,"_258":-5,"_259":1311,"_261":291},{"_240":1292,"_242":1293,"_244":615,"_246":1294,"_248":1295,"_250":291,"_251":291,"_252":1296,"_254":1297,"_255":1298,"_257":-5,"_258":-5,"_259":1299,"_261":291},{"_240":1279,"_242":1280,"_244":245,"_246":1281,"_248":1282,"_250":291,"_251":291,"_252":1283,"_254":1284,"_255":1285,"_257":-5,"_258":-5,"_259":1286,"_261":291},{"_240":1234,"_242":1235,"_244":288,"_246":1236,"_248":1237,"_250":291,"_251":291,"_252":1238,"_254":1239,"_255":1240,"_257":375,"_258":-5,"_259":1241,"_261":291},{"_240":1220,"_242":1221,"_244":288,"_246":1222,"_248":1223,"_250":291,"_251":291,"_252":1224,"_254":1225,"_255":1226,"_257":-5,"_258":-5,"_259":1227,"_261":291},{"_240":1195,"_242":1196,"_244":615,"_246":1197,"_248":1198,"_250":291,"_251":291,"_252":1199,"_254":1200,"_255":1201,"_257":-5,"_258":-5,"_259":1202,"_261":291},{"_240":1182,"_242":1183,"_244":615,"_246":1184,"_248":1185,"_250":291,"_251":291,"_252":1186,"_254":1187,"_255":1188,"_257":-5,"_258":-5,"_259":1189,"_261":291},{"_240":1129,"_242":1130,"_244":288,"_246":1131,"_248":1132,"_250":291,"_251":291,"_252":1133,"_254":1134,"_255":1135,"_257":-5,"_258":-5,"_259":1136,"_261":291},{"_240":1115,"_242":1116,"_244":288,"_246":1117,"_248":1118,"_250":291,"_251":291,"_252":1119,"_254":1120,"_255":1121,"_257":-5,"_258":-5,"_259":1122,"_261":291},{"_240":1103,"_242":1104,"_244":288,"_246":1105,"_248":1106,"_250":291,"_251":291,"_252":1107,"_254":1108,"_255":1109,"_257":-5,"_258":-5,"_259":1110,"_261":291},{"_240":1090,"_242":1091,"_244":288,"_246":1092,"_248":1093,"_250":291,"_251":291,"_252":1094,"_254":1095,"_255":1096,"_257":-5,"_258":-5,"_259":1097,"_261":291},{"_240":1078,"_242":1079,"_244":288,"_246":1080,"_248":1081,"_250":291,"_251":291,"_252":1082,"_254":1083,"_255":1084,"_257":-5,"_258":-5,"_259":1085,"_261":291},{"_240":1057,"_242":1058,"_244":288,"_246":1059,"_248":1060,"_250":291,"_251":291,"_252":1061,"_254":1062,"_255":1063,"_257":375,"_258":-5,"_259":1064,"_261":291},{"_240":1043,"_242":1044,"_244":245,"_246":1045,"_248":1046,"_250":291,"_251":291,"_252":1047,"_254":1048,"_255":1049,"_257":-5,"_258":-5,"_259":1050,"_261":291},{"_240":1030,"_242":1031,"_244":288,"_246":1032,"_248":1033,"_250":291,"_251":291,"_252":1034,"_254":1035,"_255":1036,"_257":-5,"_258":-5,"_259":1037,"_261":291},{"_240":1016,"_242":1017,"_244":245,"_246":1018,"_248":1019,"_250":291,"_251":291,"_252":1020,"_254":1021,"_255":1022,"_257":-5,"_258":-5,"_259":1023,"_261":291},{"_240":1002,"_242":1003,"_244":288,"_246":1004,"_248":1005,"_250":291,"_251":291,"_252":1006,"_254":1007,"_255":1008,"_257":-5,"_258":-5,"_259":1009,"_261":291},{"_240":988,"_242":989,"_244":245,"_246":990,"_248":991,"_250":291,"_251":291,"_252":992,"_254":993,"_255":994,"_257":-5,"_258":-5,"_259":995,"_261":291},{"_240":975,"_242":976,"_244":288,"_246":977,"_248":978,"_250":291,"_251":291,"_252":979,"_254":980,"_255":981,"_257":-5,"_258":-5,"_259":982,"_261":291},{"_240":957,"_242":958,"_244":245,"_246":959,"_248":960,"_250":291,"_251":291,"_252":961,"_254":962,"_255":963,"_257":-5,"_258":-5,"_259":964,"_261":291},{"_240":944,"_242":945,"_244":245,"_246":946,"_248":947,"_250":38,"_251":291,"_252":948,"_254":949,"_255":950,"_257":-5,"_258":-5,"_259":951,"_261":291},{"_240":932,"_242":933,"_244":389,"_246":934,"_248":935,"_250":38,"_251":291,"_252":909,"_254":936,"_255":937,"_257":-5,"_258":-5,"_259":938,"_261":291},{"_240":918,"_242":919,"_244":288,"_246":920,"_248":921,"_250":38,"_251":291,"_252":922,"_254":923,"_255":924,"_257":-5,"_258":-5,"_259":925,"_261":291},{"_240":905,"_242":906,"_244":389,"_246":907,"_248":908,"_250":38,"_251":291,"_252":909,"_254":910,"_255":911,"_257":-5,"_258":-5,"_259":912,"_261":291},{"_240":891,"_242":892,"_244":288,"_246":893,"_248":894,"_250":38,"_251":291,"_252":895,"_254":896,"_255":897,"_257":-5,"_258":-5,"_259":898,"_261":291},{"_240":878,"_242":879,"_244":288,"_246":880,"_248":881,"_250":38,"_251":291,"_252":882,"_254":883,"_255":884,"_257":-5,"_258":-5,"_259":885,"_261":291},{"_240":861,"_242":862,"_244":389,"_246":863,"_248":864,"_250":38,"_251":291,"_252":865,"_254":866,"_255":867,"_257":-5,"_258":-5,"_259":868,"_261":291},{"_240":847,"_242":848,"_244":288,"_246":849,"_248":850,"_250":38,"_251":291,"_252":851,"_254":852,"_255":853,"_257":-5,"_258":-5,"_259":854,"_261":291},{"_240":834,"_242":835,"_244":389,"_246":836,"_248":837,"_250":38,"_251":291,"_252":838,"_254":839,"_255":840,"_257":-5,"_258":-5,"_259":841,"_261":291},{"_240":821,"_242":822,"_244":288,"_246":823,"_248":824,"_250":38,"_251":291,"_252":825,"_254":826,"_255":827,"_257":-5,"_258":-5,"_259":828,"_261":291},{"_240":808,"_242":809,"_244":389,"_246":810,"_248":811,"_250":38,"_251":291,"_252":812,"_254":813,"_255":814,"_257":-5,"_258":-5,"_259":815,"_261":291},{"_240":795,"_242":796,"_244":615,"_246":797,"_248":798,"_250":38,"_251":291,"_252":799,"_254":800,"_255":801,"_257":-5,"_258":-5,"_259":802,"_261":291},{"_240":782,"_242":783,"_244":288,"_246":784,"_248":785,"_250":38,"_251":291,"_252":786,"_254":787,"_255":788,"_257":-5,"_258":-5,"_259":789,"_261":291},{"_240":765,"_242":766,"_244":389,"_246":767,"_248":768,"_250":38,"_251":291,"_252":769,"_254":770,"_255":771,"_257":-5,"_258":-5,"_259":772,"_261":291},{"_240":752,"_242":753,"_244":245,"_246":754,"_248":755,"_250":38,"_251":291,"_252":756,"_254":757,"_255":758,"_257":-5,"_258":-5,"_259":759,"_261":291},{"_240":739,"_242":740,"_244":245,"_246":741,"_248":742,"_250":38,"_251":291,"_252":743,"_254":744,"_255":745,"_257":-5,"_258":-5,"_259":746,"_261":291},{"_240":727,"_242":728,"_244":288,"_246":729,"_248":730,"_250":38,"_251":291,"_252":731,"_254":732,"_255":733,"_257":-5,"_258":-5,"_259":734,"_261":291},{"_240":714,"_242":715,"_244":288,"_246":716,"_248":717,"_250":38,"_251":291,"_252":718,"_254":719,"_255":720,"_257":-5,"_258":-5,"_259":721,"_261":291},{"_240":700,"_242":701,"_244":389,"_246":702,"_248":703,"_250":38,"_251":291,"_252":704,"_254":705,"_255":706,"_257":-5,"_258":-5,"_259":707,"_261":291},{"_240":689,"_242":690,"_244":245,"_246":481,"_248":691,"_250":38,"_251":291,"_252":692,"_254":693,"_255":694,"_257":-5,"_258":-5,"_259":695,"_261":291},{"_240":671,"_242":672,"_244":288,"_246":673,"_248":674,"_250":472,"_251":472,"_252":675,"_254":676,"_255":677,"_257":375,"_258":-5,"_259":678,"_261":38},{"_240":658,"_242":659,"_244":288,"_246":660,"_248":661,"_250":403,"_251":403,"_252":662,"_254":460,"_255":663,"_257":-5,"_258":-5,"_259":664,"_261":38},{"_240":644,"_242":645,"_244":288,"_246":646,"_248":647,"_250":403,"_251":403,"_252":648,"_254":649,"_255":650,"_257":-5,"_258":-5,"_259":651,"_261":38},{"_240":631,"_242":632,"_244":288,"_246":633,"_248":634,"_250":291,"_251":403,"_252":635,"_254":636,"_255":637,"_257":-5,"_258":-5,"_259":638,"_261":38},{"_240":613,"_242":614,"_244":615,"_246":616,"_248":617,"_250":291,"_251":291,"_252":618,"_254":619,"_255":620,"_257":-5,"_258":-5,"_259":621,"_261":38},{"_240":587,"_242":588,"_244":589,"_246":590,"_248":591,"_250":291,"_251":291,"_252":592,"_254":593,"_255":594,"_257":-5,"_258":-5,"_259":595,"_261":38},{"_240":574,"_242":575,"_244":288,"_246":576,"_248":577,"_250":291,"_251":291,"_252":578,"_254":579,"_255":580,"_257":-5,"_258":-5,"_259":581,"_261":38},{"_240":560,"_242":561,"_244":288,"_246":562,"_248":563,"_250":291,"_251":291,"_252":564,"_254":565,"_255":566,"_257":-5,"_258":-5,"_259":567,"_261":38},{"_240":547,"_242":548,"_244":288,"_246":549,"_248":550,"_250":291,"_251":291,"_252":551,"_254":552,"_255":553,"_257":-5,"_258":-5,"_259":554,"_261":38},{"_240":533,"_242":534,"_244":288,"_246":535,"_248":536,"_250":291,"_251":291,"_252":537,"_254":538,"_255":539,"_257":-5,"_258":-5,"_259":540,"_261":38},{"_240":520,"_242":521,"_244":288,"_246":522,"_248":523,"_250":291,"_251":291,"_252":524,"_254":525,"_255":526,"_257":-5,"_258":-5,"_259":527,"_261":38},{"_240":502,"_242":503,"_244":288,"_246":504,"_248":505,"_250":291,"_251":291,"_252":506,"_254":507,"_255":508,"_257":375,"_258":-5,"_259":509,"_261":38},{"_240":488,"_242":489,"_244":288,"_246":490,"_248":491,"_250":291,"_251":291,"_252":492,"_254":493,"_255":494,"_257":-5,"_258":-5,"_259":495,"_261":38},{"_240":468,"_242":469,"_244":288,"_246":470,"_248":471,"_250":38,"_251":472,"_252":473,"_254":474,"_255":475,"_257":-5,"_258":-5,"_259":476,"_261":38},{"_240":455,"_242":456,"_244":288,"_246":457,"_248":458,"_250":38,"_251":444,"_252":459,"_254":460,"_255":461,"_257":-5,"_258":-5,"_259":462,"_261":38},{"_240":440,"_242":441,"_244":288,"_246":442,"_248":443,"_250":38,"_251":444,"_252":445,"_254":446,"_255":447,"_257":-5,"_258":-5,"_259":448,"_261":38},{"_240":426,"_242":427,"_244":288,"_246":428,"_248":429,"_250":38,"_251":403,"_252":430,"_254":431,"_255":432,"_257":-5,"_258":-5,"_259":433,"_261":38},{"_240":413,"_242":414,"_244":288,"_246":415,"_248":416,"_250":38,"_251":403,"_252":417,"_254":418,"_255":419,"_257":-5,"_258":-5,"_259":420,"_261":38},{"_240":399,"_242":400,"_244":288,"_246":401,"_248":402,"_250":38,"_251":403,"_252":404,"_254":405,"_255":406,"_257":-5,"_258":-5,"_259":407,"_261":38},{"_240":368,"_242":369,"_244":288,"_246":370,"_248":371,"_250":38,"_251":291,"_252":372,"_254":373,"_255":374,"_257":375,"_258":-5,"_259":376,"_261":38},{"_240":355,"_242":356,"_244":245,"_246":357,"_248":358,"_250":38,"_251":291,"_252":359,"_254":360,"_255":361,"_257":-5,"_258":-5,"_259":362,"_261":38},{"_240":342,"_242":343,"_244":288,"_246":344,"_248":345,"_250":38,"_251":291,"_252":346,"_254":347,"_255":348,"_257":-5,"_258":-5,"_259":349,"_261":38},{"_240":328,"_242":329,"_244":288,"_246":330,"_248":331,"_250":38,"_251":291,"_252":332,"_254":333,"_255":334,"_257":-5,"_258":-5,"_259":335,"_261":38},{"_240":315,"_242":316,"_244":288,"_246":317,"_248":318,"_250":38,"_251":291,"_252":319,"_254":320,"_255":321,"_257":-5,"_258":-5,"_259":322,"_261":38},{"_240":302,"_242":303,"_244":288,"_246":304,"_248":305,"_250":38,"_251":291,"_252":306,"_254":307,"_255":308,"_257":-5,"_258":-5,"_259":309,"_261":38},{"_240":286,"_242":287,"_244":288,"_246":289,"_248":290,"_250":38,"_251":291,"_252":292,"_254":293,"_255":294,"_257":-5,"_258":-5,"_259":295,"_261":38},{"_240":273,"_242":274,"_244":275,"_246":276,"_248":277,"_250":278,"_251":278,"_252":279,"_254":280,"_255":281,"_257":-5,"_258":-5,"_259":282,"_261":38},{"_240":241,"_242":243,"_244":245,"_246":247,"_248":249,"_250":38,"_251":38,"_252":253,"_254":253,"_255":256,"_257":-5,"_258":-5,"_259":260,"_261":38},"story",{"_270":271,"_246":272},"subject","code:LBA77","kind","code","title","LBA77","summary","坦康阿妥塔单抗在ESMO 2026 LBA77公布G-HOPE-001Ⅲ期后线CLDN18.2阳性胃癌期中结果，达到PFS和OS双主要终点。IA2中位PFS为7.1个月对3.1个月，HR=0.45（95% CI 0.35–0.58）；中位OS为10.2个月对6.9个月，HR=0.57（95% CI 0.45–0.73），确认ORR为37.4%对7.7%。","participantCount","reportCount","firstAt","2026-10-23T12:40:00.000Z","latestAt","abstracts",[],"program","reading","representative",{"_262":263,"_264":249,"_265":266,"_267":268,"_269":-5},"stars","id","cpbp06lxk14d5r2x0pthc3xdi","text","translated",false,"originalUrl","https://mp.weixin.qq.com/s?__biz=MjM5Nzc4MDk2MA==&mid=2651291419&idx=1&sn=6ed99edebee579dfd282d435afa31362","handle","publicId","252673b3-dada-453a-b488-048892ace17c","ESMO 2026：Arcotatug tavatecan 胃癌三期达双终点",{"_270":285,"_246":276},"meeting:esmo-2026","meeting","ESMO 2026","JNM 在线发表 TheraPb Ⅰb 期全文，首次完整披露 ²¹²Pb-ADVC001 的 RP2D、剂量学与疗效数据，α 核素从“概念验证”走向“剂量-窗口刻画”的转折点正在形成。Perspective Therapeutics 发布 ²¹²Pb-VMT-α-NET Ⅰ/Ⅱa 期中期数据，Ⅲ 期拟 2027 年启动。",38,"2026-10-11T11:41:36.000Z","2026-10-24T12:00:00.000Z",[],{"_262":283,"_264":277,"_265":266,"_267":284,"_269":-5},"dvq5gr5n27lmkdwk818e6hqsa","https://mp.weixin.qq.com/s?__biz=MzIwNTY5NzM5NA==&mid=2247492238&idx=1&sn=e74e3ca228ef2f6a5c8b5d399853c79d","f7aeb790-ad0b-4d4f-882d-908bb349078d",{"_270":300,"_246":301},"tag:#day2","tag","#DAY2","快速口头报告环节 #GU 将于15分钟后开始\n🕐 上午10:15\n📍Bilbao Auditorium - 3号厅\n\n#ESMO26 #Day2 @myESMO @OncoAlert",2,"2026-10-24T06:59:52.000Z","2026-10-24T08:01:22.000Z",[],{"_262":296,"_264":290,"_265":297,"_267":298,"_269":299},"lf9hhe716ugs5rkfcjqp10y3j",true,"https://x.com/DrChoueiri/status/2113903664070832366","DrChoueiri","1b067cfc-7d08-4dfc-afa3-385650326ede","Rapid oral session #GU starting in 15 min Rapid oral session #GU starting in 15 min 🕐 10:15am 📍Bilbao Auditorium - Hall 3 #ESMO26 #Day2 @m",{"_270":313,"_246":314},"tag:#vhio","#VHIO","🏆 恭喜 @pablo_cresta，#VHIO’s 前列腺癌转化研究组的研究员，荣获 #ESMO2026 最佳海报奖！\n\n他的海报重点介绍了 BioChiP，这是一项学术试验，研究卡铂在转移性去势抵抗性 #prostatecancer 中的应用。\n\n👏 实至名归，Pablo！","2026-10-23T15:08:03.000Z","2026-10-23T15:56:29.000Z",[],{"_262":310,"_264":305,"_265":297,"_267":311,"_269":312},"zv22qzy3yqy5ltjntqdzl3kvt","https://x.com/VHIO/status/2113648655785689541","VHIO","3ee6a090-5477-47a6-9b31-3ba66cca25e0","🏆 Congratulations to @pablo_cresta, researcher in #VHIO’s Prostate Cancer Translational Research Group, on winning the Best Poster Award at",{"_270":326,"_246":327},"tag:#oncosteps","#ONCOSTEPS","#ESMO26 | Dato-DXd 在不符合免疫治疗条件的脑转移三阴性患者中的数据。\n\n来自马德里的 Armando Orlandi👇 \n#OncoSTEPS #mTNBC #ADCs","2026-10-24T18:19:47.000Z","2026-10-24T18:21:30.000Z",[],{"_262":323,"_264":318,"_265":297,"_267":324,"_269":325},"zq8vrcn2z0mv4ggek6zwamx1m","https://x.com/Oncoinfo_it/status/2114059291456151651","Oncoinfo_it","bdb340e0-740c-4191-8c59-3462e0d33748","#ESMO26 | Dato-DXd nelle pazienti triplo negative con metastasi cerebrali non candidabili all’immunoterapia",{"_270":340,"_246":341},"tag:#pcsm","#PCSM","关注 👀：@UCLAHealth 的医学博士 Johanna Enke 讨论了 lutetium Lu 177 vipivotide tetraxetan 在 mCRPC 患者中再次给药的 II 期研究安全性结果。\n\n在此查看 ➡️：https://www.onclive.com/view/dr-enke-on-interim-safety-data-for-lutetium-lu-177-vipivotide-tetraxetan-","2026-10-23T12:26:37.000Z","2026-10-24T15:33:38.000Z",[],{"_262":336,"_264":337,"_265":297,"_267":338,"_269":339},"qdijeb9izh29nto6e6j5wycyu","关注 👀：@UCLAHealth 的医学博士 Johanna Enke 讨论了 lutetium Lu 177 vipivotide tetraxetan 在 mCRPC 患者中再次给药的 II 期研究安全性结果。\n\n在此查看 ➡️：https://www.onclive.com/view/dr-enke-on-interim-safety-data-for-lutetium-lu-177-vipivotide-tetraxetan-retreatment-in-mcrpc\n\n#pcsm #oncology","https://x.com/OncLive/status/2114017481031352400","OncLive","9dc7d2b9-32f1-4b40-b203-ee3d405f717a","🗣️ Kicking things off with Johanna S",{"_270":353,"_246":354},"tag:#personalisedmedicine","#PERSONALISEDMEDICINE","🔬 从早期检测到治疗监测，个性化肿瘤学依赖于整个患者路径上的决策。\n\n与 IAPM 一起于 10 月 23 日探讨这些挑战。\n\n注册：https://shorturl.at/afPsg\n\n#ESMO26 #PersonalisedMedicine","2026-10-21T09:52:28.000Z","2026-10-23T07:50:13.000Z",[],{"_262":350,"_264":345,"_265":297,"_267":351,"_269":352},"tewss3xbub3boe3u4jx7xyfx4","https://x.com/united4cancer/status/2112844459063021825","united4cancer","370399ee-d0c8-4aa1-8cec-cd9eda106edb","🔬 From early detection to treatment monitoring, personalised oncology depends on decisions across the entire patient pathway",{"_270":366,"_246":367},"code:1095EP","1095EP","明天，@myESMO 2026年大会将在马德里开幕。RS-0139 的首次人体 I 期临床试验是科学项目的一部分（1095eP）。一张海报讲述了其中一部分故事，其余的则在交流中展开。#ESMO2026 见\n\nw/ @gulsahnomak11","2026-10-22T11:58:56.000Z","2026-10-24T09:57:39.000Z",[],{"_262":363,"_264":358,"_265":297,"_267":364,"_269":365},"k2lcpjnzcn85oh1ytnzm69xsz","https://x.com/RS_Research_TR/status/2113238675077149165","RS_Research_TR","cc3a11f3-df24-4a92-9d4a-b19cd2c55601","Tomorrow, @myESMO Congress 2026 opens its doors in Madrid",{"_270":397,"_246":398},"tag:#data","#DATA",".@myESMO 会议今天在马德里开始。\n#ESMO2026 顶级公司\n来源：@Larvol CLIN database\n\n#cancer #oncology #data","2026-10-23T17:11:04.000Z","2026-10-23T17:12:13.000Z",[380,381],"LB",{"_262":377,"_264":371,"_265":297,"_267":378,"_269":379},"gjhx9zr4yjgaj7ap900fsfcxv","https://x.com/robertfsiegmund/status/2113679901572141486","robertfsiegmund",{"_382":392,"_17":393,"_246":394,"_386":395,"_388":-5,"_389":-5,"_390":396},{"_382":383,"_17":384,"_246":385,"_386":387,"_388":-5,"_389":-5,"_390":391},"no","LBA79","late-breaking","Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01","url","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/249","authors","nct","clue","Rapid oral 1: Gastrointestinal tumour, upper digestive","3609P","regular","Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: A reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials","https://www.esmo.org/meeting-calendar/esmo-congress-2026","Renal cancer","80428e52-cb37-41ac-ae33-7fa42bb50bc2",".@myESMO conference has started today in Madrid. .@myESMO conference has started today in Madrid. #ESMO2026 Top Companies Source: @Larvol CL",{"_270":411,"_246":412},"tag:#cnrealtimereport","#CNREALTIMEREPORT","明天收看，@DrArturoAI 将接管 @cancernetwrk 现场直播 #ESMO26!\n\n他将深入解析肿瘤学领域的前沿 AI 突破，涵盖数字病理学、基础模型到 LLM 辅助的临床决策支持。\n\n请在 CEST 时间下午 1 点至 4 点（EST 上午 7 点至 10 点）收看报道！#CNRealtimeReport",3,"2026-10-23T21:00:01.000Z","2026-10-24T14:00:00.000Z",[],{"_262":408,"_264":402,"_265":297,"_267":409,"_269":410},"uzf83c13f6jz8htt97rseceg6","https://x.com/CancerNetwrk/status/2113737227926733016","CancerNetwrk","f05cb763-9216-4d10-b4da-21b8e4838a52","Tune in tomorrow as @DrArturoAI takes over @cancernetwrk live from #ESMO26",{"_270":424,"_246":425},"tag:#ttdenesmo26","#TTDENESMO26","Valentino Martelli 博士，来自 @hospitaldelmar、@SanMartino_Ge 和 @GrupoTTD，在 2026 年 ESMO 大会上展示了 TTD-15-01 PLATFORM-B META-ANÁLISIS HIPERSELECCIÓN NEGATIVA 研究的结果\n🏅 ESMO Merit Award\n请将此演讲加入日程 #ESMO26！ #TTDenESMO26","2026-10-23T10:20:10.000Z","2026-10-23T11:35:11.000Z",[],{"_262":421,"_264":416,"_265":297,"_267":422,"_269":423},"pvkj9t55eqnb4rmsugx1xhtpl","https://x.com/GrupoTTD/status/2113576204435595379","GrupoTTD","12c92dfd-e32b-494d-87f1-f94bc4d30cf0","El Dr",{"_270":438,"_246":439},"tag:#rocheenesmo","#ROCHEENESMO","今天开始 #ESMO2026! 🔬\n\n马德里于10月23日至27日汇聚国际肿瘤学界，分享进展并探索癌症治疗的新视角。\nRoche，我们密切关注这一推动肿瘤学创新的关键盛会。\n\n📅 10月23-27日\n📍 Madrid, España\n\nhttps://www.rocheplus.es/campaigns/roche-en-esmo-2026.html\n\n#RocheEnESMO #Oncología #InnovaciónMédi","2026-10-21T14:16:19.000Z","2026-10-23T08:48:57.000Z",[],{"_262":434,"_264":435,"_265":297,"_267":436,"_269":437},"kz88rn0boc9ggonh8amg5prnl","今天开始 #ESMO2026! 🔬\n\n马德里于10月23日至27日汇聚国际肿瘤学界，分享进展并探索癌症治疗的新视角。\nRoche，我们密切关注这一推动肿瘤学创新的关键盛会。\n\n📅 10月23-27日\n📍 Madrid, España\n\nhttps://www.rocheplus.es/campaigns/roche-en-esmo-2026.html\n\n#RocheEnESMO #Oncología #InnovaciónMédica #Salud","https://x.com/Roche_Plus/status/2113553249106059350","Roche_Plus","7a824628-8807-498e-926e-bb850b2fc8d9","¿Hacia dónde se dirige el futuro del tratamiento del cáncer de pulmón",{"_270":453,"_246":454},"tag:#uromigos","#UROMIGOS","新的机制能否改变我们靶向治疗前列腺癌的方式？\n\n在 #ESMO2026 现场，Ben Garmezy 博士与 Brian 和 Tom 一同探讨 RIPTAC 的 Phase 1 数据。这是一种新方法，利用雄激素受体 (AR) 靶向 BRD4，从而破坏癌细胞的转录。\n\n🎙️ The Uromigos Podcast 第 524 期现已上线：https://bit.ly/4z6zWaG\n\n#Uromigos #ProstateCancer",4,"2026-10-23T15:49:16.000Z","2026-10-24T19:30:04.000Z",[],{"_262":449,"_264":450,"_265":297,"_267":451,"_269":452},"b5osv54gqpu8kaucsn5ejvda5","新的机制能否改变我们靶向治疗前列腺癌的方式？\n\n在 #ESMO2026 现场，Ben Garmezy 博士与 Brian 和 Tom 一同探讨 RIPTAC 的 Phase 1 数据。这是一种新方法，利用雄激素受体 (AR) 靶向 BRD4，从而破坏癌细胞的转录。\n\n🎙️ The Uromigos Podcast 第 524 期现已上线：https://bit.ly/4z6zWaG\n\n#Uromigos #ProstateCancer #GUOncology","https://x.com/Uromigos/status/2114046327030006193","Uromigos","82de2358-1f69-44c2-ab25-7447bc931273","Could a new mechanism change how we target prostate cancer",{"_270":466,"_246":467},"tag:#oncologyai","#ONCOLOGYAI","🎙️ 正在毕尔巴鄂会场为 #ESMO26 做现场报道！\n\n@DrArturoAI 正在为入选论文专场关于 AI 与数字健康的内容做准备，接下来有三场报告：\n\n🤖 使用大型语言模型检测 Alliance 随机临床试验中的不良事件\n\n☢️ AI 基础模型如何改变放射肿瘤学中的治疗与结局预测\n\n🔬 AI 驱动的乳腺癌病理学\n\n敬请期待要点分享！👀\n\n#OncologyAI #DigitalHealth #CNRealtimeRepor","2026-10-24T13:00:01.000Z","2026-10-24T21:00:01.000Z",[],{"_262":463,"_264":464,"_265":297,"_267":465,"_269":410},"nr4lvt3yhvwbz8d50hmuzm6uv","🎙️ 正在毕尔巴鄂会场为 #ESMO26 做现场报道！\n\n@DrArturoAI 正在为入选论文专场关于 AI 与数字健康的内容做准备，接下来有三场报告：\n\n🤖 使用大型语言模型检测 Alliance 随机临床试验中的不良事件\n\n☢️ AI 基础模型如何改变放射肿瘤学中的治疗与结局预测\n\n🔬 AI 驱动的乳腺癌病理学\n\n敬请期待要点分享！👀\n\n#OncologyAI #DigitalHealth #CNRealtimeReport","https://x.com/CancerNetwrk/status/2114009023406301370","313a7546-6230-40df-8353-426bbe5e0dbf","Live from #ESMO26: @DrArturoAI recaps a session on AI and real-world data in oncology, covering guardrails for LLMs in the clinic, why verif",{"_270":486,"_246":487},"tag:#lacog","#LACOG","2026年ESMO大会汇聚全球研究人员和医疗专业人员，分享科学进展并讨论肿瘤学的未来。\n\nLACOG正在马德里。关注我们的报道！\n\n#LACOG #ESMO2026",6,"2026-10-23T19:15:23.000Z","2026-10-24T19:04:44.000Z",[480],{"_262":477,"_264":471,"_265":297,"_267":478,"_269":479},"aq31jgx90owzdqo37lukethjn","https://x.com/LACOG_group/status/2114025898504601713","LACOG_group",{"_382":481,"_17":393,"_246":482,"_386":395,"_388":-5,"_389":483,"_390":484},"2259P","Genomic biomarkers of response to extreme bipolar androgen therapy (BAT) alternating darolutamide in metastatic castration-resistant prostate cancer: An ancillary biomarker analysis of the ExBAT/LACOG 0620 trial",[485,485,485],"Metastatic prostate cancer","NCT04558866","ecdb83d2-9f1f-4764-a9a9-a0f5b0c30d87","The ESMO Congress 2026 brings together researchers and healthcare professionals worldwide to share scientific advances and discuss the futur",{"_270":500,"_246":501},"tag:#ovariancancer","#OVARIANCANCER","今天在马德里的 #ESMO26 上，我们公布了研究性 FRα 靶向抗体药物偶联物在既往接受过多种治疗的铂耐药卵巢癌患者中的最新 1 期数据。\n\n这些结果进一步增强了我们对这一方法有望帮助扩大卵巢癌患者治疗选择的信心。\n\n在此查看关键数据摘要：https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-presents-new-phase-1-data-fol","2026-10-22T19:12:34.000Z","2026-10-24T06:47:56.000Z",[],{"_262":496,"_264":497,"_265":297,"_267":498,"_269":499},"jveigfjyozcaf6e77vgtqq3gs","今天在马德里的 #ESMO26 上，我们公布了研究性 FRα 靶向抗体药物偶联物在既往接受过多种治疗的铂耐药卵巢癌患者中的最新 1 期数据。\n\n这些结果进一步增强了我们对这一方法有望帮助扩大卵巢癌患者治疗选择的信心。\n\n在此查看关键数据摘要：https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-presents-new-phase-1-data-folate-receptor-alpha-0\n\n#OvarianCancer #ADC","https://x.com/ZymeworksInc/status/2113885183263006744","ZymeworksInc","3a21845b-08f3-469c-9f96-9d160a463ba3","Heading to #ESMO26",{"_270":518,"_246":519},"tag:#mrna","#MRNA","#ESMO26：随着个性化 #mRNA #NeoantigenVaccine 终于取得令人期待的阳性生存结局，John Haanen 在其社论中讨论的一个关键问题，是如何让 #CellularTherapies 变得切实可行、可规模化且可持续\n#InsightsbyESMO ➡️ https://ow.ly/8wqg5100Kzp","2026-10-23T13:42:36.000Z","2026-10-24T17:00:21.000Z",[513],{"_262":510,"_264":505,"_265":297,"_267":511,"_269":512},"kcc5vhvv3zulb5s4av4k0c7vs","https://x.com/myESMO/status/2114039305194664150","myESMO",{"_382":514,"_17":384,"_246":515,"_386":516,"_388":-5,"_389":-5,"_390":517},"LBA1","INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346","Presidential Symposium I","867cecd5-b99c-4cf7-9628-939c67d102a1","#ESMO26: With long-awaited positive survival outcomes for a personalised #mRNA #NeoantigenVaccine, a key question discussed by John Haanen i",{"_270":531,"_246":532},"tag:#melsm","#MELSM","对于病灶内注射/TIL 而言，肿瘤大小确实很重要 #melsm #ESMO26\n\n非常信息量丰富的演讲 @amandakirane \n@StanfordMed","2026-10-23T17:34:37.000Z","2026-10-24T13:56:35.000Z",[],{"_262":528,"_264":523,"_265":297,"_267":529,"_269":530},"ybkz8ywo6hvrrmm6eyo87hgqf","https://x.com/anmwongNZ/status/2113993057117061233","anmwongNZ","ad349c89-5934-4b49-b681-4fe7b4ecf893","#melsm #ESMO26 #melsm #ESMO26 #melsm #ESMO26",{"_270":545,"_246":546},"tag:#echobox","#ECHOBOX","#ESMO26 | 欧洲肿瘤学家将减轻💉癌症治疗负担作为优先事项。\n\n👉@myESMO 将开始资助试验，旨在降低毒性并促进创新获取。\n\nhttps://www.diariomedico.com/medicina/oncologia/oncologia-europea-fija-objetivo-reducir-carga-tratamiento-cancer.html?utm_medium=Social&utm_source=Twi","2026-10-23T12:54:07.000Z","2026-10-23T21:53:49.000Z",[],{"_262":541,"_264":542,"_265":297,"_267":543,"_269":544},"ypef24nm5fg9s39qa1odaxnhc","#ESMO26 | 欧洲肿瘤学家将减轻💉癌症治疗负担作为优先事项。\n\n👉@myESMO 将开始资助试验，旨在降低毒性并促进创新获取。\n\nhttps://www.diariomedico.com/medicina/oncologia/oncologia-europea-fija-objetivo-reducir-carga-tratamiento-cancer.html?utm_medium=Social&utm_source=Twitter#Echobox=1792756005","https://x.com/diariomedico/status/2113614947145892142","diariomedico","47167004-380d-4fa8-8a3a-3b710c839f37","#ESMO26 | Los oncólogos europeos se fijan como prioridad reducir la carga del 💉tratamiento del cáncer",{"_270":558,"_246":559},"tag:#cancerdemama","#CANCERDEMAMA","研究不断推进，希望也在前行！💜。ESMO 2026 正是明证。这是欧洲最大的肿瘤学大会。目标：“让科学重新与这一事实建立联系：我们谈论的是人”👏。\n\n#ESMO2026 #CancerDeMama #ASAMMA","2026-10-24T08:10:17.000Z","2026-10-24T10:51:05.000Z",[],{"_262":555,"_264":550,"_265":297,"_267":556,"_269":557},"pz2wz8r44e9xhg2jrdlajurc5","https://x.com/asammavitoria/status/2113946376081916174","asammavitoria","6c167851-dfd5-4afb-894e-1f64ba27977b","#Cancerdemama en #ESMO26 #Cancerdemama en #ESMO26 #Cancerdemama en #ESMO26",{"_270":572,"_246":573},"tag:#cancercare","#CANCERCARE","强大的合作带来新的可能性。#CancerCare。在 #ESMO26 上，我们将与研究合作伙伴共同展示 25 篇摘要，其中包括 5 篇快速口头报告，探讨液体活检在肺癌、结直肠癌和胃癌领域的进展。这些成果体现了我们与生物制药行业、学术界及公私合作伙伴关系的优势，扩展了 MRD 监测、治疗应答和耐药研究方面的证据，进一步深化了我们对如何利用基因组学和表观基因组学见解指导癌症照护的理解。详情：https://t.co/CmI","2026-10-20T15:04:25.000Z","2026-10-24T05:00:00.000Z",[],{"_262":568,"_264":569,"_265":297,"_267":570,"_269":571},"bsvennyf8iw7og66t4djz01dx","强大的合作带来新的可能性。#CancerCare。在 #ESMO26 上，我们将与研究合作伙伴共同展示 25 篇摘要，其中包括 5 篇快速口头报告，探讨液体活检在肺癌、结直肠癌和胃癌领域的进展。这些成果体现了我们与生物制药行业、学术界及公私合作伙伴关系的优势，扩展了 MRD 监测、治疗应答和耐药研究方面的证据，进一步深化了我们对如何利用基因组学和表观基因组学见解指导癌症照护的理解。详情：https://t.co/CmI0I7iVco","https://x.com/GuardantHealth/status/2112560577964847121","GuardantHealth","05935242-6b4c-4c23-9e32-5c569e63235e","Strong collaborations drive new possibilities in #CancerCare",{"_270":585,"_246":586},"tag:#biotech","#BIOTECH","在欧洲医学肿瘤学会 #ESMO26 上关注癌症医学的四大主题，以及一份通俗易懂的生存曲线阅读指南。 https://bit.ly/4dYHfZM #ESMO2026 #Oncology #Biotech","2026-10-21T12:38:52.000Z","2026-10-23T16:28:09.000Z",[],{"_262":582,"_264":577,"_265":297,"_267":583,"_269":584},"sg7j7fck92n697yip0tmpmpx9","https://x.com/RtwLp/status/2113668812457284058","RtwLp","46a10d15-5d1b-4a1f-b487-2b9e4edeba27","What to watch in cancer medicine at the European Society for Medical Oncology #ESMO26: four themes, plus a plain-language guide to reading a",{"_270":611,"_246":612},"gene:VEGF","gene","VEGF","‼️ 嗨，#ESMO26 的家人们！\n\nFunda Meric-Bernstam 就 ADC + IO 联合应用背后的理论依据展开了精彩讨论！！ @UTMDAnderson\n\n▪️ADCs 可能诱导免疫原性细胞死亡、释放 DAMPs 并启动 TME\n▪️它们还可能提高 PD-L1 表达，有助于克服抗原异质性\n▪️VEGF–PD-(L)1 双特异性抗体旨在逆转血管免疫抑制，并改善免疫细胞进入肿瘤的能力\n\n@OncoAlert @OncoR","2026-10-24T13:40:13.000Z","2026-10-24T13:45:11.000Z",[600,601,602],{"_262":596,"_264":597,"_265":297,"_267":598,"_269":599},"jeakg3nms47myvf7hyn13yky9","‼️ 嗨，#ESMO26 的家人们！\n\nFunda Meric-Bernstam 就 ADC + IO 联合应用背后的理论依据展开了精彩讨论！！ @UTMDAnderson\n\n▪️ADCs 可能诱导免疫原性细胞死亡、释放 DAMPs 并启动 TME\n▪️它们还可能提高 PD-L1 表达，有助于克服抗原异质性\n▪️VEGF–PD-(L)1 双特异性抗体旨在逆转血管免疫抑制，并改善免疫细胞进入肿瘤的能力\n\n@OncoAlert @OncoReporte @myESMO @_SEOM","https://x.com/MarioBalsaMD/status/2113988939140735355","MarioBalsaMD",{"_382":608,"_17":393,"_246":609,"_386":395,"_388":-5,"_389":-5,"_390":610},{"_382":605,"_17":393,"_246":606,"_386":395,"_388":-5,"_389":-5,"_390":607},{"_382":603,"_17":393,"_246":604,"_386":395,"_388":-5,"_389":-5,"_390":396},"3636TIP","LITESPARK-034: Phase 3 study of belzutifan plus zanzalintinib versus belzutifan in participants with advanced renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy and VEGF-TKI","2660P","Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results","NSCLC, metastatic","1963P","First-in-human phase I study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF in advanced solid tumours","Investigational immunotherapy","a7c8d46e-a428-4fce-b751-5c30fb2ec3b3","‼️ Hey #ESMO26 family",{"_270":629,"_246":630},"drug:mipitecan","drug","mipitecan","进一步了解 FRAmework-01：这是一项 III 期研究，评估 sofetabart mipitecan（Sofe-M）用于 PROC，以及 Sofe-M + bevacizumab（Bev）用于铂类敏感性卵巢癌。\n\n#ESMO2026 的 ePoster 1448eTiP。\n\n查看大会日程详情：https://e.lilly/4yuiYms \n\n#GynOnc","2026-10-22T15:00:01.000Z","2026-10-24T06:15:01.000Z",[625],{"_262":622,"_264":617,"_265":297,"_267":623,"_269":624},"av88fh565340damj7pp1w5gvy","https://x.com/LillyOncMed/status/2113284242964725922","LillyOncMed",{"_382":626,"_17":393,"_246":627,"_386":395,"_388":-5,"_389":-5,"_390":628},"1288P","Sofetabart mipitecan (Sofe-M) in patients (pts) ≥65 y with platinum-resistant and -sensitive ovarian cancer","Gynaecological cancers","ca928eaf-b4f0-4a89-89b3-8a5b976993d9","Learn more about FRAmework-01, a Phase 3 study of sofetabart mipitecan (Sofe-M) in PROC and Sofe-M + Bevacizumab (Bev) in platinum sensitive",{"_270":642,"_246":643},"tag:#communicationcommittee","#COMMUNICATIONCOMMITTEE","非常荣幸能有机会协助制定 @myESMO 的传播策略。\n\n与一群杰出的人士一起集思广益，探索如何最大化优秀科学的传播范围，这曾经并将继续极大地激励着我！\n\n#ESMO26 #CommunicationCommittee","2026-10-24T18:15:03.000Z","2026-10-24T23:51:53.000Z",[],{"_262":639,"_264":634,"_265":297,"_267":640,"_269":641},"uk1mpbuiwbrv0ocmobr38imsg","https://x.com/PTarantinoMD/status/2114142869661667805","PTarantinoMD","7c358855-2387-4bc0-9925-57a8d31a8bda","On behalf of @myESMO and the #CommunicationCommittee huge thanks to our #ESMOAmbassadors for all the effort On behalf of @myESMO and the #Co",{"_270":656,"_246":657},"tag:#medicaloncology","#MEDICALONCOLOGY","下一站：马德里，参加 #ESMO26！\n\n我们很乐意与任何对 Mednet 感兴趣、想了解我们如何支持肿瘤学社区的人交流。请在 @ESMO - European Society for Medical Oncology Congress（10 月 23 日至 27 日）找到 @DocLHenry（肿瘤学高级医学总监）、Varsha Hotchandani（商业化负责人）和 Travis Sullivan（业务发展总监）。\n\n对 @Med","2026-10-21T12:10:36.000Z","2026-10-23T15:15:09.000Z",[],{"_262":652,"_264":653,"_265":297,"_267":654,"_269":655},"xgkxww34zxizhzo6u4aje5fqb","下一站：马德里，参加 #ESMO26！\n\n我们很乐意与任何对 Mednet 感兴趣、想了解我们如何支持肿瘤学社区的人交流。请在 @ESMO - European Society for Medical Oncology Congress（10 月 23 日至 27 日）找到 @DocLHenry（肿瘤学高级医学总监）、Varsha Hotchandani（商业化负责人）和 Travis Sullivan（业务发展总监）。\n\n对 @Mednet 有疑问？请在此处的 X 上给我们发送消息，我们会安排时间联系。\n\n#ESMO26 #Oncology #MedicalOncology #CancerResearch #MedicalEducation","https://x.com/themednet/status/2113641900569747799","themednet","3995b9d1-d08b-4521-921d-116841a8c7cf","Next stop: Madrid for #ESMO26",{"_270":669,"_246":670},"tag:#kidneycancer","#KIDNEYCANCER","在 #ESMO26，医学博士 Rahul Winayak（@cityofhope）介绍了新的转移性 #RCC 靶点——GPR65、HPK1、ENPP3、CD70——旨在克服 #immunotherapy 耐药性。\n\n🎥 观看：https://www.targetedonc.com/view/rahul-winayak-emerging-therapeutic-targets-metastatic-renal-cell-carcinom","2026-10-24T16:00:00.000Z",[],{"_262":665,"_264":666,"_265":297,"_267":667,"_269":668},"fxnwtimsie23ny0b9h63zrxdf","在 #ESMO26，医学博士 Rahul Winayak（@cityofhope）介绍了新的转移性 #RCC 靶点——GPR65、HPK1、ENPP3、CD70——旨在克服 #immunotherapy 耐药性。\n\n🎥 观看：https://www.targetedonc.com/view/rahul-winayak-emerging-therapeutic-targets-metastatic-renal-cell-carcinoma\n\n#KidneyCancer #Oncology | @RWinayak @CityofHope_GU","https://x.com/TargetedOnc/status/2114099618883731596","TargetedOnc","3e4f1743-ea95-4bc8-83f6-1a8166cbf9b1","Sharing our commitment to the #kidneycancer community at #ESMO26 Sharing our commitment to the #kidneycancer community at #ESMO26 Sharing ou",{"_270":687,"_246":688},"tag:#oncolog","#ONCOLOG","📍🟣 我们已经在这里了，#ESMO26 🙌!\n\n欧洲医学肿瘤学会 (@myESMO) 的新一届大会拉开帷幕，带来几天时间分享科学、辩论与交流，围绕 #oncología médica 的主要挑战 🔬🧬\n\n🙌 我们满怀期待地分享我们工作的成果。让我们开始吧！ 🚀","2026-10-22T09:24:29.000Z","2026-10-24T08:00:00.000Z",[682],{"_262":679,"_264":674,"_265":297,"_267":680,"_269":681},"hx0mr57xwg4n2dmvzjpn76h86","https://x.com/GEICAM/status/2113582637210014035","GEICAM",{"_382":683,"_17":384,"_246":684,"_386":685,"_388":-5,"_389":-5,"_390":686},"LBA24","Final analysis of NRG oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant therapy with a","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/240","Proffered paper 1: Breast cancer, early and advanced stage","d040fe58-47c0-422a-80fc-f2163d244de3","📍🟣 ¡Ya estamos aquí, #ESMO26 🙌",{"_270":698,"_246":699},"code:2259P","在 ESMO 2026 上，Diogo Assed Bastos 博士展示了 ExBAT 研究（LACOG 0620）的 2259P 海报，评估了 mCRPC 患者对交替使用 darolutamide 和 testosterone cypionate 产生应答的基因组生物标志物。\n\n#LACOG #ESMO2026","2026-10-24T13:47:01.000Z","2026-10-24T15:18:22.000Z",[],{"_262":696,"_264":691,"_265":297,"_267":697,"_269":479},"t9rs690a3clu2zkrk2lqkkgkk","https://x.com/LACOG_group/status/2113990650563895611","a03474f3-d884-4d6c-8b72-ba8491a1bf40","At ESMO 2026, Dr",{"_270":712,"_246":713},"nct:NCT05281406","NCT05281406","🆙#ESMO26 快速口头 I：#LCSM 转移\n🔥PACE-LUNG (AIO-TRK-0422/ass)：一项多中心、单臂、II 期临床试验，评估在奥希替尼一线治疗开始后第 3 周血浆 ctDNA EGFR 突变持续存在的 EGFR 突变 NSCLC 患者接受额外化疗的疗效\n🎙️Dr. Martin Sebastian\n🔢LBA73\n🎯ctDNA 指导的治疗强化可行\n🎯mPFS 16.3 个月（自化疗开始起）（筛选患者中","2026-10-24T05:10:48.000Z","2026-10-24T06:36:52.000Z",[],{"_262":708,"_264":709,"_265":297,"_267":710,"_269":711},"dkyqrbi2tgwdf9k5ah78zixun","🆙#ESMO26 快速口头 I：#LCSM 转移\n🔥PACE-LUNG (AIO-TRK-0422/ass)：一项多中心、单臂、II 期临床试验，评估在奥希替尼一线治疗开始后第 3 周血浆 ctDNA EGFR 突变持续存在的 EGFR 突变 NSCLC 患者接受额外化疗的疗效\n🎙️Dr. Martin Sebastian\n🔢LBA73\n🎯ctDNA 指导的治疗强化可行\n🎯mPFS 16.3 个月（自化疗开始起）（筛选患者中 29% 存在持续 ctDNA）\n🎯mOS 29.2 个月，24 个月 OS 65.4%\n☑️NCT05281406\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters","https://x.com/HHorinouchi/status/2113860739425542648","HHorinouchi","0819cca0-a895-40f1-8465-c0c0b5baf6a8","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥PACE-LUNG (AIO-TRK-0422/ass): A Multicenter, Single-Arm, Phase II Cl",{"_270":725,"_246":726},"tag:#mcbs","#MCBS","@bishalgyawali RN 在 #ESMO26 分享其关于“如何阅读试验报告”的专业见解，实际上是如何批判性评估并将大量新数据置于领域背景中！\n\n@OncologyBGLab #BGLab \n#ESMOAmbassadors @myESMO #MCBS","2026-10-23T11:38:31.000Z","2026-10-23T12:42:35.000Z",[],{"_262":722,"_264":717,"_265":297,"_267":723,"_269":724},"ez6da5q0t5iu1b4avfwjdbupk","https://x.com/darioT_/status/2113595921728430248","darioT_","46b8e7f5-c7a7-4ddc-a036-33e23b64fdd4","@bishalgyawali RN at #ESMO26 delivering his expertise on 'how to read a trial report' but truly how to critical appraise and put in context ",{"_270":737,"_246":738},"tag:#mattfreedman","#MATTFREEDMAN","隆重推介新星 @RashadNawfal——我们课题组的博士后医学博士，正在研究用于无创癌症分析的新型液体活检方法！快来认识他！ #ESMO26\n@DanaFarber_GU @DanaFarber\n\n也正在申请 IM match！千万别错过他！ @OncoAlert @SylvanBacaLab #MattFreedman","2026-10-23T14:48:54.000Z","2026-10-24T12:28:58.000Z",[],{"_262":735,"_264":730,"_265":297,"_267":736,"_269":299},"qmq2bj3shb3a40892xolj1vtu","https://x.com/DrChoueiri/status/2113643836610347376","e0e67182-cbc3-43cd-998b-d9b84e8b233f","Presenting rising star @RashadNawfal post-doc MD in our group working on novel liquid biopsy methods for non-invasive profiling of cancers",{"_270":750,"_246":751},"code:3975P","3975P","欧洲肺癌组织正在马德里参加 #ESMO26。🇪🇸\n\n对 #lungcancer 而言，这是意义重大的一年，新的试验结果可能改变治疗方式。\n\n周六，我们的总裁 Debra Montague 将介绍我们关于肺癌经济负担的研究：我们调查的人中，每三人有两人面临经济困难。\n\n📍 3975P，10 月 24 日周六，12:00\n\n#LCSM","2026-10-22T14:52:15.000Z","2026-10-24T10:35:34.000Z",[],{"_262":747,"_264":742,"_265":297,"_267":748,"_269":749},"xjoqboo6yxtgpzk8c6pxujapw","https://x.com/LungCancerEu/status/2113282288419008985","LungCancerEu","9acfee0c-518d-4925-ad9e-39fc096fdd99","Lung Cancer Europe is in Madrid for #ESMO26",{"_270":763,"_246":764},"code:HS-20122","HS-20122","#ESMO26\n💉 开发中的治疗药物\n\n📌 HS-20122：新型 EGFR/c-MET\n46% =>2L\n✔️ ORR\n✔️ #EGFRm NSCLC 在 6mg/kg 时的 ORR 为 61.3%\n💊 似乎在 L858R 中效果优于 Del19\n☣️ 44% >G3，主要为血液学毒性\n\n@OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson\n👇🏽👇🏽","2026-10-24T13:05:19.000Z","2026-10-24T13:25:30.000Z",[],{"_262":760,"_264":755,"_265":297,"_267":761,"_269":762},"cxvmvfswsyo1nhg9u4br4s7ms","https://x.com/DrMirallas/status/2113980153898442933","DrMirallas","c273542f-7448-4d0f-8667-f361c0fb66d2","#ESMO26 #ESMO26 💉 Developmental therapeutics 📌 HS-20122: novel EGFR/c-MET 46% =>2L ✔️ ORR ✔️ ORR for #EGFRm NSCLC 61",{"_270":780,"_246":781},"nct:NCT05933577","NCT05933577","🆙#ESMO26 主席论坛 I\n🔥INTerpath-001：基于mRNA的个体化新抗原治疗（INT）Intismeran Autogene（Intismeran）联合Pembrolizumab（Pembro）与单用Pembro用于辅助治疗已切除的IIB-IV期黑色素瘤（MEL）的3期研究\n🎙️ @ProfGLongMIA\n🔢LBA1\n🎯达到主要终点：RFS显著改善\n🎯24个月：82.2% vs 70.0%，HR 0.58\n","2026-10-24T05:04:07.000Z","2026-10-24T14:57:16.000Z",[776],{"_262":773,"_264":774,"_265":297,"_267":775,"_269":711},"rsav4vos9kd5b8u342c68mkkr","🆙#ESMO26 主席论坛 I\n🔥INTerpath-001：基于mRNA的个体化新抗原治疗（INT）Intismeran Autogene（Intismeran）联合Pembrolizumab（Pembro）与单用Pembro用于辅助治疗已切除的IIB-IV期黑色素瘤（MEL）的3期研究\n🎙️ @ProfGLongMIA\n🔢LBA1\n🎯达到主要终点：RFS显著改善\n🎯24个月：82.2% vs 70.0%，HR 0.58\n🎯DMFS HR 0.62\n🎯≥3级AE：23.6% vs 20.3%\n☑️NCT05933577\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346\n@OncoAlert @Larvol @myESMO","https://x.com/HHorinouchi/status/2114008329064460757",{"_382":767,"_17":393,"_246":777,"_386":778,"_388":-5,"_389":779,"_390":777},"INTerpath-001","https://clinicaltrials.gov/study/NCT05933577",[767],"a379f5dc-4b21-47b7-8cf1-d86a70863884","🆙#ESMO26 Presidential Symposium I 🆙#ESMO26 Presidential Symposium I 🔥INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoant",{"_270":793,"_246":794},"tag:#livercancer","#LIVERCANCER","🧬 #ESMO26 EMERALD-3：基于 STRIDE 的疗法能否保留中期 HCC 患者的肝功能？\n\n📊 探索性分析表明：\n\n👉 治疗期间，肝功能（ALBI & Child-Pugh 评分）总体保持稳定。\n👉 联合治疗未出现明确恶化信号","2026-10-24T12:49:17.000Z","2026-10-24T13:06:40.000Z",[],{"_262":790,"_264":785,"_265":297,"_267":791,"_269":792},"pr9qmuqanqhttjs28kcwzme4s","https://x.com/lucykflanders/status/2113980496514355447","lucykflanders","258c5cf7-6128-459f-a074-3485ff4df480","🧬 #ESMO26: BGB-B2033, a GPC3 × 4-1BB bispecific antibody, shows promising activity in advanced HCC",{"_270":806,"_246":807},"drug:disitamab","disitamab","#ESMO26 | WUTSUP-02（II期，n=42）新辅助 disitamab vedotin 联合围手术期 tislelizumab 治疗高危、非转移性 UTUC。81% HER2 阳性有前景的抗肿瘤活性 HER2 表达水平较高可能预测应答。@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily","2026-10-24T08:35:29.000Z","2026-10-24T09:06:27.000Z",[],{"_262":803,"_264":798,"_265":297,"_267":804,"_269":805},"wvmk5sx49mz4aywllgjprmm2j","https://x.com/zapatalaguadomd/status/2113920041242472896","zapatalaguadomd","ef80c2fe-53d5-4a69-84db-478c5f44b34a","#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC",{"_270":819,"_246":820},"nct:NCT06211036","NCT06211036","🆙#ESMO26 总统研讨会 I：#LCSM\n🔥DeLLphi-305：Tarlatamab 联合 Durvalumab (Durva) 对比 Durva 作为广泛期小细胞肺癌 (ES-SCLC) 在 Durva、铂类和依托泊苷后的一线维持治疗 (1LM)：III 期试验主要分析\n🎙️ @sands_jacob\n🔢LBA3\n🎯达到主要终点：总生存期 (OS) 显著改善\n🎯mOS 21.1 对 12.7 个月，HR 0.42\n","2026-10-24T05:07:43.000Z","2026-10-24T15:40:30.000Z",[],{"_262":816,"_264":817,"_265":297,"_267":818,"_269":711},"ddgsutj3fmgk3xhvwy4f7gbbm","🆙#ESMO26 总统研讨会 I：#LCSM\n🔥DeLLphi-305：Tarlatamab 联合 Durvalumab (Durva) 对比 Durva 作为广泛期小细胞肺癌 (ES-SCLC) 在 Durva、铂类和依托泊苷后的一线维持治疗 (1LM)：III 期试验主要分析\n🎙️ @sands_jacob\n🔢LBA3\n🎯达到主要终点：总生存期 (OS) 显著改善\n🎯mOS 21.1 对 12.7 个月，HR 0.42\n🎯mPFS 7.4 对 1.9 个月，HR 0.34\n🎯ORR 26.4% 对 4.1%\n🎯CRS 49.6%（多为低级别），无致死事件\n☑️NCT06211036\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346\n@OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2114019208766095425","5a7bcf4f-dc51-4ffb-88e2-9d41bf3f366d","🆙#ESMO26 Presidential Symposium I: #LCSM 🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Dur",{"_270":832,"_246":833},"tag:#neurooncology","#NEUROONCOLOGY","很高兴看到中枢神经系统肿瘤学在 @myESMO 会议上成为焦点，并在马德里举行主题演讲！Anna Berghoff 介绍 Wolfgang Wick 关于胶质母细胞瘤、脑转移和 LMD 疾病：肿瘤护理的下一个前沿。\n#ESMO2026 #NeuroOncology\n@EANOassociation","2026-10-23T13:33:07.000Z","2026-10-23T14:56:35.000Z",[],{"_262":829,"_264":824,"_265":297,"_267":830,"_269":831},"n6holq2pr89lk3y1h7xb8lz4d","https://x.com/gminniti2012/status/2113624762496987434","gminniti2012","5cafafc1-c19d-4085-9868-50801fb9a9f8","Fantastic to see CNS oncology take centre stage with a keynote lecture at @myESMO meeting in Madrid",{"_270":845,"_246":846},"nct:NCT05048797","NCT05048797","🆙#ESMO26 快速口头报告 I：#LCSM 转移\n🔥DESTINY-Lung04 (DL-04)：一线 (1L) 曲妥珠单抗德鲁替康 (T-DXd) 用于 HER2 突变 (HER2m) NSCLC 患者 (Pts)：患者报告结局 (PROs)\n🎙️Silvia Novello 博士\n🔢LBA74\n🎯T-DXd 延缓咳嗽恶化时间 vs Pembro+化疗 (26.2 对 11.0 月，HR 0.66\n☑️NCT050487","2026-10-24T05:12:28.000Z","2026-10-24T07:11:42.000Z",[],{"_262":842,"_264":843,"_265":297,"_267":844,"_269":711},"q5brs8guvhtj3dy6wp5e57ism","🆙#ESMO26 快速口头报告 I：#LCSM 转移\n🔥DESTINY-Lung04 (DL-04)：一线 (1L) 曲妥珠单抗德鲁替康 (T-DXd) 用于 HER2 突变 (HER2m) NSCLC 患者 (Pts)：患者报告结局 (PROs)\n🎙️Silvia Novello 博士\n🔢LBA74\n🎯T-DXd 延缓咳嗽恶化时间 vs Pembro+化疗 (26.2 对 11.0 月，HR 0.66\n☑️NCT05048797\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2113861160042889431","d817a90f-ec84-4d97-aa05-a1e0a0705ee3","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥DESTINY-Lung04 (DL-04): First-Line (1L) Trastuzumab Deruxtecan (T-DX",{"_270":859,"_246":860},"tag:#metastaticbreastcancer","#METASTATICBREASTCANCER","BriaCell 将在 #ESMO26 大会上展示新的临床生物标志物研究结果，重点介绍 CAML PD-L1 作为 #metastaticbreastcancer 临床预后的潜在生物标志物。\n\n“我们对这些发现感到鼓舞，结果显示，循环免疫生物标志物的动态变化与接受免疫疗法的转移性乳腺癌患者的无进展生存期和总生存期相关，”BriaCell 总裁兼首席执行官 William V. Williams 博士表示。详情请见：https://bit","2026-10-23T11:55:18.000Z","2026-10-23T17:15:09.000Z",[],{"_262":855,"_264":856,"_265":297,"_267":857,"_269":858},"zzngmx2nhxrbfqu8go21w946d","BriaCell 将在 #ESMO26 大会上展示新的临床生物标志物研究结果，重点介绍 CAML PD-L1 作为 #metastaticbreastcancer 临床预后的潜在生物标志物。\n\n“我们对这些发现感到鼓舞，结果显示，循环免疫生物标志物的动态变化与接受免疫疗法的转移性乳腺癌患者的无进展生存期和总生存期相关，”BriaCell 总裁兼首席执行官 William V. Williams 博士表示。详情请见：https://bit.ly/4yGWuOd $BCTX $BCTXL","https://x.com/BriaCell/status/2113680638070944002","BriaCell","3462cb23-1f38-4c23-b7dd-c31a830b82d5","BriaCell announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with #metastaticbreastcanc",{"_270":876,"_246":877},"nct:NCT06341114","NCT06341114","🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤\n🔥一线 BAT8008（TROP2-ADC）联合 BAT1308（抗 PD-1）治疗晚期 NSCLC：多中心 2 期研究结果\n🎙️Shaodong Hong 博士\n🔢2631RO\n🎯总体：ORR 57.9%，DCR 89.5%，6 个月 PFS 64.8%\n🎯PD-L1 TPS≥50% 患者的 ORR 为 83%\n🎯仅 7.2% 出现≥3 级口腔炎，≥3 级 TRAE","2026-10-21T13:00:02.000Z","2026-10-24T07:39:04.000Z",[872],{"_262":869,"_264":870,"_265":297,"_267":871,"_269":711},"uxmad99z1obdb3ximfr0tq3c0","🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤\n🔥一线 BAT8008（TROP2-ADC）联合 BAT1308（抗 PD-1）治疗晚期 NSCLC：多中心 2 期研究结果\n🎙️Shaodong Hong 博士\n🔢2631RO\n🎯总体：ORR 57.9%，DCR 89.5%，6 个月 PFS 64.8%\n🎯PD-L1 TPS≥50% 患者的 ORR 为 83%\n🎯仅 7.2% 出现≥3 级口腔炎，≥3 级 TRAEs 为 38.1%\n☑️NCT06341114\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2113898053040267773",{"_382":863,"_17":393,"_246":873,"_386":874,"_388":-5,"_389":875,"_390":873},"- **标题 / Title：** A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","https://clinicaltrials.gov/study/NCT06341114",[863],"21881840-7fdd-45cb-b6e6-1729c80181d9","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced",{"_270":889,"_246":890},"tag:#idweek","#IDWEEK","@PeterHotez @celinegounder @IDWeekmtg 一个杰出的团队！抱歉我今年没能亲自参加 #IDWeek，但因为我还需要在另一大洲报道重叠的 #ESMO2026，在家工作最合适。","2026-10-24T04:58:45.000Z","2026-10-24T05:00:56.000Z",[],{"_262":886,"_264":881,"_265":297,"_267":887,"_269":888},"ng5tjwx4kapqmekvam4frpqdi","https://x.com/LizHighleyman/status/2113858256477307299","LizHighleyman","c26e3c64-5106-483b-ad15-3db1c38b724c","An illustrious group",{"_270":903,"_246":904},"tag:#sciencelink","#SCIENCELINK","#ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia\n\n在 ACTICCA-1（III 期；分析了 591 例患者）中，预设的限制平均无病生存期（SLE）分析显示，在已切除胆道癌的辅助治疗中，gemcitabina + cisplatino 优于 capecitabina。\n\n⏰ 中位随访时间：4.8 年\n\n⏳ 无病生存期（SLE）中位数：25.7 vs 17.9 个月\nlo","2026-10-24T17:49:23.000Z","2026-10-24T18:11:50.000Z",[],{"_262":899,"_264":900,"_265":297,"_267":901,"_269":902},"itbxi8bbi9qkx7ygerl8x379y","#ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia\n\n在 ACTICCA-1（III 期；分析了 591 例患者）中，预设的限制平均无病生存期（SLE）分析显示，在已切除胆道癌的辅助治疗中，gemcitabina + cisplatino 优于 capecitabina。\n\n⏰ 中位随访时间：4.8 年\n\n⏳ 无病生存期（SLE）中位数：25.7 vs 17.9 个月\nlog-rank 比较未达到统计学显著性（p=0.097）。\n\n📈 前 3 年的限制平均无病生存期（SLE）\n平均延长 2.6 个月（p=0.011）。\n鉴于治疗效应随时间变化，该分析已预先指定。\n\n📊 总生存期（SG）：58.1 vs 48.2 个月\nHR 0.82; p=0.103。差异无统计学意义。\n\n⚠️ gemcitabina + cisplatino 的毒性更高，主要是血液学毒性。\n\n这些结果尚不足以将 gemcitabina + cisplatino 确立为新的辅助治疗标准。\n\n🔗 阅读/收听完整报道：https://buff.ly/8CxPRn0","https://x.com/sciencelinkonco/status/2114057290638581926","sciencelinkonco","e3193f3b-1406-4df9-af9d-5a3a28d77759","#ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia #ScienceLink #Madrid2026 #ESMO26 #ACTICCA1 #Quimioterapia En ACTICCA-1 (fase III; ",{"_270":916,"_246":917},"nct:NCT03052608","NCT03052608","🆙#ESMO26 快速口头报告 I：#LCSM 转移性病例\n🔥CROWN：表征耐药机制及早期进展和长期应答的预测指标：CROWN 研究的循环肿瘤 DNA（ctDNA）分析\n🎙️ @bensolomon1\n🔢2636RO\n🎯未发现新的 ALK 同靶点耐药突变\n🎯旁路（RTK/RAS/MAPK）通路驱动耐药；早期进展者的基线基因组复杂性更高\n🎯治疗期间 TF 下降可预测更长的 PFS\n☑️NCT03052608\n🔗 http","2026-10-21T13:00:01.000Z","2026-10-24T07:18:34.000Z",[],{"_262":913,"_264":914,"_265":297,"_267":915,"_269":711},"eswk2efskxzvmvm48hi5a4f9r","🆙#ESMO26 快速口头报告 I：#LCSM 转移性病例\n🔥CROWN：表征耐药机制及早期进展和长期应答的预测指标：CROWN 研究的循环肿瘤 DNA（ctDNA）分析\n🎙️ @bensolomon1\n🔢2636RO\n🎯未发现新的 ALK 同靶点耐药突变\n🎯旁路（RTK/RAS/MAPK）通路驱动耐药；早期进展者的基线基因组复杂性更高\n🎯治疗期间 TF 下降可预测更长的 PFS\n☑️NCT03052608\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC @ALKpositiveINT","https://x.com/HHorinouchi/status/2113892891042922538","6bce8a7e-f3bc-4d21-88bd-547a725cc75b","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥CROWN: Characterizing Resistance Mechanisms and Predictors of Early ",{"_270":930,"_246":931},"tag:#practicechanging","#PRACTICECHANGING","🚀 ESMO Congress 2026，我们来了！\n等待结束了！#ESMO26 今天正式开幕！\n我十分高兴且深感荣幸，能成为 #ESMOAmbassadors 的一员，参与全球肿瘤学界最令人兴奋且最具影响力的活动之一。\n在未来几天里，科学将登上舞台中央，汇聚全球肿瘤学界，共同分享开创性研究、挑战现有标准，并塑造癌症诊疗的未来。\n🔬 我们会看到改变临床实践的数据吗？我相信我们会的，而且我迫不及待地去探索、讨论并批判性评估这些结果！\n","2026-10-23T04:42:01.000Z","2026-10-24T14:34:35.000Z",[],{"_262":926,"_264":927,"_265":297,"_267":928,"_269":929},"tubxc7azxxzgm4906h367e42z","🚀 ESMO Congress 2026，我们来了！\n等待结束了！#ESMO26 今天正式开幕！\n我十分高兴且深感荣幸，能成为 #ESMOAmbassadors 的一员，参与全球肿瘤学界最令人兴奋且最具影响力的活动之一。\n在未来几天里，科学将登上舞台中央，汇聚全球肿瘤学界，共同分享开创性研究、挑战现有标准，并塑造癌症诊疗的未来。\n🔬 我们会看到改变临床实践的数据吗？我相信我们会的，而且我迫不及待地去探索、讨论并批判性评估这些结果！\n📢 敬请期待！我将在整个大会期间分享精彩亮点、关键发现，以及我对最激动人心进展的看法。\n让我们以科学为引领，挑战证据，并不断拓展癌症诊疗的边界。\n让科学开始吧！🔬🌍\n#ESMO26 #Oncology #CancerResearch #ClinicalTrials #PracticeChanging","https://x.com/Alfdoc2/status/2113491107975688701","Alfdoc2","79c068e2-755d-470e-8d03-ad94d7c3eb23","🚀 ESMO Congress 2026 ,Here we go",{"_270":942,"_246":943},"nct:NCT04035486","NCT04035486","🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤\n🔥FLAURA2：EGFRm 晚期 NSCLC 患者（Pts）接受一线（1L）Osimertinib（Osi）± Platinum–Pemetrexed（Plat–Pem）治疗期间，血浆 EGFRm 动态变化及相关临床结局分析\n🎙️ @dplanchard\n🔢2719RO\n🎯EGFRm 清除具有预后意义，但不具有预测意义\n🎯无论第 1、2、3、6 周的清除状态如何，Os","2026-10-24T06:42:39.000Z",[],{"_262":939,"_264":940,"_265":297,"_267":941,"_269":711},"ggr7bx8g4wsnmw4uhx9jy73fk","🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤\n🔥FLAURA2：EGFRm 晚期 NSCLC 患者（Pts）接受一线（1L）Osimertinib（Osi）± Platinum–Pemetrexed（Plat–Pem）治疗期间，血浆 EGFRm 动态变化及相关临床结局分析\n🎙️ @dplanchard\n🔢2719RO\n🎯EGFRm 清除具有预后意义，但不具有预测意义\n🎯无论第 1、2、3、6 周的清除状态如何，Osi+Plat–Pem 相较于 Osi 单药的获益均一致；两组清除率相当\n☑️NCT04035486\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters","https://x.com/HHorinouchi/status/2112891655754076171","b23d84e6-2604-4103-a145-ae0c84211227","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associat",{"_270":955,"_246":956},"code:LBA68","LBA68","在接受过治疗的非鳞状非小细胞肺癌（NSCLC）中，Sigvotatug vedotin对比多西他赛：辉瑞于6月表示该3期试验未达到OS终点。我们的专家组成员Solange Peters（@peters_solange）将在#ESMO26上展示这一数据，LBA68，10月25日（周日）11:13，6号厅。日历文件：https://t.co/T7PqGHFhac 是否已列入您的关注清单？@myESMO","2026-10-18T11:01:45.000Z","2026-10-24T11:02:14.000Z",[],{"_262":952,"_264":947,"_265":297,"_267":953,"_269":954},"j8f0t5m218qhrcpme3x76jmq3","https://x.com/LungSummit/status/2111774732383048134","LungSummit","c34edc43-21b1-474d-9753-b64f0cf68f03","Sigvotatug vedotin vs docetaxel in pretreated nonsquamous NSCLC: Pfizer said in June the phase 3 missed its OS endpoint",{"_270":973,"_246":974},"code:EV-103","EV-103","#ESMO26 EV-103长期随访（最长7年）显示出非凡的持久性，7年时约30%的应答者仍维持在缓解状态\n\n下一步是通过生物标志物（Nectin4？）识别长期应答者，并优化治疗持续时间（ctDNA？）\n\n@OncoAlert","2026-10-24T09:20:27.000Z","2026-10-24T09:25:33.000Z",[968],{"_262":965,"_264":960,"_265":297,"_267":966,"_269":967},"s04n6alwi1qozdl3e4hrynfjl","https://x.com/scocmem/status/2113924850758603027","scocmem",{"_382":969,"_17":393,"_246":970,"_386":971,"_388":-5,"_389":-5,"_390":972},"4740RO","Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/261","Rapid oral 1: Genitourinary tumours, renal and urothelial","77760006-8973-4b2c-8016-6d3752b7e5ad","#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years #ESMO26 ",{"_270":986,"_246":987},"tag:#oaonthego","#OAONTHEGO","🎬来自 #ESMO26 的全新 #OAOnTheGo 🇪🇸 \n我们的 #OncoAlertAF 同事 Dr\n@MarioBalsaMD 🇪🇸 探讨如何治疗不符合临床试验入组条件的 #melanoma 患者 👇 @OncoAlert","2026-10-24T10:34:56.000Z","2026-10-24T10:35:23.000Z",[],{"_262":983,"_264":978,"_265":297,"_267":984,"_269":985},"so54qoja2241tz1w2wb42ivby","https://x.com/JankovicK/status/2113942308450136298","JankovicK","ea321ca2-8682-4cef-936a-c135765fd167","🎬New #OAOnTheGo from #ESMO26 🇪🇸 🎬New #OAOnTheGo from #ESMO26 🇪🇸 Our #OncoAlertAF collegue Dr @MarioBalsaMD 🇪🇸 on treating #melanoma ",{"_270":1000,"_246":1001},"code:KEYNOTE-091","KEYNOTE-091","OncoAlert 4Sight 摘要将在 #ESMO26 发布\n辅助用帕博利珠单抗治疗切除后早期非小细胞肺癌 (NSCLC) 的最终分析：PEARLS/KEYNOTE-091 Ⅲ 期研究\n\n @LuisPaz_Ares\n @AlxMtzMarti\n @BenjaminBesseMD\n @peters_solange \n\n 🫁 Ⅲ 期 (n=1177)：切除后 IB–IIIA 期 NSCLC 中辅助帕博利珠单抗对照安慰剂。最终分析；中","2026-10-23T08:00:05.000Z","2026-10-23T08:59:19.000Z",[],{"_262":996,"_264":997,"_265":297,"_267":998,"_269":999},"c3ywl19zsrkf40kwfv1fab2by","OncoAlert 4Sight 摘要将在 #ESMO26 发布\n辅助用帕博利珠单抗治疗切除后早期非小细胞肺癌 (NSCLC) 的最终分析：PEARLS/KEYNOTE-091 Ⅲ 期研究\n\n @LuisPaz_Ares\n @AlxMtzMarti\n @BenjaminBesseMD\n @peters_solange \n\n 🫁 Ⅲ 期 (n=1177)：切除后 IB–IIIA 期 NSCLC 中辅助帕博利珠单抗对照安慰剂。最终分析；中位随访 87.7 个月。\n ➡️ DFS HR 0.85 (0.73–0.98)；中位 58.7 对 43.3 个月\n ➡️ OS HR 0.98 (0.81–1.18)；6 年 OS 68.5% 对 66.4%\n ➡️ LCSS HR 0.81 (0.63–1.03)；≥3 级不良事件 34.0% 对 25.6%\n ✅ DFS 获益一致，LCSS 呈有利趋势且安全性可控；OS 未显著改善，且研究未为 OS 设计统计效力。\n\n 🎙️ Mary O’Brien\n 👥 Luis Paz-Ares · Sandrine Marreaud · Urania Dafni · Kersti Oselin · Libor Havel · Emilio Esteban · Dolores Isla · Alex Martinez-Marti · Martin Faehling · Masahiro Tsuboi · Jong-Seok Lee · Kazuhiko Nakagawa · Jing Yang · Ayman Samkari · Steven Keller · Murielle Mauer · Nitish Jha · Rolf Stahel · Benjamin Besse · Solange Peters \n\n(4Sight 基于 ESMO 网站公开的摘要制作)\n\nPinging our faculty\n@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD \n\n@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers","https://x.com/OncoAlert/status/2113540950865608795","OncoAlert","7d1a3fb0-fec4-4d18-9adf-0ed65942757d","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Final Analysis of Adjuvant Pembr",{"_270":1014,"_246":1015},"tag:#medicaleducation","#MEDICALEDUCATION","🚨 #ESMO26 来了 — @OncoAlert PULSE Faculty 也来了。🇪🇸\n\n很荣幸能成为这个国际团队的一员，现场从马德里报道，并帮助将海量的会议数据转化为同事真正需要的内容：\n\n📊 可能改变实践的试验\n🧬 改变我们思维的生物学\n🎯 标题背后的临床问题\n💬 来自各肿瘤类型的专家视角\n\n无论你身在马德里还是在家关注，目标很简单：\n\n少噪音。多背景。更有用的科学。\n\n一如既往地与 @OncoAlert 同行：","2026-10-22T17:30:14.000Z","2026-10-23T08:57:31.000Z",[],{"_262":1010,"_264":1011,"_265":297,"_267":1012,"_269":1013},"uld8kpx7niyb5vgtruo3mk4tv","🚨 #ESMO26 来了 — @OncoAlert PULSE Faculty 也来了。🇪🇸\n\n很荣幸能成为这个国际团队的一员，现场从马德里报道，并帮助将海量的会议数据转化为同事真正需要的内容：\n\n📊 可能改变实践的试验\n🧬 改变我们思维的生物学\n🎯 标题背后的临床问题\n💬 来自各肿瘤类型的专家视角\n\n无论你身在马德里还是在家关注，目标很简单：\n\n少噪音。多背景。更有用的科学。\n\n一如既往地与 @OncoAlert 同行：\n\n由同事，为同事。\n\n期待与这支杰出的师资团队分享最相关的 #ESMO26 更新：\n\n@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists\n\n#OncoAlert #ESMO26 #Oncology #MedicalEducation #CancerResearch","https://x.com/nataliagandur/status/2113555406261793040","nataliagandur","aad71156-584e-4c91-a8e1-3a26411b32e7","🚨 #ESMO26 is here — and so is the @OncoAlert PULSE Faculty",{"_270":1028,"_246":1029},"code:LBA21","LBA21","⚡ ACTICCA-1 III期：胆道癌中辅助治疗 Gemcitabine 联合 Cisplatin 与 Capecitabine 的比较\n\n在 #ESMO26 上，Henning Weige 介绍了 III期 ACTICCA-1 试验（LBA21）的结果。该试验评估了胆道癌患者接受以治愈为目的的切除术后，辅助治疗 Gemcitabine 联合 Cisplatin 与 Capecitabine 的疗效。\n\n主要结果：\n👉 中位DFS：","2026-10-24T10:41:52.000Z","2026-10-24T14:26:21.000Z",[],{"_262":1024,"_264":1025,"_265":297,"_267":1026,"_269":1027},"fha9hca60uwoaedmo35unbmme","⚡ ACTICCA-1 III期：胆道癌中辅助治疗 Gemcitabine 联合 Cisplatin 与 Capecitabine 的比较\n\n在 #ESMO26 上，Henning Weige 介绍了 III期 ACTICCA-1 试验（LBA21）的结果。该试验评估了胆道癌患者接受以治愈为目的的切除术后，辅助治疗 Gemcitabine 联合 Cisplatin 与 Capecitabine 的疗效。\n\n主要结果：\n👉 中位DFS：25.7 vs 17.9个月（HR 0.82；95% CI 0.67–1.01；log-rank p=0.097）。\n👉 预设的RMST分析：Gemcitabine 联合 Cisplatin 在三年内可额外延长DFS 2.6个月（95% CI 0.6–4.68；p=0.011）。\n👉 中位OS：58.1 vs 48.2个月（HR 0.82；p=0.103）。\n👉 安全性：Gemcitabine 联合 Cisplatin 与毒性增加相关，主要为血液学毒性。\n\n结论：预设的RMST分析支持 Gemcitabine 联合 Cisplatin，但log-rank DFS比较和总生存期分析均未显示出具有统计学意义的改善。\n\n@oncodaily @myESMO\n\nhttps://oncodaily.com/gastrointestinal-oncology/acticca-1\n\n#ESMO26 #ESMO2026 #ACTICCA1 #OncoDaily","https://x.com/OncoDailyGI/status/2113944056074043455","OncoDailyGI","d45c11dc-c013-49a4-bbcc-9b1302e79c84","⚡ Phase III ACTICCA-1: Adjuvant Gemcitabine Plus Cisplatin Versus Capecitabine in Biliary Tract Cancer ⚡ Phase III ACTICCA-1: Adjuvant Gemci",{"_270":1041,"_246":1042},"tag:#vacuna","#VACUNA","#ESMO26 | 📌 首次成功：一种个性化 #vacuna 采用 #ARNm 针对 #cáncer。\n\n👉数据显示，针对高风险 #melanoma，复发或死亡风险降低 42%，根据 @myESMO 的数据\n\n https://www.diariomedico.com/medicina/oncologia/primer-exito-fase-iii-vacuna-personalizada-arnm-cancer.html?utm_","2026-10-23T10:52:16.000Z","2026-10-23T19:50:50.000Z",[],{"_262":1038,"_264":1039,"_265":297,"_267":1040,"_269":544},"r0jt789ctl33j0esrdyvrgqrq","#ESMO26 | 📌 首次成功：一种个性化 #vacuna 采用 #ARNm 针对 #cáncer。\n\n👉数据显示，针对高风险 #melanoma，复发或死亡风险降低 42%，根据 @myESMO 的数据\n\n https://www.diariomedico.com/medicina/oncologia/primer-exito-fase-iii-vacuna-personalizada-arnm-cancer.html?utm_medium=Social&utm_source=Twitter#Echobox=1792749241","https://x.com/diariomedico/status/2113584282669105437","06e4fa3c-2b6d-4f85-9031-be488a2da7ee","#ESMO26 | 📌 Primer éxito de con una #vacuna personalizada de #ARNm para #cáncer",{"_270":1055,"_246":1056},"code:LBA31","LBA31","#ESMO26 | LBA31\nPRABITAS：务实的 III 期双周 FTD/TPI + bev 与常规 FTD/TPI + bev 在 mCRC 中的对比（非劣效性）\n▪️OS：11.3 对 10.3 月，HR 0.93，95% CI 0.80-1.08 (<1.25)\n▪️PFS：3.9 对 3.9 月，HR 0.93，95% CI 0.81-1.06\n▪️安全性\n- ≥G3 中性粒细胞减少：13% 对 39%\n- FN：1% ","2026-10-24T05:04:20.000Z","2026-10-24T14:03:01.000Z",[],{"_262":1051,"_264":1052,"_265":297,"_267":1053,"_269":1054},"yrocd9a268xq2uh0cg60zzhon","#ESMO26 | LBA31\nPRABITAS：务实的 III 期双周 FTD/TPI + bev 与常规 FTD/TPI + bev 在 mCRC 中的对比（非劣效性）\n▪️OS：11.3 对 10.3 月，HR 0.93，95% CI 0.80-1.08 (<1.25)\n▪️PFS：3.9 对 3.9 月，HR 0.93，95% CI 0.81-1.06\n▪️安全性\n- ≥G3 中性粒细胞减少：13% 对 39%\n- FN：1% 对 5%\n- ≥G2 厌食：15% 对 26%\n👉双周 FTD/TPI + bev 显示非劣效 OS 且毒性更低！\n@myESMO @OncoAlert","https://x.com/DaisukeKotani/status/2113859113499169206","DaisukeKotani","67152a8c-4cf9-47bb-821a-470f78f87de7","#ESMO26 | LBA31 #ESMO26 | LBA31 PRABITAS: Pragmatic Ph3 biweekly FTD/TPI + bev vs conventional FTD/TPI + bev in mCRC (non-inferiority) ▪️OS:",{"_270":1076,"_246":1077},"tag:#tnbc","#TNBC","B-STRONGER-I 中令人印象深刻的 ctDNA 动态！\n\nI–III 期 TNBC 的基线检出率为 95.1%。\n至 C3D1：80.8% 清除，ctDNA 水平中位数下降 99.8%。\n\n在手术前即可窥见早期治疗反应的显著窗口。\n\n#ESMO26 #TNBC #ctDNA @Larvol @OncoAlert","2026-10-23T20:05:09.000Z","2026-10-24T13:03:04.000Z",[1068,1069],{"_262":1065,"_264":1060,"_265":297,"_267":1066,"_269":1067},"wv5r79gfl2qo2vrn9h82t7zi6","https://x.com/Dr_ElvinaA/status/2113723420001149266","Dr_ElvinaA",{"_382":1074,"_17":384,"_246":1075,"_386":1072,"_388":-5,"_389":-5,"_390":1073},{"_382":1070,"_17":384,"_246":1071,"_386":1072,"_388":-5,"_389":-5,"_390":1073},"LBA96","First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts ","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/254","Proffered paper 2: Breast cancer, early and advanced stage","LBA26","Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial","6f9c97b5-b309-4e8b-888b-0bfaef07235e","Impressive ctDNA dynamics in B-STRONGER-I",{"_270":1088,"_246":1089},"tag:#insightsbyesmo","#INSIGHTSBYESMO","#ESMO26 转化研究奖表彰 @landau_lab 通过创新的基因组学与计算领域 #research 推进我们对 #cancer 演化的理解所作出的开创性贡献。\n了解更多：https://ow.ly/OEiq50ZZjCI\n\n #InsightsbyESMO","2026-10-23T12:30:14.000Z","2026-10-24T06:50:04.000Z",[],{"_262":1086,"_264":1081,"_265":297,"_267":1087,"_269":512},"i543zo3tq9yuigk47ihc4w9s8","https://x.com/myESMO/status/2113608938377687074","e03dc6d5-c14e-4cb1-9893-21619d8264f3","The #ESMO26 Award for Translational Research recognises @landau_lab pioneering contributions to advancing our understanding of #cancer evolu",{"_270":1101,"_246":1102},"tag:#escatv2","#ESCATV2","在马德里举行的 #ESMO26 之前推出 @myESMO #ESCATv2，时机再合适不过了。感谢 @AyaHelali 和 @BenWestphalen 的领导，以及其他共同作者（太多啦，名字都列不完！😁）共同完成这份重要文件，推动 #precisiononcology 领域向前发展！\n\n@apoddc @APCLC_2023 @CUHKMedicine @hkumed #ESMOAmbassadors","2026-10-22T08:45:51.000Z","2026-10-24T13:04:22.000Z",[],{"_262":1098,"_264":1093,"_265":297,"_267":1099,"_269":1100},"cr0k7tp9wfeqcveswqeqd1c9e","https://x.com/herbloong/status/2113190082240725243","herbloong","ce91cea0-7a8d-4864-b38c-b8b89b6c1a58","Excellent timing for the launch of @myESMO #ESCATv2 ahead of #ESMO26 in Madrid 🇪🇸",{"_270":1113,"_246":1114},"tag:#tropionbreast02","#TROPIONBREAST02","Dato-DXd 的 CNS 活性令人期待！\n#TROPIONBreast02：在 61 例 mTNBC 伴无症状脑转移的患者中，中位 CNS PFS 为 9.5 个月，对比化疗的 2.6 个月（HR 0.27）。\n纳入了既往未接受 CNS 针对性治疗的患者——这是一项关键优势。\n#ESMO26 #BCSM @Larvol @OncoAlert","2026-10-24T07:42:36.000Z","2026-10-24T09:24:06.000Z",[],{"_262":1111,"_264":1106,"_265":297,"_267":1112,"_269":1067},"wstz23xcpcvcsrzij7pq5mm3x","https://x.com/Dr_ElvinaA/status/2113898941406122355","5e674de3-61e3-4752-979b-401a6b1628fa","Promising CNS activity with Dato-DXd",{"_270":1127,"_246":1128},"tag:#tumoredellaprostata","#TUMOREDELLAPROSTATA","#Tumoredellaprostata复发风险较高：darolutamide联合ADT和放射治疗可将转移或死亡风险降低58%。\n\n来自#ESMO26的数据：https://www.medinews.it/comunicati/tumore-della-prostata-ad-alto-rischio-di-recidiva-darolutamide-piu-adt-e-radioterapia-riduce-il-rischio-di","2026-10-24T07:32:10.000Z","2026-10-24T07:33:20.000Z",[],{"_262":1123,"_264":1124,"_265":297,"_267":1125,"_269":1126},"rx2r84tut6b2ujvcd8pv4rqji","#Tumoredellaprostata复发风险较高：darolutamide联合ADT和放射治疗可将转移或死亡风险降低58%。\n\n来自#ESMO26的数据：https://www.medinews.it/comunicati/tumore-della-prostata-ad-alto-rischio-di-recidiva-darolutamide-piu-adt-e-radioterapia-riduce-il-rischio-di-metastasi-o-di-morte-del-58/\n\n@myESMO","https://x.com/Medinews_/status/2113896314387972230","Medinews_","901861f7-558f-4053-9fb9-4a5c401ae0dd","#Tumoredellaprostata, ad #ESMO26 presentati i nuovi dati late-breaking dello studio di Fase III DASL-HiCa",{"_270":1180,"_246":1181},"tag:#ctdna","#CTDNA","TALAPRO-3 研究中来自 @AzadOncology 在 #ESMO26 的 ctDNA 肿瘤分数 🧬 在 HRR 缺陷的 mCSPC 中，基线 ctDNA 阳性（TF ≥1%）在两组中均对 rPFS 具有预后意义。第 5 周也很重要：82% 的 ctDNA 阳性患者在 TALA + ENZA 组清除，而 PBO + ENZA 组为 68%，且清除与更长的 rPFS 相关（HR 0.36 对比持续 ctDNA 阳性）。早期治疗中","2026-10-22T14:30:12.000Z","2026-10-23T12:21:37.000Z",[1141,1142,1143,1144,1145,1146,1147,1148],{"_262":1137,"_264":1138,"_265":297,"_267":1139,"_269":1140},"etyn2bpul91ne1zykpzc24lvy","TALAPRO-3 研究中来自 @AzadOncology 在 #ESMO26 的 ctDNA 肿瘤分数 🧬 在 HRR 缺陷的 mCSPC 中，基线 ctDNA 阳性（TF ≥1%）在两组中均对 rPFS 具有预后意义。第 5 周也很重要：82% 的 ctDNA 阳性患者在 TALA + ENZA 组清除，而 PBO + ENZA 组为 68%，且清除与更长的 rPFS 相关（HR 0.36 对比持续 ctDNA 阳性）。早期治疗中 ctDNA 可能成为风险分层和监测的真实工具。接下来要看它是否在 PSA 之外增加价值。#MRD #ctDNA #ProstateCancer","https://x.com/alantanmd/status/2113606769515626599","alantanmd",{"_382":1177,"_17":393,"_246":1178,"_386":1173,"_388":-5,"_389":1179,"_390":1175},{"_382":1171,"_17":393,"_246":1172,"_386":1173,"_388":-5,"_389":1174,"_390":1175},{"_382":1167,"_17":393,"_246":1168,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1164,"_17":393,"_246":1165,"_386":395,"_388":-5,"_389":-5,"_390":1166},{"_382":1160,"_17":393,"_246":1161,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":1158,"_17":393,"_246":1159,"_386":1156,"_388":-5,"_389":-5,"_390":1157},{"_382":1154,"_17":393,"_246":1155,"_386":1156,"_388":-5,"_389":-5,"_390":1157},{"_382":1149,"_17":393,"_246":1150,"_386":395,"_388":-5,"_389":1151,"_390":1152},"806P","Extended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer",[1153,1153,1153],"Colon cancer","NCT04787341","542RO","Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/248","Rapid oral: Breast cancer, early stage","540RO","Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study","4734O","ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/242","Proffered paper 1: Genitourinary tumour, renal and urothelial","4260P","Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors","Translational research and biomarkers","2636RO","Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255","Rapid oral 1: NSCLC, metastatic","2220RO","Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/243",[1176],"Rapid oral: Genitourinary tumours, prostate, penile and testis","NCT04746300","2219RO","Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta",[1176],"b6b5c4e3-3305-4d45-886f-703068bb9ed5","ctDNA tumor fraction in TALAPRO-3 from @AzadOncology at #ESMO26 🧬 In HRR-deficient mCSPC, baseline ctDNA+ (TF ≥1%) was prognostic for rPFS ",{"_270":1193,"_246":1194},"drug:zidesamtinib","zidesamtinib","🎥 #ESMO26 新内容 🚨#Podium2Screen\n| Dr. @alexdrilon 🇺🇸 来自 @MSKCancerCenter 为我们解读 ARROS-1，该研究在首尔 🇰🇷 的 #WCLC26 总统研讨会上发表\n\nZidesamtinib 用于 TKI 未治疗的 ROS1+ #NSCLC \n🎯 ORR 94%（88/94），CR 15%\n⏳ 86% 的缓解在 12 个月时持久\n🧠 颅内 ORR 100%（","2026-10-23T10:59:48.000Z","2026-10-23T14:13:11.000Z",[],{"_262":1190,"_264":1191,"_265":297,"_267":1192,"_269":999},"rzqmcfsdxv2fhjfz3gu0vuyeb","🎥 #ESMO26 新内容 🚨#Podium2Screen\n| Dr. @alexdrilon 🇺🇸 来自 @MSKCancerCenter 为我们解读 ARROS-1，该研究在首尔 🇰🇷 的 #WCLC26 总统研讨会上发表\n\nZidesamtinib 用于 TKI 未治疗的 ROS1+ #NSCLC \n🎯 ORR 94%（88/94），CR 15%\n⏳ 86% 的缓解在 12 个月时持久\n🧠 颅内 ORR 100%（10/10），iCR 70%\n✅ 剂量减少和停药率低\n\nROS1+ 肺癌是否将迎来新的一线选择？👇 观看完整解读\n#LCSM #ROS1 #LungCancer \n\n@bensolomon1, @DrSanjayPopat, @EnriquetaFelip, @alexdrilon, @BenjaminBesseMD, @dwightowenmd, @ramon_yarza, @AkamatsuHiroaki, @marinagarassino \n\n@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @JordiRemon @JulienMazieres @TerriConneran @HenningWillers","https://x.com/OncoAlert/status/2113586180746858745","0f9d53b8-56c6-486a-af53-9d5dd5221067","🎥 NEW for #ESMO26 🚨#Podium2Screen 🎥 NEW for #ESMO26 🚨#Podium2Screen | Dr",{"_270":1218,"_246":1219},"drug:pertuzumab","pertuzumab","DB09では、T-DXd+pertuzumabに内分泌療法の維持療法をした方が13%程度いました。一部は、T-DXd+pertuzumab+内分泌療法だったのかもしれません。でも、この内分泌療法の上乗せ効果は、前向き試験では示されていません。今のところは患者さんにお勧めはし難い気持ち。 #ESMO26","2026-10-23T13:34:08.000Z","2026-10-24T11:53:46.000Z",[1206,1207,1208],{"_262":1203,"_264":1198,"_265":266,"_267":1204,"_269":1205},"y6krf1d5mwa3y274jswm1kw9y","https://x.com/shimoi_oncology/status/2113625017154187390","shimoi_oncology",{"_382":1214,"_17":393,"_246":1215,"_386":1216,"_388":-5,"_389":-5,"_390":1217},{"_382":1211,"_17":393,"_246":1212,"_386":395,"_388":-5,"_389":-5,"_390":1213},{"_382":1209,"_17":393,"_246":1210,"_386":1156,"_388":-5,"_389":-5,"_390":1157},"543RO","DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (","1780P","Safety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study","HER2+ breast cancer","1766RO","Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/259","Rapid oral 1: Breast cancer, advanced stage","a3b3a3b4-b85a-4b09-86ff-fca5b0a09852","DB09では、T-DXd+pertuzumabに内分泌療法の維持療法をした方が13%程度いました。一部は、T-DXd+pertuzumab+内分泌療法だったのかもしれません。 DB09では、T-DXd+pertuzumabに内分泌療法の維持療法をした方が13%程度いました。一部は",{"_270":1232,"_246":1233},"tag:#cancervaccines","#CANCERVACCINES","当肿瘤学界齐聚马德里参加 #ESMO26 之际，一项黑色素瘤三期试验的新结果让个性化 mRNA 癌症疫苗成为焦点。\n\nMerck 和 Moderna 报告称，与单独使用免疫疗法相比，在免疫疗法的基础上加用一种实验性 mRNA 疫苗，可使黑色素瘤复发或死亡的风险降低 42%。纪念斯隆凯特琳癌症中心（MSK）是参与该试验的机构之一。\n\n在 Hertz 夏季研讨会上，我们采访了 2024 年 Hertz Fellow David Hoyos。","2026-10-23T13:42:08.000Z","2026-10-24T20:53:04.000Z",[],{"_262":1228,"_264":1229,"_265":297,"_267":1230,"_269":1231},"s8i5xfz4qzq80jek7yaedwln9","当肿瘤学界齐聚马德里参加 #ESMO26 之际，一项黑色素瘤三期试验的新结果让个性化 mRNA 癌症疫苗成为焦点。\n\nMerck 和 Moderna 报告称，与单独使用免疫疗法相比，在免疫疗法的基础上加用一种实验性 mRNA 疫苗，可使黑色素瘤复发或死亡的风险降低 42%。纪念斯隆凯特琳癌症中心（MSK）是参与该试验的机构之一。\n\n在 Hertz 夏季研讨会上，我们采访了 2024 年 Hertz Fellow David Hoyos。他是 MSK Benjamin Greenbaum Lab 的研究员，谈到了 mRNA 技术如何推动下一代癌症疫苗的发展。\n\nHoyos 正在研究如何教会免疫系统识别突变型 p53——一种与许多癌症相关的蛋白。他的研究重点是利弗劳梅尼综合征，这是一种遗传性疾病，会大幅增加患多种癌症的风险，包括乳腺癌。\n\n在癌症疫苗试验探索治疗癌症或预防癌症复发的方法之际，Hoyos 正在研究 mRNA 疫苗能否在未来的某一天帮助预防或延缓利弗劳梅尼综合征女性的乳腺癌。他还希望，这项研究能揭示如何训练免疫系统在更广泛的癌症中靶向突变型 p53。\n\n#CancerVaccines #CancerResearch #breastcancer","https://x.com/HertzFoundation/status/2114097866645917717","HertzFoundation","90e445a5-8209-4a04-8d34-34554193af6e","Did we find the answer",{"_270":1277,"_246":1278},"tag:#cancers","#CANCERS","👋 我们将参加 #ESMO26！\n超过 10 年来，#oncology 一直是我们的首要任务 — 近 70% 的研发预算用于推进癌症研究。如今，我们的管线包含 36 个项目，重点关注罕见 #cancers。\n请到 8064 号展位 🏢 与我们会面，并参加我们的专题研讨会以了解更多。\n了解我们对肿瘤学的承诺 🔗 https://f.mtr.cool/j3236wrjk8\n#CancerResearch #patient @myESM","2026-10-21T14:16:27.000Z","2026-10-23T15:20:35.000Z",[1246,1247,1248,1249,1250,1251,1252,1253],{"_262":1242,"_264":1243,"_265":297,"_267":1244,"_269":1245},"yg1b3mi3ofijazokkmykovaod","👋 我们将参加 #ESMO26！\n超过 10 年来，#oncology 一直是我们的首要任务 — 近 70% 的研发预算用于推进癌症研究。如今，我们的管线包含 36 个项目，重点关注罕见 #cancers。\n请到 8064 号展位 🏢 与我们会面，并参加我们的专题研讨会以了解更多。\n了解我们对肿瘤学的承诺 🔗 https://f.mtr.cool/j3236wrjk8\n#CancerResearch #patient @myESMO","https://x.com/Servier/status/2113651807893201128","Servier",{"_382":1275,"_17":393,"_246":1276,"_386":1256,"_388":-5,"_389":-5,"_390":1257},{"_382":1273,"_17":393,"_246":1274,"_386":1256,"_388":-5,"_389":-5,"_390":1257},{"_382":1269,"_17":393,"_246":1270,"_386":395,"_388":-5,"_389":1271,"_390":628},{"_382":626,"_17":393,"_246":627,"_386":395,"_388":-5,"_389":-5,"_390":628},{"_382":1265,"_17":393,"_246":1266,"_386":395,"_388":-5,"_389":1267,"_390":628},{"_382":1261,"_17":393,"_246":1262,"_386":1263,"_388":-5,"_389":-5,"_390":1264},{"_382":1258,"_17":393,"_246":1259,"_386":395,"_388":-5,"_389":-5,"_390":1260},{"_382":1254,"_17":384,"_246":1255,"_386":1256,"_388":-5,"_389":-5,"_390":1257},"LBA36","Clinical utility of circulating tumor DNA (ctDNA) for participants with resected, high-risk dMMR endometrial cancer (EC) receiving adjuvant treatment: Results from the ENGOT-en11/GOG-3053/KEYNOTE-B21 study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/264","Proffered paper: Gynaecological cancers","1844P","Gene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers","HR+ breast cancer","170O","RADIANT: A radiotherapy foundation model for treatment planning and outcome prediction across cancers","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/262","Proffered paper: AI and digital health","1331P","Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Updated results from the phase 2 dose-optimization part of REJOICE-Ovarian01",[1268,1268,1268],"NCT06161025","1259P","Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)",[1272,1272,1272],"NCT05642780","1240O","Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase","1239O","NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer","e628b496-28cb-43e8-b3a1-a85eca7926f3","🔹 Gustave Roussy au congrès de l’#ESMO26 🔹 🔹 Gustave Roussy au congrès de l’#ESMO26 🔹 @myESMO tient son congrès annuel du 23 au 27 octob",{"_270":1290,"_246":1291},"code:LBA82","LBA82","#LBA82 亚组分析 RASolute 302 #PDAC \n➡️各亚型的 OS HR 为 0.32-0.46\n➡️G12R 0.61（0.29-1.30）\n➡️RAS WT 样本量较少（3%），但仍有 OS 获益！\n🤔或许 ORR 和 mPFS 在这些人群中的改善不那么明显！\n✅标准二线治疗\n@myESMO #ESMO26 @OncoAlert","2026-10-23T12:48:34.000Z","2026-10-23T17:53:38.000Z",[],{"_262":1287,"_264":1282,"_265":297,"_267":1288,"_269":1289},"ps2tkwknvu7ndsiz9jz4l2ojq","https://x.com/graokane/status/2113613553173402101","graokane","42c77921-439f-4201-badf-107bab273bf0","#LBA82 subgroup analysis RASolute 302 #PDAC #LBA82 subgroup analysis RASolute 302 #PDAC ➡️HR for OS across subtypes 0",{"_270":1302,"_246":1303},"drug:avelumab","avelumab","自豪地分享我们在 #ESMO26 @BartsECMC 的 DISCUS 探索性分析 \n- 34% 的患者从未接受 avelumab\n- 3C 与 6C 对比增加了转换率（74% 对 57%），且 PD/死亡事件更少\n- QoL 在 ICI 治疗期间保持稳定，基线 PS 是唯一的区分因素 @OncoAlert","2026-10-23T15:57:57.000Z","2026-10-23T22:19:17.000Z",[],{"_262":1300,"_264":1295,"_265":297,"_267":1301,"_269":967},"qedqs66mgwlr87m6lcwhjvocw","https://x.com/scocmem/status/2113757176804307246","be15e2d8-cac5-44e7-8f90-6457a5e58e6b","Proud to share our exploratory analysis from DISCUS at #ESMO26 @BartsECMC Proud to share our exploratory analysis from DISCUS at #ESMO26 @Ba",{"_270":1321,"_246":1322},"drug:cabazitaxel","cabazitaxel","#ESMO26：PROFIT 真实世界研究：西班牙 mCRPC 中 Ra-223 的用药序贯（n=224）\n\n🔹 59% 在 mPC 前 2 线治疗中接受 Ra-223；41% 在 ≥3L 治疗中接受\n🔹 较早使用 Ra-223 与更长的 OS 相关：12.4 vs 9.3 mo（p=0.024）\n🔹 ≥5 次注射与更长的 OS 密切相关：14.1 vs 7.1 mo（p<0.001）\n🔹 62.5% 完成 5–6 次注射\n🔹","2026-10-24T10:01:40.000Z","2026-10-24T17:39:31.000Z",[1316],{"_262":1312,"_264":1313,"_265":297,"_267":1314,"_269":1315},"uopud9y48blskisq3b9vz30d2","#ESMO26：PROFIT 真实世界研究：西班牙 mCRPC 中 Ra-223 的用药序贯（n=224）\n\n🔹 59% 在 mPC 前 2 线治疗中接受 Ra-223；41% 在 ≥3L 治疗中接受\n🔹 较早使用 Ra-223 与更长的 OS 相关：12.4 vs 9.3 mo（p=0.024）\n🔹 ≥5 次注射与更长的 OS 密切相关：14.1 vs 7.1 mo（p<0.001）\n🔹 62.5% 完成 5–6 次注射\n🔹 48.7% 随后接受 mCRPC 治疗；最常见的是 cabazitaxel 或 docetaxel\n🔑 在常规诊疗中，较早纳入 Ra-223 并持续治疗与生存改善相关。\n@urotoday","https://x.com/RKSayyid/status/2114049158000840746","RKSayyid",{"_382":1317,"_17":393,"_246":1318,"_386":395,"_388":-5,"_389":1319,"_390":484},"2300TIP","BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer",[1320,1320,1320],"NCT07365995","6aa9ffed-e309-4e09-9e82-6685531ba040","#ESMO26: PROFIT real-world study of Ra-223 sequencing in mCRPC in Spain (n=224) #ESMO26: PROFIT real-world study of Ra-223 sequencing in mCR",{"_270":1337,"_246":1338},"drug:bemarituzumab","bemarituzumab","#ESMO26 🧬 FORTITUDE-101/102 | FGFR2\n\n🔎 FGFR2b+ GC/GEJ 的探索性生物标志物分析\n\n🧪 FGFR2 扩增：约 16–19%\n\n📈 若扩增，Bemarituzumab OS 信号：\n🔹 F101: HR 0.50\n🔹 F102: HR 0.67\n\n💡 FGFR2 扩增能否指导患者选择？\n\n@OncoAlert","2026-10-23T15:33:34.000Z","2026-10-23T15:33:36.000Z",[1334],{"_262":1331,"_264":1326,"_265":297,"_267":1332,"_269":1333},"ema4hsay3euzdhr3gs7ikc0vw","https://x.com/DraMartinezLago/status/2113655077592256622","DraMartinezLago",{"_382":1335,"_17":393,"_246":1336,"_386":387,"_388":-5,"_389":-5,"_390":391},"2883RO","Efficacy of bemarituzumab in patients with advanced gastric and gastroesophageal junction cancer (GC/GEJ) by FGFR2 amplification status: Exploratory biomarker analysis from FORTITUDE-101 (F101) and FORTITUDE-102 (F102)","97862025-d0af-42b4-86c4-236987115d57","#ESMO26 🧬 FORTITUDE-101/102 | FGFR2 #ESMO26 🧬 FORTITUDE-101/102 | FGFR2 🔎 Exploratory biomarker analysis in FGFR2b+ GC/GEJ 🧪 FGFR2 ampli",{"_270":1352,"_246":1353},"drug:bemotrizumab","bemotrizumab","#ESMO26 🧬 TQB2102 | 第II期\n\n👥 86 例 | 一线 HER2+ GC/GEJ\n💊 HER2 ADC + bemotrizumab ± capecitabine\n\n🎯 ORR:\n• 双药组: 69.6%\n• 三药组: 84.2% (6 mg/kg 时 95.8%)\n\n📈 mPFS: 12.68 对比 11.04 个月\n⏳ OS 数据不成熟\n\n🔎 活性令人期待；仍需随机对照验证。\n\n@OncoAlert","2026-10-23T14:32:36.000Z","2026-10-23T14:34:01.000Z",[1349],{"_262":1347,"_264":1342,"_265":297,"_267":1348,"_269":1333},"k1gea0lz7jiu49jgbabpevxke","https://x.com/DraMartinezLago/status/2113640091021156458",{"_382":1350,"_17":393,"_246":1351,"_386":387,"_388":-5,"_389":-5,"_390":391},"2876RO","TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II study","7fce215b-d882-479c-8689-0fe0d6ace9d4","#ESMO26 🧬 TQB2102 | Phase II #ESMO26 🧬 TQB2102 | Phase II 👥 86 pts | 1L HER2+ GC/GEJ 💊 HER2 ADC + bemotrizumab ± capecitabine 🎯 ORR: • ",{"_270":1366,"_246":1367},"code:4741RO","4741RO","III期 NIAGARA：膀胱癌围手术期使用 durvalumab 的分子亚型与 EFS 结局\n\n在 #ESMO26 上，Matthew D. Galsky 介绍了 III期 NIAGARA 试验（4741RO）的一项探索性分子分析，评估肌肉浸润性膀胱癌（MIBC）中的基因组改变及基于转录组定义的亚型。\n\n主要发现：\n▫️ 总体人群：durvalumab 联合新辅助化疗的 24个月 EFS 为 68%，而单纯化疗为 60%（HR 0.6","2026-10-24T10:31:37.000Z","2026-10-24T11:25:01.000Z",[],{"_262":1362,"_264":1363,"_265":297,"_267":1364,"_269":1365},"zdsqcrkvy0opd40es2zifipyt","III期 NIAGARA：膀胱癌围手术期使用 durvalumab 的分子亚型与 EFS 结局\n\n在 #ESMO26 上，Matthew D. Galsky 介绍了 III期 NIAGARA 试验（4741RO）的一项探索性分子分析，评估肌肉浸润性膀胱癌（MIBC）中的基因组改变及基于转录组定义的亚型。\n\n主要发现：\n▫️ 总体人群：durvalumab 联合新辅助化疗的 24个月 EFS 为 68%，而单纯化疗为 60%（HR 0.68；95% CI 0.56–0.82）。\n▫️ 基因组亚组：在 TP53 突变（HR 0.51）、FGFR3 突变（HR 0.24）和 TMB 高肿瘤（HR 0.44）中，EFS HR 在数值上有利于 durvalumab。\n▫️ 分子亚型：在基底鳞状（HR 0.47；95% CI 0.20–1.11）、腔型（HR 0.52）和腔浸润型（HR 0.67）亚组中，EFS HR 有利于 durvalumab，但在腔乳头型亚组中则不然（HR 1.35）。\n\n要点：探索性发现提示，在多个分子亚组中，围手术期使用 durvalumab 普遍与有利的 EFS 结局相关。这些分析未实施 α 控制，需谨慎解读。\n\n@tompowles1 @ZakhariaYousef @oncodaily @myESMO \n\nhttps://oncodaily.com/genitourinary-oncology/niagara-esmo-2026\n\n#ESMO26 #ESMO2026 #NIAGARA","https://x.com/OncoDailyGU/status/2113954914040750376","OncoDailyGU","96389a38-28d4-47b2-953a-4468751bd328","Phase III NIAGARA: Molecular Subtypes and EFS Outcomes With Perioperative Durvalumab in Bladder Cancer Phase III NIAGARA: Molecular Subtypes",{"_270":1379,"_246":1380},"code:2215O","2215O","🚨⭐🔵 #ESMO26 | 摘要 2215O | PEACE-1\n\nPEACE-1 III期试验中，abiraterone acetate 联合 prednisone 治疗新发转移性去势敏感性前列腺癌（mCSPC）的长期总生存期\n\n由 Karim Fizazi 教授报告 🇫🇷\n@OncoAlert @myESMO\n\n🔬 7.7年随访：初始治疗强化能否转化为持久的生存获益？\nPEACE-1 给出了令人信服的回答！\n\n📊 III","2026-10-24T09:02:52.000Z","2026-10-24T10:24:17.000Z",[],{"_262":1376,"_264":1377,"_265":297,"_267":1378,"_269":1013},"xcs1sqwwqisqsxmgd5ysoundq","🚨⭐🔵 #ESMO26 | 摘要 2215O | PEACE-1\n\nPEACE-1 III期试验中，abiraterone acetate 联合 prednisone 治疗新发转移性去势敏感性前列腺癌（mCSPC）的长期总生存期\n\n由 Karim Fizazi 教授报告 🇫🇷\n@OncoAlert @myESMO\n\n🔬 7.7年随访：初始治疗强化能否转化为持久的生存获益？\nPEACE-1 给出了令人信服的回答！\n\n📊 III期 | N=1,173\n\n采用随机 2×2 析因设计，评估在标准治疗（ADT ± docetaxel）基础上加用 abiraterone + prednisone 和/或前列腺放疗。\n\n中位随访时间：7.7年。\n\n📈 1️⃣ 总体人群\n\n✅ OS HR 0.75（95% CI 0.65–0.87）\n✅ p=0.0001\n\n中位 OS：\n🔹 使用 abiraterone：6.1年\n🔹 不使用 abiraterone：4.6年\n\n➡️ 死亡危险度持续相对降低25%。\n\n💥 2️⃣ 三联治疗 | N=710\n\nADT + docetaxel + abiraterone 与 ADT + docetaxel：\n\n✅ 中位 OS：6.2 vs 4.4年\n✅ HR 0.68（95% CI 0.56–0.82）\n\n⭐ 中位生存期额外增加1.8年！\n\n📊 8年总生存率\n\n✅ 三联治疗：40.3%\n🔹 双联治疗：27.1%\n\n➡️ 绝对差异：+13.2个百分点。\n\n这些是具有临床意义的长期结局，其意义不止于早期缓解率或替代终点。\n\n🔬 3️⃣ 转移负荷是否重要？\n\n🔵 高转移负荷疾病\n\n✅ 中位 OS：4.6 vs 3.5年\n✅ HR 约为0.68\n\n具有明确且持久的生存优势。\n\n🔵 低转移负荷疾病\n\n📈 中位 OS：7.8 vs 6.2年\nHR 0.74（95% CI 0.52–1.05）\n\n数值上呈现有利趋势，但亚组 CI 跨越1。\n\n📌 按疾病负荷划分未见显著交互作用（p=0.56）。\n\n⚠️ 这并不能证明两个亚组获得相同的治疗获益。\n\n⭐ 我的观点 | 临床启示\n\n长期随访才能检验一种治疗策略的真正价值。\n\n与早期缓解信号不同，PEACE-1 提供了成熟证据，表明初始全身治疗强化可转化为显著更长的生存期。\n\n💡 对于经恰当筛选且适合接受 docetaxel 的新发 mCSPC 患者，这些发现有力支持初始三联治疗的作用。\n\n如今，临床问题已不再只是是否强化治疗，而是哪些患者应接受三联治疗、如何最佳整合局部治疗，以及如何保持生活质量。\n\n🎯 精准很重要；但在已有经证实的生存优势时，及早行动也同样重要。\n\n👏 祝贺 Karim Fizazi 教授及整个 PEACE-1 团队为前列腺癌诊疗作出的这一重要长期贡献！\n@urologysummit @gbanna74 @ravikanesvaran @Uromigos @LosUromigos\n\n@neerajaiims @Silke_Gillessen @EfstathiouEleni @AOmlin @declangmurphy @cdanicas @montypal @DrScottTagawa\n\n@ecancer @UrologyTimes @urotoday @wearemedsir @OpenMedicineHQ\n\n#ProstateCancer #mCSPC #mHSPC #GUOncology #PEACE1 #TripletTherapy","https://x.com/nataliagandur/status/2113939631079113083","9f961552-1adc-412d-8326-c14676e4684e","🚨⭐🔵 #ESMO26 | Abstract 2215O | PEACE-1 🚨⭐🔵 #ESMO26 | Abstract 2215O | PEACE-1 Long-term overall survival with abiraterone acetate plus p",{"_270":1391,"_246":1392},"code:170O","RADIANT 使用 119,782 例 RT 病例进行训练，并在多个中心测试了分割、剂量和结局预测。\n\n接下来我想要的是临床效用：使用它是否能优化治疗计划决策、减少毒性或改善结局？仅有准确性还不够。\n\n#ESMO26 #radonc\n\nhttps://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/presentation/list?q=170O","2026-10-22T23:24:55.000Z","2026-10-24T19:00:02.000Z",[],{"_262":1388,"_264":1383,"_265":297,"_267":1389,"_269":1390},"tmv0uipd7k9s3s69w4tbfatfo","https://x.com/jryckman3/status/2113411308284789113","jryckman3","1e6a35f2-f814-4a95-a3e3-d2031eccddb8","RADIANT trained on 119,782 RT cases and tested segmentation, dose and outcome prediction across sites",{"_270":1404,"_246":1405},"tag:#testicularcancer","#TESTICULARCANCER","#ESMO26 上公布的难治性 GCT 早期数据令人鼓舞\n\nCLDN6 靶向 ADC ixotatug vedotin (TORL-1-23)：\n• ORR 45.5% (5/11)\n• DCR 72.7%\n• 即使在 HDCT/ASCT 后也出现缓解\n\n在未满足需求极高的患者群体中，I 期数据令人鼓舞。仍需进一步验证。\n\n#TesticularCancer","2026-10-23T11:57:56.000Z","2026-10-24T13:15:05.000Z",[],{"_262":1401,"_264":1396,"_265":297,"_267":1402,"_269":1403},"oyjcb3648m6bg13ygyxljwpro","https://x.com/pokrivcak/status/2113600811808825807","pokrivcak","dd7c9ebf-01c8-42ed-bfa5-5521d125d097","TORL-1-23: Safety and Efficacy of Ixotatug Vedotin, a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors",{"_270":1417,"_246":1418},"code:KN-866","KN-866","🎯 开始 GU 口头报告环节！#ESMO26 @JensBedke 展示了 MIBC KN-866 的 III 期研究\n一项 Cis-Gem + Pembro 与 Cis-Gem 围手术期对比的阴性研究。🤷‍♂️\nNIAGARA 研究怎么样？🤨 @OncoAlert @myESMO @DrFelixGuerrero @GuardConsortium @UroTarget","2026-10-23T11:57:24.000Z","2026-10-23T12:15:51.000Z",[],{"_262":1414,"_264":1409,"_265":297,"_267":1415,"_269":1416},"zikhij68ad4oyrbpy97791r1u","https://x.com/cdanicas/status/2113605316520837547","cdanicas","e2d6e4c7-1392-47b1-b0cf-2aa182aadea0","🎯 Starting the GU oral session",{"_270":1430,"_246":1431},"tag:#daslhicap","#DASLHICAP","#ESMO26 #DASLHiCaP @ANZUPtrials","2026-10-24T17:09:53.000Z","2026-10-24T21:19:00.000Z",[],{"_262":1427,"_264":1422,"_265":266,"_267":1428,"_269":1429},"lqh5qdh7j7nnue0ywwp2ozobm","https://x.com/Prof_IanD/status/2114104395394936882","Prof_IanD","f2dde502-c900-452e-9e58-8234a632a0a8","#ESMO26 #DASLHiCaP #ProstateCancer #pcsm Thread 👇 #ESMO26 #DASLHiCaP #ProstateCancer #pcsm Thread 👇 #ESMO26 #DASLHiCaP #ProstateCancer #pc",{"_270":1443,"_246":1444},"nct:NCT05029882","NCT05029882","🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤\n🔥Telisotuzumab Adizutecan 在非鳞状非小细胞肺癌（NSQ NSCLC）患者（Pts）中的总体生存期（OS）分析：I 期首次人体研究\n🎙️Dr. David Sommerhalder\n🔢2658RO\n🎯在既往接受过多线治疗的患者中，中位 OS 为 13.8 个月（EGFR WT，n=48）和 16.2 个月（EGFR MUT，n=41）\n🎯c-Me","2026-10-08T11:45:00.000Z","2026-10-24T07:45:00.000Z",[],{"_262":1440,"_264":1441,"_265":297,"_267":1442,"_269":711},"wf8l0vgjgqzq47iko7iyl96cv","🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤\n🔥Telisotuzumab Adizutecan 在非鳞状非小细胞肺癌（NSQ NSCLC）患者（Pts）中的总体生存期（OS）分析：I 期首次人体研究\n🎙️Dr. David Sommerhalder\n🔢2658RO\n🎯在既往接受过多线治疗的患者中，中位 OS 为 13.8 个月（EGFR WT，n=48）和 16.2 个月（EGFR MUT，n=41）\n🎯c-Met 高表达患者的 OS 更长（25.2 个月，EGFR WT ≥3+/≥10%）\n☑️NCT05029882\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC","https://x.com/HHorinouchi/status/2113899546254389469","f86538f4-0367-4ffc-a728-e3cfa7664969","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patien",{"_270":1457,"_246":1458},"code:SUNRAY-01","SUNRAY-01","欢迎参加 #ESMO2026，聆听关于 1L olomorasib 联合化学免疫治疗用于 KRAS G12C 突变型 NSCLC 的口头报告，报告来自 SUNRAY-01 Safety Lead-in 队列试验。\n\n2652RO | 10月25日 | 9:19 - 09:24 | 巴塞罗那礼堂9号厅\n\n查看议程详情：https://e.lilly/3VmFpLN\n\n#LungCancer","2026-10-22T14:00:01.000Z",[1454],{"_262":1452,"_264":1448,"_265":297,"_267":1453,"_269":624},"rruifku839yzco4eeu6l19mdn","https://x.com/LillyOncMed/status/2113269144166522952",{"_382":1455,"_17":393,"_246":1456,"_386":395,"_388":-5,"_389":-5,"_390":607},"2683P","First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01","5a41dd66-d5eb-4815-a124-68bee465953e","Join us at #ESMO2026 for an oral presentation on 1L olomorasib plus chemoimmunotherapy in KRAS G12C-mutant NSCLC, from the SUNRAY-01 Safety ",{"_270":1470,"_246":1471},"tag:#oncoalert5k","#ONCOALERT5K","在 #ESMO26 举办的 #OncoAlert5k 跑步俱乐部活动非常精彩\n向大家大声喝彩！尽管天气寒冷、夜色昏暗，我们的会员依然展现出积极健康的态度，而且简直全力以赴！！\n\n期待我们的下一场跑步活动在我们自己的主场城市——德克萨斯州圣安东尼奥——举办 #SABCS26\n\n@cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @sto","2026-10-24T16:10:43.000Z","2026-10-24T16:21:49.000Z",[],{"_262":1467,"_264":1468,"_265":297,"_267":1469,"_269":999},"roln1lbxyjgcpomv2d8eb0aa6","在 #ESMO26 举办的 #OncoAlert5k 跑步俱乐部活动非常精彩\n向大家大声喝彩！尽管天气寒冷、夜色昏暗，我们的会员依然展现出积极健康的态度，而且简直全力以赴！！\n\n期待我们的下一场跑步活动在我们自己的主场城市——德克萨斯州圣安东尼奥——举办 #SABCS26\n\n@cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein3","https://x.com/OncoAlert/status/2114026811231199642","31d49694-9b5b-4123-9654-dda63bffd90f","A Great time at the #OncoAlert5k Running Club Run at #ESMO26 A Great time at the #OncoAlert5k Running Club Run at #ESMO26 Huge shout out to ",{"_270":1485,"_246":1486},"drug:drozuntecan","drozuntecan","🚨 #ESMO26 | Elfe-D + pumitamig 在实体瘤中的应用\n\nB7-H3 ADC elfetabart drozuntecan + PD-L1×VEGF-A bsAb pumitamig 首次公布肺癌以外的临床数据！\n\n📊 疗效可评估人群 N=139：uORR 48.9% | cORR 39.6% | DCR 87.8%\n\n👀 黑色素瘤（n=26）：uORR 30.8% | cORR 26.9% | DCR 8","2026-10-19T01:40:00.000Z","2026-10-24T13:18:41.000Z",[1483],{"_262":1480,"_264":1481,"_265":297,"_267":1482,"_269":599},"voyoya5j0svy4jge50hcu0v9l","🚨 #ESMO26 | Elfe-D + pumitamig 在实体瘤中的应用\n\nB7-H3 ADC elfetabart drozuntecan + PD-L1×VEGF-A bsAb pumitamig 首次公布肺癌以外的临床数据！\n\n📊 疗效可评估人群 N=139：uORR 48.9% | cORR 39.6% | DCR 87.8%\n\n👀 黑色素瘤（n=26）：uORR 30.8% | cORR 26.9% | DCR 80.8%\n\n安全性似乎可控，主要为 G1–2 GI/血液学 TRAEs，未见 DLTs 或治疗相关死亡，报告了 2 例研究者报告的 ILD 病例 👍🏼 \n\n一个问题：这种活性究竟由 IO、抗血管生成作用驱动，还是源于两者的协同作用？？ 🤔 \n@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma","https://x.com/MarioBalsaMD/status/2113983520045498516",{"_382":1317,"_17":393,"_246":1318,"_386":395,"_388":-5,"_389":1484,"_390":484},[1320,1320,1320],"1b990677-cae5-403f-8d03-4c349f4d6519","🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors 🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors First clinical data beyond lung canc",{"_270":1498,"_246":1499},"tag:#crcsm","#CRCSM","CheckMate 8HW 最终 OS 结果于 #ESMO26：在经中心确认的 MSI-H/dMMR mCRC 中，NIVO+IPI\n\n▪️ 所有治疗线 vs NIVO：HR 0.61（0.46–0.82），p=0.0009；5年 OS 为 74% vs 62%\n▪️ 1L vs NIVO：HR 0.66（0.44–0.99），p=0.043，未达到预先设定的界值（p<0.0058）；5年 OS 为 77% vs 66%\n▪️ 1L v","2026-10-21T16:45:30.000Z","2026-10-24T17:11:01.000Z",[],{"_262":1495,"_264":1496,"_265":297,"_267":1497,"_269":1140},"usz7dk3we334lzqqs19vx5v9h","CheckMate 8HW 最终 OS 结果于 #ESMO26：在经中心确认的 MSI-H/dMMR mCRC 中，NIVO+IPI\n\n▪️ 所有治疗线 vs NIVO：HR 0.61（0.46–0.82），p=0.0009；5年 OS 为 74% vs 62%\n▪️ 1L vs NIVO：HR 0.66（0.44–0.99），p=0.043，未达到预先设定的界值（p<0.0058）；5年 OS 为 77% vs 66%\n▪️ 1L vs 化疗：OS HR 0.37，p<0.0001\n▪️ 中位随访时间约68个月；安全性稳定，3/4级事件发生率低\n\n#CRCSM #MSIH","https://x.com/alantanmd/status/2113993624958484808","e7dae91e-e806-4701-b027-eda4c49c8c61","📺 WATCH: @FASinicropeMD, of @MayoClinic, previews 2 colorectal cancer studies to watch at the 2026 ESMO Congress, including adjuvant treatm",{"_270":1517,"_246":1518},"tag:#mcrpc","#MCRPC","来自 #ESMO2026 的重要数据，关于 #mCRPC：\n\n🧬 56% 的液体活检检测到的 HRR 突变被预测源自克隆性造血 (CH)。\n\n⚠️ 仅携带 CH 相关 HRR 突变的患者似乎未从 PARPi 单药治疗中获益。\n\n区分 CH 与肿瘤源性突变对治疗选择至关重要。 #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert","2026-10-23T16:00:44.000Z","2026-10-23T22:27:20.000Z",[1511,1512],{"_262":1508,"_264":1503,"_265":297,"_267":1509,"_269":1510},"mavwq9txzr0alsnrosbzhif4g","https://x.com/YuWeiChenMD/status/2113759202812592278","YuWeiChenMD",{"_382":1514,"_17":393,"_246":1515,"_386":1173,"_388":-5,"_389":1516,"_390":1175},{"_382":1171,"_17":393,"_246":1172,"_386":1173,"_388":-5,"_389":1513,"_390":1175},[1176],"2218RO","Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)",[1176],"25dcd516-62f2-46fa-afaa-d32f0c0b2484","Important data from #ESMO2026 in #mCRPC: Important data from #ESMO2026 in #mCRPC: 🧬 56% of HRR alterations detected by liquid biopsy were p",{"_270":1529,"_246":1530},"tag:#podium2screen","#PODIUM2SCREEN","来自 @OncoAlert #ESMO26 主席会议的一段 #Podium2Screen 👇","2026-10-24T09:24:45.000Z","2026-10-24T16:09:24.000Z",[],{"_262":1527,"_264":1522,"_265":297,"_267":1528,"_269":985},"lkob3m3nhld1v3ct4c7hduvs9","https://x.com/JankovicK/status/2114026480359571577","86dad846-d5a0-49f4-9480-4f6e973af5cd","From the podium to your screen",{"_270":1542,"_246":1543},"tag:#oncologycommunity","#ONCOLOGYCOMMUNITY","肿瘤学界的一些顶尖专家本周齐聚马德里参加 #ESMO26。我们将关注的一个话题：越来越多的证据表明，让免疫系统识别肿瘤的“预激活”能让现有的免疫疗法对更多人有效。\n\n路径虽多，终点同一。好科学在前方。\n\n$SONA #OncologyCommunity #Immunotherapy","2026-10-22T14:00:02.000Z","2026-10-24T18:30:02.000Z",[],{"_262":1539,"_264":1534,"_265":297,"_267":1540,"_269":1541},"o9n2mpysqfuyg6neocb5671ip","https://x.com/SonaNanotech/status/2113269147815584139","SonaNanotech","79c6427c-88bc-4f92-9a10-4d38b23568b2","Some of oncology's biggest minds gather in Madrid this week for #ESMO26",{"_270":1555,"_246":1556},"tag:#liquidbiopsy","#LIQUIDBIOPSY","@ChristianRolfo (@RolfoLab) 来自 @OhioStateMedOnc 在 #ESMO26 上谈论 #liquidbiopsy 如何使早期药物开发更快、更好、更高效\n\n8 个应用，从患者选择到早期信号活性和耐药性。\n\n@isliquidbiopsy @myESMO","2026-10-22T15:00:34.000Z","2026-10-23T14:39:40.000Z",[],{"_262":1552,"_264":1547,"_265":297,"_267":1553,"_269":1554},"y1o9mzm09x3mkpm2lj4yne3ex","https://x.com/RobertoBoreaMD/status/2113641511166582872","RobertoBoreaMD","800d2f35-6365-4732-a023-efaa567f9c3d","@ChristianRolfo (@RolfoLab) from @OhioStateMedOnc at #ESMO26 on how #liquidbiopsy can make early phase drug development faster, better and m",{"_270":1571,"_246":1572},"drug:zimberelimab","zimberelimab","TROPHY-U-01 Cohort 7: SG + EV + zimberelimab 显示出有希望的疗效（ORR 81%，n=21）。\n\n期待更大规模 II/III 期试验的结果！\n\n#ESMO26","2026-10-23T12:06:15.000Z","2026-10-23T17:30:10.000Z",[1568],{"_262":1565,"_264":1560,"_265":297,"_267":1566,"_269":1567},"cyhsthi0o3auenlgccxpjnw36","https://x.com/KohjiToncol/status/2113602903491629064","KohjiToncol",{"_382":1569,"_17":393,"_246":1570,"_386":1162,"_388":-5,"_389":-5,"_390":1163},"4742O","Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7","7530a0da-0aa8-4c2e-8eae-ff1f68e3f731","At #ESMO26, Randy Sweis, MD, presents interim results from cohort 7 of the phase 1b TROPHY-U-01 trial, testing SG + EV + zimberelimab as fir",{"_270":1586,"_246":1587},"drug:ribociclib","ribociclib","随访 6 年后，辅助使用 ribociclib 仍保持 iDFS 获益（Δ 5.3%）和良好的 OS（Δ 2.1%）（所有患者均已停用 ribo）。疗效与 abema（monarchE）相当，但毒性特征不同，适用人群更广（N+ 和高危 N0）。#ESMO26 #ESMOAmbassadors","2026-10-23T12:51:15.000Z","2026-10-24T21:47:36.000Z",[1583],{"_262":1581,"_264":1576,"_265":297,"_267":1582,"_269":641},"upof2kksfglci0jcaiw9rymbb","https://x.com/PTarantinoMD/status/2113614225822335063",{"_382":1584,"_17":384,"_246":1585,"_386":685,"_388":-5,"_389":-5,"_390":686},"LBA25","Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes","78fa9f5d-3c1c-4550-be20-a3b26ffce19a","Maintained iDFS benefit (Δ 5",{"_270":1602,"_246":1603},"drug:lazertinib","lazertinib","COCOON 改写 EGFR 治疗格局的速度令人惊叹！\n≥2 级 AEs：75% → 42%。\n如今，采用简化预防措施 + lazertinib 导入期的早期数据显示：39% → 18%。\n\n不仅是在控制毒性，更是在改变其发展轨迹。\n\n#ESMO26 #LungCancer","2026-10-24T06:51:05.000Z","2026-10-24T08:18:58.000Z",[1599],{"_262":1596,"_264":1591,"_265":297,"_267":1597,"_269":1598},"j6kewf4umbotteegzb25d32q4","https://x.com/APassaroMD/status/2113900687914684746","APassaroMD",{"_382":1600,"_17":393,"_246":1601,"_386":1169,"_388":-5,"_389":-5,"_390":1170},"2700RO","Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort","c3fb725e-1248-43ed-94fe-891a1156acae","💅 Optimizing dermatologic prophylaxis and lead-in lazertinib significantly reduce Dermatolgic AEs",{"_270":1639,"_246":1640},"drug:enfortumab","enfortumab","前往 #ESMO26，带来膀胱癌的重要新进展\n\n欧洲委员会批准 enfortumab vedotin + pembrolizumab 作为肌层浸润性膀胱癌的围手术期治疗，无论是否符合顺铂资格\n\n一个将在马德里引发广泛讨论的新治疗格局 @OncoAlert \n\nhttps://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev","2026-10-09T00:00:00.000Z","2026-10-23T15:00:46.000Z",[1616,1617,1618,1619,1620,1621,1622,1623],{"_262":1612,"_264":1613,"_265":297,"_267":1614,"_269":1615},"gsplo27drmv1crii4k19gt2co","前往 #ESMO26，带来膀胱癌的重要新进展\n\n欧洲委员会批准 enfortumab vedotin + pembrolizumab 作为肌层浸润性膀胱癌的围手术期治疗，无论是否符合顺铂资格\n\n一个将在马德里引发广泛讨论的新治疗格局 @OncoAlert \n\nhttps://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/","https://x.com/LosUromigos/status/2113241849745801540","LosUromigos",{"_382":1637,"_17":393,"_246":1638,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":1160,"_17":393,"_246":1161,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":1635,"_17":393,"_246":1636,"_386":971,"_388":-5,"_389":-5,"_390":972},{"_382":969,"_17":393,"_246":970,"_386":971,"_388":-5,"_389":-5,"_390":972},{"_382":1569,"_17":393,"_246":1570,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":1631,"_17":393,"_246":1632,"_386":395,"_388":-5,"_389":1633,"_390":1629},{"_382":1626,"_17":393,"_246":1627,"_386":395,"_388":-5,"_389":1628,"_390":1629},{"_382":1624,"_17":384,"_246":1625,"_386":516,"_388":-5,"_389":-5,"_390":517},"LBA2","Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial","4771TIP","GB-4362, an MMAE-neutralizing antibody, in combination with enfortumab vedotin (EV) and pembrolizumab in advanced urothelial cancer: Phase 1 trial-in-progress",[1630,1630,1630],"Urothelial cancer","NCT07484022","4761P","Enfortumab Vedotin Plus Pembrolizumab (EV+P) For Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Updated Exploratory Analysis of EV-302 in Older Patients (pts) and Those With Comorbidities",[1634,1634,1634],"NCT04223856","4738RO","Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEY","4733O","Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905","b5b0f143-b2ec-4eca-ade8-b2d02d7fba73","De camino a #ESMO26 con novedades importantes en cáncer de vejiga De camino a #ESMO26 con novedades importantes en cáncer de vejiga La Comis",{"_270":1651,"_246":1652},"drug:emactuzumab","emactuzumab","#ESMO26 🚀 TANGENT | III期\n\n👥 136例患者 | TGCT\n💊 Emactuzumab（抗-CSF-1R）vs 安慰剂\n💉 8周内输注5次\n\n🎯 6个月 ORR（RECIST）：30% vs 2%\n📈 ORR（TVS）：54% vs 7%\n✅ 疼痛、僵硬和功能改善（p<0.001）\n\n⚠️ ≥3级治疗相关不良事件（TRAEs）：48% vs 2%\n\n💡 短疗程治疗有效！\n\n@OncoAlert","2026-10-24T12:57:30.000Z","2026-10-24T15:02:14.000Z",[],{"_262":1649,"_264":1644,"_265":297,"_267":1650,"_269":1333},"ihvcgypl07vzeuoy2o6vegmn4","https://x.com/DraMartinezLago/status/2113978187491205372","aeda9e32-14c5-408b-b35d-0c775dd94b67","Results from the TANGENT trial in TGCT showed that emactuzumab is active and tolerable vs placebo",{"_270":1664,"_246":1665},"drug:darovasertib","darovasertib","#ESMO26 上公布的 OptimUM 试验最新结果支持将 darovasertib + crizotinib 用于治疗葡萄膜 #Melanoma\n\n新辅助 darovasertib 使 85.7% 的患者肿瘤缩小！💡\n\n在此处阅读更多：\n🔗 https://bit.ly/4zMvXA1","2026-10-23T10:39:01.000Z","2026-10-24T16:56:04.000Z",[],{"_262":1661,"_264":1656,"_265":297,"_267":1662,"_269":1663},"msxqhy3cru12j37nfs85agdja","https://x.com/CancerTherAdvsr/status/2114038224586699130","CancerTherAdvsr","a65efd49-0943-4b64-a785-28614245cb0f","@MeredithMcKean joined by Dr",{"_270":1677,"_246":1678},"drug:cabozantinib","cabozantinib","👏 向我的朋友 @JHernando3 表示热烈祝贺，他在 #ESMO26 上展示了 GETNE-T2216/CABOTHYROID 试验！\n卡博替尼在晚期甲状腺癌中的结果令人期待：ORR 24%，DCR 89.7%，中位 PFS 16.1 个月。\n@GrupoGetne 🇪🇸 做得太棒了！@Ja_Capdevila @OncoAlert","2026-10-23T15:30:59.000Z","2026-10-24T14:33:48.000Z",[],{"_262":1674,"_264":1669,"_265":297,"_267":1675,"_269":1676},"flqejxt2pp8gm3egbssg2j67t","https://x.com/DrVilmaPBarcia/status/2113655465334952193","DrVilmaPBarcia","c9df8130-0ec0-46ee-b6e4-8c5fadaa26e6","👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26",{"_270":1690,"_246":1691},"code:KEYNOTE-869","KEYNOTE-869","Ib/II 期 EV-103：Enfortumab Vedotin 联合 Pembrolizumab 治疗尿路上皮癌的长期结局\n\n在 #ESMO26 上，Jose Pablo Maroto Rey 介绍了 EV-103/KEYNOTE-869（4740RO）的长期结果。该研究评估一线 enfortumab vedotin（EV）联合或不联合 pembrolizumab 治疗不适合接受顺铂的局部晚期或转移性尿路上皮癌患者。\n\n主要 fin","2026-10-24T10:05:01.000Z","2026-10-24T17:00:02.000Z",[],{"_262":1687,"_264":1688,"_265":297,"_267":1689,"_269":1365},"vilsi780y15yvg37u8h1a3yf5","Ib/II 期 EV-103：Enfortumab Vedotin 联合 Pembrolizumab 治疗尿路上皮癌的长期结局\n\n在 #ESMO26 上，Jose Pablo Maroto Rey 介绍了 EV-103/KEYNOTE-869（4740RO）的长期结果。该研究评估一线 enfortumab vedotin（EV）联合或不联合 pembrolizumab 治疗不适合接受顺铂的局部晚期或转移性尿路上皮癌患者。\n\n主要 findings：\n▫️ EV + pembrolizumab（汇总 DE/A/K；n=121）：中位 DOR 为 29.6 个月，中位 PFS 为 10.4 个月，中位 OS 为 27.7 个月。\n▫️ 五年 OS：汇总 EV + pembrolizumab 队列中为 33.0%，EV 单药队列（K；n=73）中为 23.9%。\n▫️ ≥3 级治疗相关 AE：EV + pembrolizumab 组为 64.5%，EV 单药组为 47.9%。未观察到新的安全性信号。\n\n结论：长期随访表明，一线 EV 联合 pembrolizumab 可带来持续缓解和生存获益。K 队列未进行正式的组间统计比较。\n\n@oncodaily @myESMO @tompowles1 @DrRosenbergMSK \n\nhttps://oncodaily.com/genitourinary-oncology/ev-103-esmo-2026\n\n#ESMO26 #ESMO2026 #EV103","https://x.com/OncoDailyGU/status/2113934781180203053","3ae9377f-b7e1-48b8-a277-4acbf16ec1ab","Phase Ib/II EV-103: Long-Term Outcomes With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer Phase Ib/II EV-103: Long-Term Outcome",{"_270":1702,"_246":1703},"code:788RO","788RO","#ESMO26 | 788RO ECLYPse：Ph2 EC 联合 FOLFIRI 治疗进展后的 BRAF V600E mCRC @myESMO @OncoAlert https://t.co/SPahzMo1m0","2026-10-19T09:06:00.000Z","2026-10-24T14:56:11.000Z",[],{"_262":1700,"_264":1695,"_265":297,"_267":1701,"_269":1054},"he9p7zc7e5z5i5wq5j07abkc8","https://x.com/DaisukeKotani/status/2112107988689260587","18ebc941-a84f-4ea7-97e0-083845d99026","#ESMO26 | 788RO ECLYPse: Ph2 EC beyond progression in combination with FOLFIRI in BRAF V600E mCRC @myESMO @OncoAlert #ESMO26 | 788RO ECLYPse",{"_270":1715,"_246":1716},"tag:#weareoncoalert","#WEAREONCOALERT","我们在这里 #ESMO26 \n#WeAreOncoAlert 🚨 \n\n我们的每日 #ESMO26 通讯将于明天开始\n免费注册 👉 https://buff.ly/N5gYtAc \n每天早上直接发送到您的收件箱!! \n在社交媒体上关注 OncoAlert 或访问 http://www.OncoAlert360.com\n\n@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolam","2026-10-23T10:13:12.000Z","2026-10-23T20:16:13.000Z",[],{"_262":1712,"_264":1713,"_265":297,"_267":1714,"_269":999},"oci6hoj4w5bbfj01zabo39n9m","我们在这里 #ESMO26 \n#WeAreOncoAlert 🚨 \n\n我们的每日 #ESMO26 通讯将于明天开始\n免费注册 👉 https://buff.ly/N5gYtAc \n每天早上直接发送到您的收件箱!! \n在社交媒体上关注 OncoAlert 或访问 http://www.OncoAlert360.com\n\n@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3","https://x.com/OncoAlert/status/2113574454605287717","ca1d7b5b-701b-4c47-9e4d-2399084c86f0","WE are HERE #ESMO26 WE are HERE #ESMO26 #WeAreOncoAlert 🚨 OUR DAILY #ESMO26 NEWSLETTER STARTS TOMORROW REGISTER for Free 👉 https://buff",{"_270":1736,"_246":1737},"drug:abemaciclib","abemaciclib","在既往 Al/CDK4/6i 治疗后疾病进展的情况下，总生存期在数值上倾向于 abemaciclib + fulvestrant；中位数为 32.1 vs 24.6 个月\nHR 0.80, 95% CI 0.60-1.06) @KalinskyKevin @OncoAlert #ESMO26","2026-10-23T14:22:05.000Z","2026-10-24T12:27:11.000Z",[1728,1729],{"_262":1725,"_264":1720,"_265":297,"_267":1726,"_269":1727},"e0jt156yms651al16z1egt0om","https://x.com/DrSGraff/status/2113924023524765836","DrSGraff",{"_382":1734,"_17":393,"_246":1735,"_386":1216,"_388":-5,"_389":-5,"_390":1217},{"_382":1730,"_17":393,"_246":1731,"_386":395,"_388":-5,"_389":1732,"_390":1166},"4498P","Association of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE",[1733,1733,1733],"NCT03155997","1RO","Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy","6c1e66b4-1bd1-46c6-bbec-7a461d393213","Overall survival numerically favored abemaciclib + fulvestrant following disease progression on prior Al/CDK4/6i; median 32",{"_270":1754,"_246":1755},"tag:#hnscc","#HNSCC","@Rakuten Medical #ESMO26 \n我喜欢它把其他新的免疫检查点选择推迟到后线，实际上在复发后保留了新的选择。其治疗可能具有非常好的消融效应。甚至可能与其他后线检查点抑制剂联合使用。","2026-10-21T15:08:39.000Z","2026-10-24T07:49:21.000Z",[1749],{"_262":1746,"_264":1741,"_265":297,"_267":1747,"_269":1748},"y83qo8bsc3cg9hj2ahukslvjo","https://x.com/Water46333865/status/2113801828152619073","Water46333865",{"_382":1750,"_17":393,"_246":1751,"_386":1752,"_388":-5,"_389":1753,"_390":1751},"NCT06295731","- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","https://clinicaltrials.gov/study/NCT06295731",[1750],"33ba464a-b564-437f-9239-d12605bdde13","#ESMO26 #ESMO26 Oneof the best summaries that you can see these days about the management of HPV+ early disease #HNSCC Kudos Dr Sandra Schmi",{"_270":1769,"_246":1770},"tag:#aiom","#AIOM","在马德里开幕 #ESMO26。\n\n肿瘤学家 #AIOM：“意大利保证获得经EMA批准的89%抗癌药物，但等待时间仍过长”。\n\n文章：https://www.medinews.it/comunicati/tumori-in-europa-meno-78-di-morti-negli-uomini-dal-2020-al-2026-in-italia-servono-ancora-15-mesi-per-accedere-alle-nuov",5,"2026-10-23T08:55:19.000Z","2026-10-23T13:26:32.000Z",[],{"_262":1765,"_264":1766,"_265":297,"_267":1767,"_269":1768},"cizaap8xcw9lfx2fhatlusvzw","在马德里开幕 #ESMO26。\n\n肿瘤学家 #AIOM：“意大利保证获得经EMA批准的89%抗癌药物，但等待时间仍过长”。\n\n文章：https://www.medinews.it/comunicati/tumori-in-europa-meno-78-di-morti-negli-uomini-dal-2020-al-2026-in-italia-servono-ancora-15-mesi-per-accedere-alle-nuove-terapie/\n\n@myESMO","https://x.com/AIOMtweet/status/2113555106092200149","AIOMtweet","84dd3393-3bd6-4e5c-b193-af9606874251","A Madrid 40mila oncologi da tutto il mondo per il congresso della società europea di oncologia medica",{"_270":1782,"_246":1783},"tag:#oncoalertaf","#ONCOALERTAF","亲爱的 #ESMO26，我们全都是 @OncoAlert 🚨\n致同行……由同行\n\n@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @sc","2026-10-23T13:37:12.000Z","2026-10-24T10:36:07.000Z",[],{"_262":1779,"_264":1780,"_265":297,"_267":1781,"_269":999},"ekw8e9mjyeaspyk67e0octlv5","亲爱的 #ESMO26，我们全都是 @OncoAlert 🚨\n致同行……由同行\n\n@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen\n@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @scocmem @niklas_kluemper @Markuseckstein3 @AndreaNecchi @weoncologists","https://x.com/OncoAlert/status/2113896439306736117","755f89a6-d425-458c-9cfd-028a61014223","📌Keynote lecture 1 📌Keynote lecture 1 CNS disease as the next frontier in oncology care: Glioblastoma, metastases, and leptomeningeal dise",{"_270":1794,"_246":1795},"drug:cemiplimab","cemiplimab","R2810-ONC-1901\n\n新辅助 cemiplimab：单臂 II 期，可切除 II-IV (M0) cSCC → 手术。\n\npCR 51%；54-mo EFS 76.2%，OS 79.4%。\n\n术后 RT、cemiplimab 或观察：研究者选择。这无法确立安全省略 RT。\n\n#ESMO26 #OncTwitter\n\nhttps://doi.org/10.1200/JCO-26-02166","2026-10-23T13:16:00.000Z","2026-10-24T22:38:02.000Z",[],{"_262":1792,"_264":1787,"_265":297,"_267":1793,"_269":1390},"m0iopjfnk1wman4keysgl37k3","https://x.com/jryckman3/status/2114124282095714667","d48aafb5-4da2-42ce-95ae-35367ac117d2","‼️ #ESMO26 simultaneous publication by Gross, et al",{"_270":1810,"_246":1811},"drug:ramucirumab","ramucirumab","OncoAlert 4Sight 摘要将在 #ESMO26 展示\n FOLFIRI 联合 Ramucirumab 与 Paclitaxel 联合 Ramucirumab 作为紫杉烷预治疗的晚期或转移性胃食管腺癌患者的二线治疗：III 期 IKFs602/AIO RAMIRIS 研究的最终结果\n\n 🔬 III 期 (n=317)：FOLFIRI + ramucirumab 对比 paclitaxel + ramucirumab，二线，用","2026-10-22T16:02:12.000Z","2026-10-23T19:01:43.000Z",[1807],{"_262":1804,"_264":1805,"_265":297,"_267":1806,"_269":999},"qhqwi23ct60macv874tw4unxx","OncoAlert 4Sight 摘要将在 #ESMO26 展示\n FOLFIRI 联合 Ramucirumab 与 Paclitaxel 联合 Ramucirumab 作为紫杉烷预治疗的晚期或转移性胃食管腺癌患者的二线治疗：III 期 IKFs602/AIO RAMIRIS 研究的最终结果\n\n 🔬 III 期 (n=317)：FOLFIRI + ramucirumab 对比 paclitaxel + ramucirumab，二线，用于紫杉烷预治疗的晚期 GEA。共同主要终点：OS 和 ORR。\n ➡️ 中位 OS 8.7 对 7.5 个月；HR 0.95；p=.33\n ➡️ ORR 25.3% 对 22.6% (p=.29)；中位 PFS 5.5 对 3.7 个月，HR 0.7 (p=.003)\n ➡️ 3-5 级不良事件 70% 对 68%\n ✅ 共同主要终点未达标；PFS 明显改善，支持在紫杉烷预治疗的晚期 GEA 中做个性化治疗决策。\n\n 🎙️ Magdalena Scheck\n\n(4Sight 由 ESMO 网站公开的摘要制作)\n\n正在通知 OncoAlert 教职团队\n\n@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, \n, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,","https://x.com/OncoAlert/status/2113299893473128857",{"_382":1808,"_17":393,"_246":1809,"_386":387,"_388":-5,"_389":-5,"_390":391},"2878RO","FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study","594d8404-eb34-4098-b4dc-c5be29117981","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 FOLFIRI Plus Ramucirumab Versus ",{"_270":1823,"_246":1824},"gene:LAG3","LAG3","🎬 全新 #OAOnTheGo 🎥，来自 #ESMO26\n\n我们的 #OncoAlertAF 同事及黑色素瘤专家 @MarioBalsaMD 博士（巴塞罗那临床医院）探讨如何治疗不符合临床试验入组条件的患者：\n\n🤰 妊娠期黑色素瘤：数据非常有限，anti-LAG3 则完全没有数据\n移植受者：免疫检查点抑制剂可能有效，但约每 3 例就有 1 例发生排斥反应\n免疫治疗从来不只是针对肿瘤本身 👇\n#ESMO26 #Melanoma \n","2026-10-24T09:01:39.000Z","2026-10-24T18:39:02.000Z",[],{"_262":1820,"_264":1821,"_265":297,"_267":1822,"_269":999},"u838hjtndw5e55ead92hqgjvy","🎬 全新 #OAOnTheGo 🎥，来自 #ESMO26\n\n我们的 #OncoAlertAF 同事及黑色素瘤专家 @MarioBalsaMD 博士（巴塞罗那临床医院）探讨如何治疗不符合临床试验入组条件的患者：\n\n🤰 妊娠期黑色素瘤：数据非常有限，anti-LAG3 则完全没有数据\n移植受者：免疫检查点抑制剂可能有效，但约每 3 例就有 1 例发生排斥反应\n免疫治疗从来不只是针对肿瘤本身 👇\n#ESMO26 #Melanoma \n\n@DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein","https://x.com/OncoAlert/status/2113939561466171547","2ef5a7be-5347-4511-8921-450fdb1b39d6","🎬 New #OAOnTheGo 🎥 from #ESMO26 🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr",{"_270":1839,"_246":1840},"drug:visugromab","visugromab","在 #ESMO26：一项 2a 期试验中，使用 GDF15 中和抗体 visugromab + nivolumab 治疗免疫检查点抑制剂初治膀胱癌患者，取得了令人鼓舞的应答，且未出现新的安全性信号 @AndreaNecchi dlvr.it/TW32cC","2026-10-24T09:33:45.000Z","2026-10-24T21:18:33.000Z",[1836],{"_262":1833,"_264":1828,"_265":297,"_267":1834,"_269":1835},"qvq6c48oatgiifbit5hcnd1ng","https://x.com/NatureMedicine/status/2114104283142722002","NatureMedicine",{"_382":1837,"_17":393,"_246":1838,"_386":971,"_388":-5,"_389":-5,"_390":972},"4757RO","Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)","a147877e-08dd-4310-a02a-35470508119b","At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing ant",{"_270":1863,"_246":1864},"drug:amivantamab","amivantamab","🦋 让 amivantamab + lazertinib 更安全：#ESMO26 的 COCOON 新数据！\nCOCOON 研究的新结果表明，简化皮肤预防措施联合皮下注射 amivantamab + lazertinib，可能大幅减少一线 EGFR 突变型 NSCLC 的治疗相关皮肤毒性。关键发现：≥2 级皮肤 AE：标准启动方案为 39%，而 lazertinib 1 周期导入方案为 18%。简化预防措施似乎可提供与原 COCOON","2026-10-24T06:51:02.000Z","2026-10-24T06:57:48.000Z",[1852,1853,1854],{"_262":1849,"_264":1850,"_265":297,"_267":1851,"_269":929},"hdqkaq5zeoamg032x4ucvntk4","🦋 让 amivantamab + lazertinib 更安全：#ESMO26 的 COCOON 新数据！\nCOCOON 研究的新结果表明，简化皮肤预防措施联合皮下注射 amivantamab + lazertinib，可能大幅减少一线 EGFR 突变型 NSCLC 的治疗相关皮肤毒性。关键发现：≥2 级皮肤 AE：标准启动方案为 39%，而 lazertinib 1 周期导入方案为 18%。简化预防措施似乎可提供与原 COCOON 方案相当的保护作用。SC 可显著减少 IRR 反应。新队列并非随机分组，不同启动策略之间的比较属于探索性分析。\n个人看法：毫无疑问，ami 用得更少，毒性也更低。问题在于，在 Flaura2 时代，疗效是否仍能保持不变？！\n#ESMOAmbassador #ESMO26 #LungCancer #NSCLC #EGFR #COCOON #Oncology #CancerResearch","https://x.com/Alfdoc2/status/2113887665351258196",{"_382":1600,"_17":393,"_246":1601,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1859,"_17":393,"_246":1860,"_386":1861,"_388":-5,"_389":1862,"_390":1860},{"_382":1855,"_17":393,"_246":1856,"_386":1857,"_388":-5,"_389":1858,"_390":1856},"NCT07276399","- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","https://clinicaltrials.gov/study/NCT07276399",[1855],"NCT06385080","- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","https://clinicaltrials.gov/study/NCT06385080",[1859],"d9aa9974-5855-441e-9fe7-87e3ee0ba921","#ESMO26 Dr",{"_270":1876,"_246":1877},"code:HOPE-001","HOPE-001","後方ラインのCLDN18.2 ADCアルコタツグタバテカン、PFSが0.4台でOSが0.5台…。予想してたよりもはるかにすごい、、G-HOPE-001試験 #ESMO26","2026-10-23T11:42:28.000Z","2026-10-23T13:14:18.000Z",[],{"_262":1873,"_264":1868,"_265":266,"_267":1874,"_269":1875},"ilfcja10nc4qiudwm6xaxd728","https://x.com/m0370/status/2113620028075692508","m0370","01b2e3bb-fe6c-4e74-976e-60bb2005d61d","後方ラインのCLDN18",{"_270":1889,"_246":1890},"gene:DLL3","DLL3","👏👏 在 #Neuroendocrinetumirs 的 #ESMO26 上举行了一场精彩的快速口头报告会！！！！\n向报告人和讨论者表示祝贺！！新的基于 Pb 的放射性配体和 DLL3 驱动的药物是该领域有前景的新策略。\n@Ja_Capdevila @OncoThor @GrupoGetne @myESMO @OncoAlert @Netespana","2026-10-23T12:00:24.000Z","2026-10-24T14:45:14.000Z",[],{"_262":1886,"_264":1881,"_265":297,"_267":1887,"_269":1888},"i3fmmtgudv7jkqmjvvptwzu94","https://x.com/drenriquegrande/status/2113644057570185713","drenriquegrande","33077416-18db-4772-a253-98789f906844","👏👏 Amazing rapid orals session in #Neuroendocrinetumirs at #ESMO26",{"_270":1910,"_246":1864},"drug:telisotuzumab","telisotuzumab","#ESMO26 David Sommerhalder 医生介绍 M21-404 的 OS 数据：telisotuzumab adizutecan (Temab-A)，一种以 c-MET 为靶点、搭载 topo-1 载荷的 ADC。EGFR 野生型：mPFS 6.8个月，OS 13.8个月。EGFR 突变型：mPFS 10.9个月，OS 16.2个月。cMET 表达可预测 EGFRwt 患者的结局，但在 EGFRmt 中并非如此。","2026-10-14T12:00:00.000Z","2026-10-24T12:45:00.000Z",[1902,1903],{"_262":1899,"_264":1894,"_265":297,"_267":1900,"_269":1901},"yi5cr6a9d43u9hyw1q0jzuyvl","https://x.com/StephenVLiu/status/2113899551618637853","StephenVLiu",{"_382":1908,"_17":393,"_246":1909,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1904,"_17":393,"_246":1905,"_386":1906,"_388":-5,"_389":-5,"_390":1907},"791RO","Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/263","Rapid oral: Gastrointestinal tumours, lower digestive","2658RO","Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study","81d2f255-e14f-4063-8b54-49595298b238",{"_270":1921,"_246":1922},"tag:#sarcoma","#SARCOMA","欢迎来到马德里！ 🇪🇸\n\n@ManuPalmerini 和我期待为您带来来自 @myESMO #ESMO26 的最新 #sarcoma 见解。\n\n祝您今晚休息好，明早精神饱满见。\n\n#ESMOAmbassadors","2026-10-22T21:13:51.000Z","2026-10-24T14:41:26.000Z",[],{"_262":1919,"_264":1914,"_265":297,"_267":1920,"_269":1100},"dchd0vugja343dset2lfefm9l","https://x.com/herbloong/status/2113378323346903437","ebb404bb-68e4-465b-8db9-663907a758f1","Welcome to Madrid",{"_270":1935,"_246":1936},"tag:#precisiononcology","#PRECISIONONCOLOGY","🚨 ⭐ 请在日历上标记日期，并报名参加西班牙马德里 #ESMO26 Meeting 周边的一场活动 @myESMO \n\n📌 我很期待于2026年10月23日在马德里参加国际个性化医学联盟 @united4cancer 的活动。 \n\n👉 这次活动将汇聚专家和利益相关者，讨论个性化医学面临的挑战与机遇，促进对话，探讨如何将创新转化为对患者切实有益的成果。 \n\n👉 期待参与讨论，并在马德里与同行交流！ #128467;️ 2026年1","2026-10-21T08:52:17.000Z","2026-10-24T15:55:02.000Z",[],{"_262":1931,"_264":1932,"_265":297,"_267":1933,"_269":1934},"p0e2w1rcsjdk3vonemdwcn3i8","🚨 ⭐ 请在日历上标记日期，并报名参加西班牙马德里 #ESMO26 Meeting 周边的一场活动 @myESMO \n\n📌 我很期待于2026年10月23日在马德里参加国际个性化医学联盟 @united4cancer 的活动。 \n\n👉 这次活动将汇聚专家和利益相关者，讨论个性化医学面临的挑战与机遇，促进对话，探讨如何将创新转化为对患者切实有益的成果。 \n\n👉 期待参与讨论，并在马德里与同行交流！ #128467;️ 2026年10月23日 \n场地；IFEMA Congress Centre，A4.2会议室，夹层，马德里 @OncoAlert @oncodaily \n点击此处报名免费活动：\nhttps://docs.google.com/forms/d/e/1FAIpQLSdIzkMdzJ2L359NIW_ep0-c_2iHKZAG0cgitf1aCCXCKh6RWA/viewform","https://x.com/VivekSubbiah/status/2112920298412560626","VivekSubbiah","34e98629-1493-45cc-b244-90018f153fde","🚨 ⭐ Mark your calenders and register for an event around #ESMO26 Meeting, Madrid, Spain @myESMO 🚨 ⭐ Mark your calenders and register for a",{"_270":1950,"_246":1951},"gene:AKT","AKT","Peter Fasching 总结了专题讨论2前3场演讲中关于 HR+ 疾病的主题，@myesmo @OncoAlert #ESMO2026","2026-10-23T12:20:18.000Z","2026-10-24T15:50:39.000Z",[1948],{"_262":1945,"_264":1940,"_265":297,"_267":1946,"_269":1947},"iz510io8m5rwo4grlslx7pjp4","https://x.com/hoperugo/status/2113890866066751612","hoperugo",{"_382":1171,"_17":393,"_246":1172,"_386":1173,"_388":-5,"_389":1949,"_390":1175},[1176],"eb253426-4d2e-48f7-a72a-5d30e36ea10d","Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026 Peter Faschin",{"_270":1967,"_246":1968},"gene:TROP2","TROP2","TROPION-Breast02 脑转移分析（#ESMO26，Dent）。一线 Dato-DXd vs 化疗，mTNBC，n=61，伴有 BMs：\n\nCNS PFS：9.5 vs 2.6 个月，HR 0.27\n可测量病灶的 icORR：62.5% vs 37.5%\n未经治疗的 BMs：OS HR 0.35\n最长 icDoR 约 27 个月\n\n脑转移首选 Trop2 ADC！@RebeccaDSing\n探索性研究，样本量小，但存在真实的 ","2026-10-22T17:13:56.000Z","2026-10-24T08:07:02.000Z",[1964],{"_262":1960,"_264":1961,"_265":297,"_267":1962,"_269":1963},"pqybcapw0jaqmy3ypx57nf6c7","TROPION-Breast02 脑转移分析（#ESMO26，Dent）。一线 Dato-DXd vs 化疗，mTNBC，n=61，伴有 BMs：\n\nCNS PFS：9.5 vs 2.6 个月，HR 0.27\n可测量病灶的 icORR：62.5% vs 37.5%\n未经治疗的 BMs：OS HR 0.35\n最长 icDoR 约 27 个月\n\n脑转移首选 Trop2 ADC！@RebeccaDSing\n探索性研究，样本量小，但存在真实的 CNS 信号。#bcsm","https://x.com/drsarahsam/status/2113905090897568042","drsarahsam",{"_382":1965,"_17":393,"_246":1966,"_386":1169,"_388":-5,"_389":-5,"_390":1170},"2631RO","First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study","4aa1d09b-73da-4146-9b90-fa210f6904bc","TROPION-Breast02 brain mets analysis at #ESMO26 (Dent)",{"_270":1980,"_246":1981},"gene:PIK3CA","PIK3CA","VIKTORIA-1 #ESMO26\n\n在 PIK3CA 突变的 HR+/HER2− 晚期 #BreastCancer 接受 CDK4/6i 治疗后，基于 gedatolisib 的方案较 alpelisib + fulvestrant 改善了 PFS，且因不良事件导致治疗中止的情况更少（4–5% vs 19%）。\n\n@OncoAlert #bcsm @GustaveRoussy","2026-10-24T08:23:23.000Z","2026-10-24T11:41:28.000Z",[],{"_262":1977,"_264":1972,"_265":297,"_267":1978,"_269":1979},"q3zrenoacd995btowzizhtaj0","https://x.com/Dr_Oncologista/status/2113920013010702638","Dr_Oncologista","398e2750-3519-4479-a236-f1c538a7e061","VIKTORIA-1 #ESMO26 VIKTORIA-1 #ESMO26 In PIK3CA-mutated HR+/HER2− advanced #BreastCancer post-CDK4/6i, gedatolisib-based regimens improved P",{"_270":1994,"_246":1995},"code:KEYNOTE-564","KEYNOTE-564","7 年后，辅助性 pembrolizumab 仍是高危 ccRCC 的标准治疗吗？🤔\n\nKEYNOTE-564 的最终分析给出的答案是肯定的 👇\n✅ 7 年 OS：82.3% vs 76.6%\n✅ 7 年 DFS：57.2% vs 44.6%\n\n目前只有摘要。完整数据将在 #ESMO26 亮相 🎤\n#OncoAlert4SIGHT 🚨 #KidneyCancer","2026-10-16T00:00:00.000Z","2026-10-23T22:52:41.000Z",[1993],{"_262":1990,"_264":1985,"_265":297,"_267":1991,"_269":1992},"cljq1ywowbwy78gygrgqx1lvy","https://x.com/weoncologists/status/2113580241318817802","weoncologists",{"_382":392,"_17":393,"_246":394,"_386":395,"_388":-5,"_389":-5,"_390":396},"b6a67c9b-d7f4-417c-b1c6-050112212c41","Is adjuvant pembrolizumab still the standard for high-risk ccRCC after 7 years",{"_270":2006,"_246":2007},"gene:TP53","TP53","#ESMO26 | NIAGARA 围手术期 durva+ 化疗改善了 MIBC 分子亚型的 EFS。TMB-high：HR 0.44 TP53-mut：HR 0.51 FGFR3-mut：HR 0.24 B-s 和 luminal-Inf 肿瘤呈现免疫特征，且 pCR 更高 @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily","2026-10-24T07:21:16.000Z","2026-10-24T11:00:44.000Z",[],{"_262":2004,"_264":1999,"_265":297,"_267":2005,"_269":805},"umxzzo1oubc4xonk37e2b2oww","https://x.com/zapatalaguadomd/status/2113925651962937494","ba728c00-9f72-449d-83ed-dc067ae1266f","#ESMO26 | NIAGARA Perioperative durva+ chemo improved EFS in molecular subtypes of MIBC",{"_270":2037,"_246":2038},"drug:encorafenib","encorafenib","Encorafenib联合cetuximab在FOLFIRI基础上用于EC治疗期间出现进展的BRAF V600E mCRC患者的超越进展治疗：ECLYPse II期试验结果\n#ESMO26 #ESMOAmbassadors\n👉 mPFS: 7.1\n👉 mOS: NR\n👉ORR 15%\n🧐继续使用EC的信号令人关注，若有更多转化数据会更好\n@myESMO @ASCO",7,"2026-10-24T12:56:43.000Z","2026-10-24T18:22:32.000Z",[2020,2021,2022,2023],{"_262":2017,"_264":2011,"_265":297,"_267":2018,"_269":2019},"s2g3wxylknrrv4d9ec8xxxt00","https://x.com/ArndtVogel/status/2113977989767557189","ArndtVogel",{"_382":2033,"_17":393,"_246":2034,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":1694,"_17":393,"_246":2032,"_386":1906,"_388":-5,"_389":-5,"_390":1907},{"_382":2028,"_17":393,"_246":2029,"_386":2030,"_388":-5,"_389":2031,"_390":2029},{"_382":2024,"_17":393,"_246":2025,"_386":2026,"_388":-5,"_389":2027,"_390":2025},"NCT06640166","- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","https://clinicaltrials.gov/study/NCT06640166",[2024],"NCT06578559","- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","https://clinicaltrials.gov/study/NCT06578559",[2028],"Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial","2071O","STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/250","Proffered paper: Melanoma and other skin tumours","0f51bdcb-23f7-4c9a-8f3a-41e297f7579e","Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse pha",{"_270":2064,"_246":2065},"tag:#nsclc","#NSCLC","🧿 在 #ESMO26 上塑造 #NSCLC 的未来\n\n很荣幸今天在马德里与 @MARIANOPROVENCI、Enriqueta Felip 及 Marcia K. Horn @Exon20Group 共同主持研讨会\n\n将科学进展转化为造福患者的成果，造福今日与未来。","2026-10-22T19:00:00.000Z","2026-10-24T07:44:58.000Z",[2049,2050,2051,2052,2053,2054,2055,2056],{"_262":2047,"_264":2042,"_265":297,"_267":2048,"_269":1598},"fos7kf0aj8buszuypwc8r5ugr","https://x.com/APassaroMD/status/2113503094231204217",{"_382":2059,"_17":393,"_246":2060,"_386":395,"_388":-5,"_389":2061,"_390":2062},{"_382":1965,"_17":393,"_246":1966,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1167,"_17":393,"_246":1168,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1908,"_17":393,"_246":1909,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":605,"_17":393,"_246":606,"_386":395,"_388":-5,"_389":-5,"_390":607},{"_382":1455,"_17":393,"_246":1456,"_386":395,"_388":-5,"_389":-5,"_390":607},{"_382":1600,"_17":393,"_246":1601,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":2057,"_17":393,"_246":2058,"_386":1169,"_388":-5,"_389":-5,"_390":1170},"2719RO","FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)","2551TIP","Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer",[2063,2063,2063],"NSCLC, early stage","NCT07541170","fcc804e5-69c6-4c05-9c79-d23e1dabc3f9","🧿 Shaping the future of #NSCLC at #ESMO26 🧿 Shaping the future of #NSCLC at #ESMO26 Delighted to co-chair today’s symposium in Madrid with",{"_270":2077,"_246":2078},"drug:sintilimab","sintilimab","🚨 我的前 4 大 #Melanoma #ESMO26 GC101 TIL：没有完整毒性负担的 TIL？\n\n≥2 线抗 PD-1 耐药黑色素瘤的随机 II 期试验！值得注意的是 73% 为肢端/黏膜型！！！\n\n▪️PFS：4.37 对 1.61 个月（HR 0.44）\n💥 ORR：44% 对 8%\n- 肢端型：ORR 45% 对 8%\n- 黏膜型：ORR 50% 对 0%\n\n无 IL-2 + 降低强度淋巴清除 👀，讨论者质疑 50","2026-10-16T12:00:00.000Z","2026-10-23T15:37:38.000Z",[],{"_262":2074,"_264":2075,"_265":297,"_267":2076,"_269":599},"zth9mi308zoog195t00ory9bw","🚨 我的前 4 大 #Melanoma #ESMO26 GC101 TIL：没有完整毒性负担的 TIL？\n\n≥2 线抗 PD-1 耐药黑色素瘤的随机 II 期试验！值得注意的是 73% 为肢端/黏膜型！！！\n\n▪️PFS：4.37 对 1.61 个月（HR 0.44）\n💥 ORR：44% 对 8%\n- 肢端型：ORR 45% 对 8%\n- 黏膜型：ORR 50% 对 0%\n\n无 IL-2 + 降低强度淋巴清除 👀，讨论者质疑 50% 剂量 sintilimab 是否真的改变很多……\n\n@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma","https://x.com/MarioBalsaMD/status/2113656100012589476","a1b4f0eb-409b-48b0-ab92-199cb1295ed6","🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage",{"_270":2099,"_246":2100},"tag:#sclc","#SCLC","当我看到总生存曲线的那一刻，我就想站起来鼓掌！👏\n\n在#ESMO26，我们这40,000人怀着同样的兴奋与希望，不是为了我们自己，而是为了我们的患者。❤️\n\n这是#SCLC中一个真正令人动情的时刻。\n\n#DeLLphi305 @StephenVLiu @sands_jacob @lungoncdoc","2026-10-22T13:01:52.000Z","2026-10-24T22:03:18.000Z",[2090,2091,2092,2093,2094,2095,2096,2097],{"_262":2087,"_264":2082,"_265":297,"_267":2088,"_269":2089},"ruji5da44k6ld27v1hnk2119k","https://x.com/ErulEnes/status/2114026261475361270","ErulEnes",{"_382":2059,"_17":393,"_246":2060,"_386":395,"_388":-5,"_389":2098,"_390":2062},{"_382":1965,"_17":393,"_246":1966,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1167,"_17":393,"_246":1168,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1908,"_17":393,"_246":1909,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":605,"_17":393,"_246":606,"_386":395,"_388":-5,"_389":-5,"_390":607},{"_382":1455,"_17":393,"_246":1456,"_386":395,"_388":-5,"_389":-5,"_390":607},{"_382":1600,"_17":393,"_246":1601,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":2057,"_17":393,"_246":2058,"_386":1169,"_388":-5,"_389":-5,"_390":1170},[2063,2063,2063],"340a9b59-4a18-4364-b154-17f5c2c034d4","The moment I saw the overall survival curves, I wanted to stand up and applaud",{"_270":2111,"_246":2112},"code:POTOMAC","POTOMAC","#ESMO26 POTOMAC 研究数据聚焦于仅乳头状的高危 NMIBC。Durva + BCG 降低了高危事件（13% vs 20%），并改善了无膀胱切除生存期（HR 0.59）\n\n鉴于 G3/4 AEs 的发生率更高（23% vs 3%），获益–毒性权衡仍是关键\n\n@OncoAlert","2026-10-24T08:24:13.000Z","2026-10-24T14:00:01.000Z",[],{"_262":2109,"_264":2104,"_265":297,"_267":2110,"_269":967},"g4x9cyad5tdbmesw4y8igg8g0","https://x.com/scocmem/status/2113910780034707742","95a9c47d-2cee-4f8c-a79d-ddf2593a4e91","#ESMO26 Data from POTOMAC focusing on papillary-only high-risk NMIBC",{"_270":2128,"_246":2129},"drug:cetuximab","cetuximab","QTX3034（一种口服 G12D 偏好型 KRAS 抑制剂）联合 cetuximab ± mFOLFOX6 治疗 KRASG12D-mCRC 的初步临床结果\n#ESMO26 #ESMOAmbassadors\n👉ORR：25% vs 50%，DCR：75 vs 90%\n👉未发现新的安全性信号\n🧐支持与 CTx 联用\n@myESMO @ASCO","2026-10-12T00:00:00.000Z","2026-10-24T13:28:45.000Z",[2123,2124,2125],{"_262":2121,"_264":2116,"_265":297,"_267":2122,"_269":2019},"uvg4atpki52hzehlxy3a8f6gq","https://x.com/ArndtVogel/status/2113984837975523708",{"_382":1694,"_17":393,"_246":2032,"_386":1906,"_388":-5,"_389":-5,"_390":1907},{"_382":2028,"_17":393,"_246":2029,"_386":2030,"_388":-5,"_389":2127,"_390":2029},{"_382":2024,"_17":393,"_246":2025,"_386":2026,"_388":-5,"_389":2126,"_390":2025},[2024],[2028],"c05d4c58-f003-4c5d-a0b4-ee1535ba8e15","Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC Preliminary clini",{"_270":2145,"_246":2146},"drug:toripalimab","toripalimab","在 #ESMO26 上公布了局部晚期阴茎癌的令人振奋数据！\n\n新辅助 toripalimab + TIP 在 II 期研究（n=25）中实现了 84% 的 ORR 和 48% 的 pCR。@OncoAlert #HuiHan","2026-10-19T04:40:00.000Z","2026-10-24T13:00:21.000Z",[2141],{"_262":2138,"_264":2133,"_265":297,"_267":2139,"_269":2140},"omjkltb952p4dh3ocjqyrzc8w","https://x.com/dmukherji/status/2113595068271763785","dmukherji",{"_382":2142,"_17":393,"_246":2143,"_386":1173,"_388":-5,"_389":2144,"_390":1175},"1209RO","Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial",[1176],"58d570f7-97d1-419f-89c6-30abe5e9cef7","Promising data in locally advanced penile cancer at #ESMO26",{"_270":2159,"_246":2160},"code:PSMA-617","PSMA-617","Re-LuPSMA: II期临床试验中期安全性：177Lu-PSMA-617 在 mCRPC 中的再治疗 @urotoday #ESMO26 @CalaisJeremie \n\n📌n=20/40\n📌中位再治疗周期：3（IQR 2–5）\n📌165 例不良事件，88 例可能与治疗相关：1级（n=53）；2级（n=14）；3级（n=13）；4级（n=8）\n📌最常见治疗相关不良事件：白细胞减少（n=12）、贫血（n=15）、血小板减少（n","2026-10-20T14:48:00.000Z","2026-10-24T22:22:06.000Z",[],{"_262":2155,"_264":2156,"_265":297,"_267":2157,"_269":2158},"evwxovwzlciw0uzbcq6dsaw03","Re-LuPSMA: II期临床试验中期安全性：177Lu-PSMA-617 在 mCRPC 中的再治疗 @urotoday #ESMO26 @CalaisJeremie \n\n📌n=20/40\n📌中位再治疗周期：3（IQR 2–5）\n📌165 例不良事件，88 例可能与治疗相关：1级（n=53）；2级（n=14）；3级（n=13）；4级（n=8）\n📌最常见治疗相关不良事件：白细胞减少（n=12）、贫血（n=15）、血小板减少（n=10）、口干（n=10）","https://x.com/zklaassen_md/status/2113637996943515837","zklaassen_md","001e5e8d-cb81-4f7f-8e2f-994ab4f2ac01","Re-LuPSMA: Interim Safety of a Ph II Trial of 177Lu-PSMA-617 Retreatment in mCRPC @urotoday #ESMO26 @CalaisJeremie Re-LuPSMA: Interim Safety",{"_270":2172,"_246":2173},"tag:#lungcancer","#LUNGCANCER","#ESMO26 最棒的事情之一？与好友和鼓舞人心的同事重逢！\n很高兴能与 @g_mountzios 重聚。不同的旅程，同一个共同愿望：改善患者的生活，并为能够治愈癌症的未来而努力。\n科学让我们走到一起。友谊让这段旅程更加美好！💙 #ESMOAmbassador\n#ESMO26 #Oncology #LungCancer #CancerResearch",10,"2026-10-20T20:29:23.000Z","2026-10-24T11:10:56.000Z",[],{"_262":2170,"_264":2164,"_265":297,"_267":2171,"_269":929},"kesiunlt0497aymcbgn2te7ga","https://x.com/Alfdoc2/status/2113583483658342876","4388aff3-721c-42da-a5b8-81f6e878e90d","One of the best things about #ESMO26",{"_270":2185,"_246":2186},"drug:lenvatinib","lenvatinib","正在为 @myESMO #ESMO26 的 #NETs 环节中的 #RapidOral 场次做准备\n\n@FRANCES88189587 @GCarboneroLab #MariannePavel #AnjaRinke\n\n#WiN #ESMOAmbassadors","2026-10-13T12:00:00.000Z","2026-10-24T17:20:10.000Z",[],{"_262":2182,"_264":2177,"_265":297,"_267":2183,"_269":2184},"w88j3rhdoili3c1puhi8j7vgy","https://x.com/DrAngelaLamarca/status/2113636779240927326","DrAngelaLamarca","6b22f0e8-db8d-4f90-b74c-36fb24d69a82","Getting ready for the #RapidOral session in #NETs at @myESMO #ESMO26 Getting ready for the #RapidOral session in #NETs at @myESMO #ESMO26 @F",{"_270":2197,"_246":2198},"drug:tislelizumab","tislelizumab","🎯 #ESMO2026 第2天：GU非前列腺快速口头报告专场。@Uro_Oncologist介绍了EV-304围手术期MIBC的HRQL！！ \nEV +pembro与总体HRQoL或膀胱切除术特异性HRQoL出现具有临床意义的下降无关联！！ @OncoAlert @myESMO @GuardConsortium @DrChoueiri @tompowles1 @urotoday @PGrivasMDPhD","2026-10-24T09:54:19.000Z",[2196],{"_262":2194,"_264":2190,"_265":297,"_267":2195,"_269":1416},"tbmej8ykajtom81v96bm0vzhp","https://x.com/cdanicas/status/2113913260277665962",{"_382":383,"_17":384,"_246":385,"_386":387,"_388":-5,"_389":-5,"_390":391},"dff7b13c-ad69-44ca-a6ee-efb62fc9f875","🎯 #ESMO2026 2º day Rapid oral GU non-prostate session",{"_270":2235,"_246":2236},"tag:#melanoma","#MELANOMA","对 #melanoma 癌症患者来说是个好消息：根据在今年马德里举行的 #ESMO26 会议上展示的研究，一种旨在防止手术后黑色素瘤复发的个性化 #cancervaccine 新结果显示了积极成果。\n\n研究发现，将专门定制的癌症疫苗添加到标准免疫治疗中，与单独使用标准免疫治疗相比，成功将黑色素瘤复发的风险降低了 42%。\n\n“这种治疗的思路是，通过专门增强患者的免疫系统以识别其自身的肿瘤细胞，我们可以降低癌症复发的风险，”MSK 黑色素","2026-10-23T20:54:30.000Z","2026-10-24T14:57:22.000Z",[2211,2212,2213,2214,2215,2216,2217,2218],{"_262":2207,"_264":2208,"_265":297,"_267":2209,"_269":2210},"j1r6zxwduldk8zhka82pesp42","对 #melanoma 癌症患者来说是个好消息：根据在今年马德里举行的 #ESMO26 会议上展示的研究，一种旨在防止手术后黑色素瘤复发的个性化 #cancervaccine 新结果显示了积极成果。\n\n研究发现，将专门定制的癌症疫苗添加到标准免疫治疗中，与单独使用标准免疫治疗相比，成功将黑色素瘤复发的风险降低了 42%。\n\n“这种治疗的思路是，通过专门增强患者的免疫系统以识别其自身的肿瘤细胞，我们可以降低癌症复发的风险，”MSK 黑色素瘤服务主任 Michael Postow 博士表示。“即使在 CT 或 PET 扫描上看不到任何癌症，我们也知道它往往仍然存在——因为如此高比例的患者最终会出现癌症复发。这就是为什么对这种治疗有巨大需求。”\n\n了解更多关于试验中接受治疗的三位 MSK 患者之一的信息：https://bit.ly/3W0Voj2","https://x.com/MSKCancerCenter/status/2113735841184944170","MSKCancerCenter",{"_382":2033,"_17":393,"_246":2034,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":2233,"_17":393,"_246":2234,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":2231,"_17":393,"_246":2232,"_386":395,"_388":-5,"_389":-5,"_390":2226},{"_382":2228,"_17":393,"_246":2229,"_386":395,"_388":-5,"_389":2230,"_390":2226},{"_382":2223,"_17":393,"_246":2224,"_386":395,"_388":-5,"_389":2225,"_390":2226},{"_382":514,"_17":384,"_246":515,"_386":516,"_388":-5,"_389":-5,"_390":517},{"_382":2221,"_17":384,"_246":2222,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":2219,"_17":384,"_246":2220,"_386":2035,"_388":-5,"_389":-5,"_390":2036},"LBA55","Autologous tumor-infiltrating lymphocytes (GC101 TIL) in advanced melanoma: Extended follow-up of a randomized, open-label, pivotal phase II trial","LBA54","Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma","2099P","Impact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial",[2227,2227,2227],"Melanoma","NCT04949113","2081P","Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity",[2227,2227,2227],"2079P","Transcriptomic and epigenomic profiling of TIL products identifies determinants of clinical benefit in advanced melanoma","2072O","Efficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study","81df9bd1-8b05-4a56-8276-46fa9e485193","Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after su",{"_270":2249,"_246":1864},"drug:lorlatinib","lorlatinib","很荣幸在 #ESMO2026 分享科威特癌症控制中心使用 lorlatinib 治疗 ALK+ NSCLC 的长期真实世界经验\n\n单中心回顾性队列 (N=26)：\nORR: 83%\nDCR: 96%\n持续用药时间最长：>85 个月\n\n#LCSM #ALK","2026-10-24T07:16:02.000Z","2026-10-24T13:34:17.000Z",[2248],{"_262":2245,"_264":2240,"_265":297,"_267":2246,"_269":2247},"odrehulapuljdyaslj8a6x0tv","https://x.com/DrZ_84/status/2113987443242455333","DrZ_84",{"_382":1167,"_17":393,"_246":1168,"_386":1169,"_388":-5,"_389":-5,"_390":1170},"594fb838-594f-476d-9294-077ed7f00114",{"_270":2265,"_246":2266},"drug:palbociclib","palbociclib","🟣❓ 循环生物标志物的组合能否帮助识别出具有更高进展风险的转移性乳腺癌患者？\\n\\n🔬 在 #ESMO26 框架下，@GEICAM 展示了 II 期 FLIPPER 临床试验（GEICAM/2014-12）的一项回顾性分析新结果，该试验由 Federico Rojo 博士和 Joan Albanell 博士领导，证实了在 RH+/HER2− 转移性乳腺癌绝经后患者中，作为一线治疗给予 palbociclib（CDK4/6 抑制剂）联",8,"2026-10-08T00:00:00.000Z","2026-10-24T21:04:59.000Z",[2262],{"_262":2259,"_264":2260,"_265":297,"_267":2261,"_269":681},"yevnvqm8od8e3f2aicxtcdwoi","🟣❓ 循环生物标志物的组合能否帮助识别出具有更高进展风险的转移性乳腺癌患者？\\n\\n🔬 在 #ESMO26 框架下，@GEICAM 展示了 II 期 FLIPPER 临床试验（GEICAM/2014-12）的一项回顾性分析新结果，该试验由 Federico Rojo 博士和 Joan Albanell 博士领导，证实了在 RH+/HER2− 转移性乳腺癌绝经后患者中，作为一线治疗给予 palbociclib（CDK4/6 抑制剂）联合 fulvestrant（内分泌治疗）的获益。\\n\\n🩸 这项基于液体活检的新转化分析评估了循环肿瘤 DNA (ctDNA) 及胸苷激酶酶活性 (TKa，肿瘤增殖生物标志物) 的预后和预测潜力。\\n\\n📊 分析纳入了 187 例（99%）患者的 903 份连续血浆样本。无论是在治疗开始前还是第 12 周，ctDNA 中检测到 ≥2 个突变以及 TKa 水平升高，均独立与早期进展和生存期缩短相关。\\n\\n🔎 ≥2 个突变的检测与接受 fulvestrant 治疗的患者预后较差关联更紧密，而 TKa 升高则与接受 fulvestrant 联合 palbociclib 的患者预后较差相关。\\n\\n🧬 两种生物标志物的整合识别出一个高风险亚组，占分析患者的 7%，其无进展生存期约缩短一半，早期疾病进展的概率高出六倍以上。\\n\\n🧪 分子监测显示，在进展时 ESR1 和 TP53 突变增加，反映了治疗期间肿瘤分子谱的演变，并为可能的耐药机制提供了线索。\\n\\n🎯 这些结果由 Dr. Federico Rojo 以海报形式呈现，他是 transGEICAM 协调员兼本研究主要研究者，支持整合循环生物标志物以改善风险分层，并推动更个性化治疗策略的研究。\\n\\n🔗 https://www.geicam.org/wp-content/uploads/2026/10/ESMO-2026_FLIPPER-TKa_ctDNA_v4.pdf\\n\\n🟣 #ESMO2026\\n🔬 @myESMO \\n\\n#CáncerDeMama #BreastCancer #Oncología #InvestigaciónOncológica #Biomarcadores #BiopsiaLíquida #MedicinaPersonalizada #PrecisionOncology","https://x.com/GEICAM/status/2113619233800163734",{"_382":2263,"_17":384,"_246":2264,"_386":1216,"_388":-5,"_389":-5,"_390":1217},"LBA16","VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)","26e2ec17-5695-4d30-90bd-01e9baa4697b","🟣❓ ¿Puede la combinación de biomarcadores circulantes ayudar a identificar a pacientes con cáncer de mama metastásico con mayor riesgo de p",{"_270":2282,"_246":2283},"code:CAPITELLO-281","CAPITELLO-281","从生物学研究走向患者获益。\nCAPItello-281 让 PTEN 靶向治疗更接近临床实践。很荣幸参与这项研究。\n@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @Annals_Oncology @tompowles1","2026-10-23T11:55:00.000Z","2026-10-24T09:30:13.000Z",[2278],{"_262":2275,"_264":2270,"_265":297,"_267":2276,"_269":2277},"u42j6r5r2jzb1hfwecnap0amz","https://x.com/DrYukselUrun/status/2113645014882398350","DrYukselUrun",{"_382":2279,"_17":384,"_246":2280,"_386":1173,"_388":-5,"_389":2281,"_390":1175},"LBA56","Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281",[1176],"023c8fb8-2b56-463f-aa4d-2f76decd9e89","From biology to patient benefit",{"_270":2298,"_246":2299},"drug:atirmociclib","atirmociclib","#ESMO26 大会 #BreastCancer 分会口头报告摘要：在内分泌耐药患者中，使用 #CDK4 抑制剂 #atirmociclib 联合 #fulvestrant 的2期结果，由杰出的 @antgiorda 🇮🇹 报告\n\n@OncoAlert @myESMO @Annals_Oncology","2026-10-22T22:01:00.000Z","2026-10-24T07:49:11.000Z",[2295],{"_262":2292,"_264":2287,"_265":297,"_267":2293,"_269":2294},"oxzwn2fsrk5tf3covxut30xw4","https://x.com/matteolambe/status/2113889857181209084","matteolambe",{"_382":2296,"_17":393,"_246":2297,"_386":1072,"_388":-5,"_389":-5,"_390":1073},"1842O","Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)","3c906539-bc2c-4b5f-a335-c635b317c5f0","Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented",{"_270":2314,"_246":2315},"drug:ipatasertib","ipatasertib","FINER 表明，ipatasertib + fulvestrant 可改善 ITT 和 AKT 通路改变队列的 PFS（但不能改善 OS），并伴有值得注意的 AEs\n\n#ESMO26 @OncoAlert",9,"2026-10-23T22:30:58.000Z","2026-10-24T22:54:04.000Z",[2311],{"_262":2309,"_264":2303,"_265":297,"_267":2310,"_269":1727},"t1ch3i0mp5e81jlkalzfqmzeq","https://x.com/DrSGraff/status/2113887289084624919",{"_382":2312,"_17":384,"_246":2313,"_386":1072,"_388":-5,"_389":-5,"_390":1073},"LBA14","A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/","9302d91f-3089-4c1d-a39a-e4bdd19f433e","At #ESMO26 Proffered Paper 2️⃣ on #breastcancer At #ESMO26 Proffered Paper 2️⃣ on #breastcancer Results of the FINER trial Ipatasertib + ful",{"_270":2328,"_246":2329},"tag:#madrid","#MADRID","前往 #Madrid 参加 #ESMO26\\n作为放射肿瘤科医生，我挑选的 5 篇 *摘要*\\n1. Athletico Madrid vs Deportivo (Metropolitano)\\n2. “El Classico” - Barcelona Vs Real Madrid (马德里的任意酒吧)\\n3. 最新消息：Onco-Karaoke - 待定\\n4. SARON results - (Alicante)\\n5. 我原本想说","2026-10-22T05:58:05.000Z","2026-10-24T16:37:53.000Z",[],{"_262":2324,"_264":2325,"_265":297,"_267":2326,"_269":2327},"ewapn1w8100wokyws1fepnyyb","前往 #Madrid 参加 #ESMO26\\n作为放射肿瘤科医生，我挑选的 5 篇 *摘要*\\n1. Athletico Madrid vs Deportivo (Metropolitano)\\n2. “El Classico” - Barcelona Vs Real Madrid (马德里的任意酒吧)\\n3. 最新消息：Onco-Karaoke - 待定\\n4. SARON results - (Alicante)\\n5. 我原本想说 “top 4”","https://x.com/cpeedell/status/2113147864444490068","cpeedell","da55e6ed-627b-4fca-890f-5123a1344adf","Heading to #Madrid for #ESMO26 Heading to #Madrid for #ESMO26 My top 5 *abstracts* as a radiation oncologist 1",{"_270":2350,"_246":2351},"drug:bevacizumab","bevacizumab","Temab-A (ABBV-400) + bevacizumab 治疗 3L+ CRC：更新的 I 期数据\n👉 使用 FTD-TPI + Bev 时，mOS 为 14.7 vs 10.2 个月\n👉 HR 0.62 (95% CI 0.33–1.18)\nADC 信号令人鼓舞。在 Annals of Oncology 同步发表！\n#ESMO26 #ESMOAmbassadors @OncoAlert","2026-10-24T15:30:15.000Z",[2340,2341,2342,2343,2344],{"_262":2337,"_264":2333,"_265":297,"_267":2338,"_269":2339},"c5cqg3nhots6nvjh0tzk6wxma","https://x.com/EvelynWongYT/status/2113986916626637146","EvelynWongYT",{"_382":1273,"_17":393,"_246":1274,"_386":1256,"_388":-5,"_389":-5,"_390":1257},{"_382":1904,"_17":393,"_246":1905,"_386":1906,"_388":-5,"_389":-5,"_390":1907},{"_382":2348,"_17":393,"_246":2349,"_386":395,"_388":-5,"_389":-5,"_390":1152},{"_382":1045,"_17":384,"_246":2347,"_386":1906,"_388":-5,"_389":-5,"_390":1907},{"_382":2345,"_17":384,"_246":2346,"_386":1256,"_388":-5,"_389":-5,"_390":1257},"LBA38","Final overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic","Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial","833P","Outcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study","1a84b238-955c-4cb3-9842-ba16ed68192d","Temab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data Temab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data 👉 mOS 1",{"_270":2372,"_246":2373},"gene:EGFR","EGFR","#PANKUBreast01\n \nIII 期结果显示，iza bren（双特异性 EGFR/HER3 ADC）与 TPC 化疗在既往治疗过的 HR+/HER- MBC 中的对比\n\n🔹mPFS：4.0 对 8.1 月，HR 0.41 \n🔹 ORR：20% 对 40%\n🔹 DoR：4.2 对 6.9 月\n🔹 ILD：仅 1.1% 且均为 1/2 级\n\n#ESMO26 #ESMOAmbassadors",13,"2026-10-23T10:32:17.000Z","2026-10-24T14:44:47.000Z",[2364,2365,2366],{"_262":2361,"_264":2355,"_265":297,"_267":2362,"_269":2363},"z4ofbmaj1029yuyl3nlaght7p","https://x.com/ErikaHamilton9/status/2113614882889437329","ErikaHamilton9",{"_382":1600,"_17":393,"_246":1601,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":1149,"_17":393,"_246":1150,"_386":395,"_388":-5,"_389":2371,"_390":1152},{"_382":2367,"_17":393,"_246":2368,"_386":2369,"_388":-5,"_389":2370,"_390":2368},"NCT06110663","- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","https://clinicaltrials.gov/study/NCT06110663",[2367],[1153,1153,1153],"bee61ca0-29fd-4c17-bbee-c3240d703f33","#PANKUBreast01 #PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPF",{"_270":2389,"_246":2390},"drug:osimertinib","osimertinib","#ESMO26 Martin Sebastian 医生介绍了 PACE-LUNG：一项 osimertinib 单药治疗 EGFR NSCLC 的 II 期研究。在第3周检测 ctDNA，若呈阳性，则加用4个周期的化疗。第3周时，72/255 例患者的 ctDNA 呈阳性。从开始使用 osi 起，mPFS 为17.8个月，OS 为31.5个月——无对照组，但结果令人鼓舞。",12,"2026-10-15T12:00:00.000Z","2026-10-24T10:42:51.000Z",[2385,2386],{"_262":2383,"_264":2377,"_265":297,"_267":2384,"_269":1901},"s18hebg52i51uqwu7bwpz7gvr","https://x.com/StephenVLiu/status/2113882584367165877",{"_382":2057,"_17":393,"_246":2058,"_386":1169,"_388":-5,"_389":-5,"_390":1170},{"_382":2387,"_17":384,"_246":2388,"_386":1169,"_388":-5,"_389":-5,"_390":1170},"LBA73","PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line","4f169784-6465-4ef4-b6d3-f08957469667","#ESMO2026 opened today in Madrid, and a big focus for EGFR+ #lungcancer is what happens when osimertinib stops working",{"_270":2407,"_246":2408},"drug:anbenitamab","anbenitamab","安贝尼单抗联合化疗用于既往治疗过的HER2阳性GC/GEJC：KC-WISE的OS更新分析 🇨🇳\n#ESMO26 #ESMOAmbassadors\n👉 ORR：56% vs 13%\n👉 mOS：19.6 vs 9.7个月\n👉 未观察到意外安全性信号\n🧐 支持HER2的序贯靶向\n@myESMO @ASCO","2026-10-23T14:26:29.000Z","2026-10-24T17:55:33.000Z",[2401,2402],{"_262":2399,"_264":2394,"_265":297,"_267":2400,"_269":2019},"jk5a1eekxlx52lt5rrsvbaomx","https://x.com/ArndtVogel/status/2113638192481960446",{"_382":2405,"_17":384,"_246":2406,"_386":1072,"_388":-5,"_389":-5,"_390":1073},{"_382":2403,"_17":384,"_246":2404,"_386":387,"_388":-5,"_389":-5,"_390":391},"LBA80","Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE","LBA15","Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study","d30a328a-b251-4d72-9467-509ef4da11a9","Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳 Anbenitamab plus chemotherap",{"_270":2431,"_246":2432},"drug:sacituzumab","sacituzumab","为 @LucaVisani2 和我们的佛罗伦萨团队感到自豪，他们代表一个国际联盟展示了这份海报——关于将 sacituzumab govitecan 与 #radiotherapy 联合用于 #breastcancer 的全新数据\n\n敬请期待更多内容！ #ESMO26\n\n#OncoAlert @OncoAlert @AOUCareggi @UNI_FIRENZE",15,"2026-10-19T11:55:00.000Z","2026-10-24T16:10:37.000Z",[2421,2422,2423,2424],{"_262":2418,"_264":2412,"_265":297,"_267":2419,"_269":2420},"r8vgi0f3crjy92iccz6n5bp27","https://x.com/Icro_Meattini/status/2114026787130814606","Icro_Meattini",{"_382":1269,"_17":393,"_246":1270,"_386":395,"_388":-5,"_389":2430,"_390":628},{"_382":2427,"_17":393,"_246":2428,"_386":395,"_388":-5,"_389":-5,"_390":2429},{"_382":2425,"_17":393,"_246":2426,"_386":971,"_388":-5,"_389":-5,"_390":972},{"_382":1569,"_17":393,"_246":1570,"_386":1162,"_388":-5,"_389":-5,"_390":1163},"4739RO","Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)","35P","Comparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching","Advanced breast cancer, other",[1272,1272,1272],"a5b76b50-84f3-432e-a00e-425788823503","Proud of @LucaVisani2 and our Florence team presenting this poster on behalf of an international consortium - brand new data on combining sa",{"_270":2445,"_246":2446},"code:JNJ-6143","JNJ-6143","🚨⭐🔵 #ESMO26 mCRPC 中新型 AR 靶向疗法\n🎤 由 Alice Bernard-Tessier 主讲\n@OncoAlert\n\n🔬 雄激素受体（AR）仍是 mCRPC 的核心治疗靶点，但该领域显然正在发展，并超越传统 ARPI。\n📌 关键概念\n\n🧬 1. AR 改变十分常见\nAR 改变在 mCRPC 中十分常见，在高达 80% 的患者中可发现，包括：\n• AR 扩增\n• AR 突变\n• AR 剪接变体\n• AR",14,"2026-10-23T14:34:20.000Z","2026-10-24T19:54:24.000Z",[],{"_262":2442,"_264":2443,"_265":297,"_267":2444,"_269":1013},"v3dhzxhkne3xf26qvfwnlpdpx","🚨⭐🔵 #ESMO26 mCRPC 中新型 AR 靶向疗法\n🎤 由 Alice Bernard-Tessier 主讲\n@OncoAlert\n\n🔬 雄激素受体（AR）仍是 mCRPC 的核心治疗靶点，但该领域显然正在发展，并超越传统 ARPI。\n📌 关键概念\n\n🧬 1. AR 改变十分常见\nAR 改变在 mCRPC 中十分常见，在高达 80% 的患者中可发现，包括：\n• AR 扩增\n• AR 突变\n• AR 剪接变体\n• AR 重排\n\n这些改变与预后不佳相关，但它们作为 ARPI 耐药预测性生物标志物的作用尚未得到充分验证。\n\n💊 2. 下一代 AR 靶向治疗的版图正在扩大\n本次会议回顾了标准 AR 通路抑制之外的多种新策略：\n• 下一代 AR 抑制剂\n• AR 降解剂\n• CYP11A1 抑制\n• RIPTACs，一种利用 AR 存在性而非经典 AR 依赖性的全新概念\n🧪 3. AR 降解剂正获得发展势头\n新出现的化合物和试验提示，AR 降解可能克服当前 ARPI 尚未充分解决的耐药机制。\n讨论中提到的例子包括：\n• Luxdegalutamide\n• BMS-986460\n• 其他处于临床开发阶段的 AR 降解剂\n🧬 4. 基因型可能越来越多地指导用药选择\n这次报告传达的一项重要实用信息：\n“基因型决定用药。”\n\n不同新型策略可能更适合不同的 AR 改变：\n• 当肿瘤携带 AR 改变时，AR 降解剂和 CYP11A1 抑制可能尤其相关\n• AR 激活性突变可能揭示生物学上不同的治疗易感点\n\n💥 5. RIPTACs 可能改变范式\nRIPTAC 概念尤其引人关注，因为它推动该领域：\n➡️ 从 AR 依赖性转向 AR 存在性\n\n即使在经典 AR 依赖性不太明确的肿瘤中，这也可能扩大 AR 靶向治疗的适用范围。\nJNJ-6143 的早期 1 期数据显示，在不同剂量和异质性分子背景下均出现了 PSA 应答。\n📌 核心要点\n1️⃣ AR 仍是治疗靶点。\n2️⃣ AR 改变十分常见，并驱动 ARPI 耐药。\n3️⃣ 基因型可能日益决定治疗选择。\n4️⃣ RIPTACs 为 AR 靶向治疗引入了一个潜在的新框架。\n⭐ 我的观点 | 临床启示\n\n这次报告进一步表明，mCRPC 正进入一个生物学分层更加精细的时代。\n未来并非只是“更多 AR 阻断”，而是更明智的 AR 靶向治疗——针对正确的耐药生物学机制，选择正确的作用机制。\n\n💡 真正的转变是从一刀切的 AR 抑制走向精准的 AR 靶向治疗。\n在日常实践中，这意味着分子表征将变得愈发重要——不仅用于判断预后，也用于在 ARPI 耐药出现后选择下一治疗策略。\n\n@urologysummit @gbanna74 @ravikanesvaran @Uromigos @LosUromigos @nataliagandur\n@brian_rini @tompowles1 @montypal @declangmurphy @salvolarosa @RenuEapen @seanmcbride @DrJaVallejo @Silke_Gillessen @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @cdanicas @AOmlin\n\n@ecancer @UrologyTimes @urotoday @wearemedsir @OpenMedicineHQ @gu_onc\n#ProstateCancer #mCRPC #GUOncology #AR #PrecisionOncology #ESMO","https://x.com/nataliagandur/status/2113640169928585613","820ff03f-1551-4ccb-ad7e-c1ac93b38cdd","🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC 🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC 🎤 Presented by Alice Bernard-Tessier ",{"_270":2463,"_246":2464},"drug:paclitaxel","paclitaxel","Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 \n➡️既往接受过治疗的 #BTC，无可靶向的基因组改变\n➡️ORR 17.1% vs 5.3%；DCR 62% vs 37%\n➡️mPFS 4.7 vs 2.6个月——PFS2 时观察到获益，同时需注意存在交叉治疗\n➡️OS 无显著差异，但需注意存在交叉治疗\n@myESMO #ESMO26 @OncoAlert",18,"2026-10-09T12:00:00.000Z","2026-10-24T22:54:50.000Z",[2458,2459,2460],{"_262":2456,"_264":2450,"_265":297,"_267":2457,"_269":1289},"zb3n0qbfe1b1htjsrf7jf2rv7","https://x.com/graokane/status/2113910837471490108",{"_382":1808,"_17":393,"_246":1809,"_386":387,"_388":-5,"_389":-5,"_390":391},{"_382":1209,"_17":393,"_246":1210,"_386":1156,"_388":-5,"_389":-5,"_390":1157},{"_382":2461,"_17":384,"_246":2462,"_386":1256,"_388":-5,"_389":-5,"_390":1257},"LBA37","Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud","3424c2aa-8cd7-49e9-afb7-1cf54bca0386","Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 Paclitaxel +\\-tovecimig: COMPANION-002 ph2/3 ➡️prev treated #BTC wo actionable alterations ➡️OR",{"_270":2479,"_246":2480},"code:KEYNOTE-B49","KEYNOTE-B49","再次提醒，免疫疗法并非万能方案。\nKEYNOTE-B49 凸显了改进患者筛选的必要性。\n@myESMO @OncoAlert @OpenMedicineHQ #ESMO26",28,"2026-10-22T21:00:01.000Z","2026-10-24T19:22:31.000Z",[2476],{"_262":2474,"_264":2468,"_265":297,"_267":2475,"_269":2277},"k1cx3gx6dpsy2gbgft1jjj59m","https://x.com/DrYukselUrun/status/2113892065390002338",{"_382":2477,"_17":384,"_246":2478,"_386":1072,"_388":-5,"_389":-5,"_390":1073},"LBA51","Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)","6b80ea58-8c41-43bb-b10f-4ab4202503cc","Another reminder that immunotherapy is not a universal solution",{"_270":2494,"_246":2495},"tag:#prostatecancer","#PROSTATECANCER","昨天我们很荣幸接待了 @ResearchWyatt，他就 #prostatecancer 中的 ctDNA 做了一场精彩的研讨会。感谢 Alex 在 #ESMO26 之前访问 @VHIO 以加强合作！",19,30,"2026-10-22T10:00:00.000Z","2026-10-24T19:45:04.000Z",[],{"_262":2491,"_264":2484,"_265":297,"_267":2492,"_269":2493},"lxpn4i2cmzhjzuo3xsd6hhvjm","https://x.com/quimmateo/status/2113325269184639037","quimmateo","295b505c-115b-4046-9f33-cf6f61b82b95","Yesterday we had the pleasure of hosting @ResearchWyatt, who gave a fantastic seminar on ctDNA in #prostatecancer",{"_270":2511,"_246":2512},"drug:dostarlimab","dostarlimab","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\n多斯特利单抗在局部 dMMR/MSI-H 食管胃腺癌中的观察等待策略：GERCOR-GONO DEWI II 期研究首次中期分析结果\n\n🔬 II 期，首次中期分析（24 例可评估患者）：多斯特利单抗配合观察等待策略用于局部 dMMR/MSI-H 食管胃腺癌。主要终点：无手术的 1 年完全临床缓解 (cCR)。\n➡️ 1 年 cCR：62.5%（15/24）\n➡️ 达到",20,"2026-10-19T16:22:47.000Z","2026-10-24T20:50:04.000Z",[2508],{"_262":2505,"_264":2506,"_265":297,"_267":2507,"_269":999},"gti4rvs8yj1htu0qk1fblwiut","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\n多斯特利单抗在局部 dMMR/MSI-H 食管胃腺癌中的观察等待策略：GERCOR-GONO DEWI II 期研究首次中期分析结果\n\n🔬 II 期，首次中期分析（24 例可评估患者）：多斯特利单抗配合观察等待策略用于局部 dMMR/MSI-H 食管胃腺癌。主要终点：无手术的 1 年完全临床缓解 (cCR)。\n➡️ 1 年 cCR：62.5%（15/24）\n➡️ 达到 1 年 cCR 的患者无复发或死亡（中位随访 16.20 个月）\n➡️ 3-4 级多斯特利单抗相关不良事件：21%；9/24 接受手术，均为 R0 切除\n✅ 首次中期分析显示多斯特利单抗实现 62.5% 的 1 年 cCR，使器官保留成为可能。\n🎙️ Thierry André\n👥 Christelle de la Fouchardière\n\n(4Sight 由 ESMO 网站公开的摘要制作)\n\n@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, \n, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,","https://x.com/OncoAlert/status/2113178581404721160",{"_382":2509,"_17":393,"_246":2510,"_386":387,"_388":-5,"_389":-5,"_390":391},"2877RO","Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study","d9125f62-20a9-4d9c-85fb-ecd5553882f0","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Watch-and-Wait Strategy for Dost",{"_270":2537,"_246":2538},"drug:durvalumab","durvalumab","POP-Durva | #ESMO26\n\n短疗程 durvalumab 重塑了早期 TNBC 的免疫微环境，尽管 pCR 有限，sTILs 中位数仍从 10% 提升至 22%。\n\n免疫激活能否转化为临床获益？\n@OncoAlert #BreastCancer #bcsm",23,24,"2026-10-16T18:42:11.973Z","2026-10-24T18:42:08.000Z",[2525,2526,2527,2528,2529,2530],{"_262":2523,"_264":2516,"_265":297,"_267":2524,"_269":1979},"o03i9ljpogv56d8bb02d4qrh2","https://x.com/Dr_Oncologista/status/2113905156215452130",{"_382":2535,"_17":393,"_246":2536,"_386":387,"_388":-5,"_389":-5,"_390":391},{"_382":2533,"_17":393,"_246":2534,"_386":971,"_388":-5,"_389":-5,"_390":972},{"_382":1624,"_17":384,"_246":1625,"_386":516,"_388":-5,"_389":-5,"_390":517},{"_382":1074,"_17":384,"_246":1075,"_386":1072,"_388":-5,"_389":-5,"_390":1073},{"_382":2531,"_17":384,"_246":2532,"_386":516,"_388":-5,"_389":-5,"_390":517},{"_382":2461,"_17":384,"_246":2462,"_386":1256,"_388":-5,"_389":-5,"_390":1257},"LBA3","Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial","4737RO","Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT","2879RO","Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial","26a6e52e-7a35-4396-8314-2684c69100bc","POP-Durva | #ESMO26 POP-Durva | #ESMO26 Short-course durvalumab reshaped the immune microenvironment in early TNBC, increasing median sTILs ",{"_270":2558,"_246":2559},"drug:tarlatamab","tarlatamab","在ES-SCLC中采用Tarlatamab+Durvalumab维持治疗，中位OS近2年 = 改变临床实践！\n➡️ 挑战仍在于广泛且公平地实施Tarlatamab治疗，使所有ES-SCLC患者都能从这一革命性疗法中获益。\n@OncoAlert #ESMO26 @NEJM","2026-10-22T00:00:00.000Z","2026-10-24T19:47:35.000Z",[2550,2551,2552],{"_262":2547,"_264":2542,"_265":297,"_267":2548,"_269":2549},"w263tn385sfsnh5nxx163xost","https://x.com/christine_lovly/status/2114071129442963880","christine_lovly",{"_382":2556,"_17":393,"_246":2557,"_386":395,"_388":-5,"_389":-5,"_390":2555},{"_382":2553,"_17":393,"_246":2554,"_386":395,"_388":-5,"_389":-5,"_390":2555},{"_382":2531,"_17":384,"_246":2532,"_386":516,"_388":-5,"_389":-5,"_390":517},"3848P","Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis","SCLC","3821P","Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study","1c38d894-4870-47ae-8d50-4b9c804cc0a5","Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing",{"_270":2570,"_246":2571},"tag:#charisma","#CHARISMA","很高兴能加入这个令人难以置信的 @DanaFarber 同事名单，在 #ESMO26 上发言\n\n别错过我们周一上午的 #CHARISMA 报告！","2026-10-22T13:50:02.000Z","2026-10-23T09:18:25.000Z",[],{"_262":2568,"_264":2563,"_265":297,"_267":2569,"_269":641},"a38tkpgoydmlg61o0sonfnegv","https://x.com/PTarantinoMD/status/2113266634249142450","fc6c4903-532d-4e5d-a4ed-05d1b8e7e720","Excited to join this incredible list of @DanaFarber colleagues presenting at #ESMO26 Excited to join this incredible list of @DanaFarber col",{"_270":2582,"_246":2583},"nct:NCT06120140","NCT06120140","🆙#ESMO26 快速口头报告 I：#LCSM 转移\n🔥COCOON：改善接受一线(1L)皮下注射(SC) Amivantamab + Lazertinib治疗的EGFR突变晚期NSCLC中重度皮肤科不良事件的预防：新COCOON队列的首批结果\n🎙️ @cbcbc1971\n🔢2700RO\n🎯通过补充锌优化皮肤科管理\n🎯截至第12周，≥2级DAEIs占34%\n🎯头皮5%，甲周炎18%；剂量下调11%，停药3%\n☑️NCT06","2026-10-24T06:49:30.000Z",[],{"_262":2579,"_264":2580,"_265":297,"_267":2581,"_269":711},"gpl6cwmrc14scik99iwmv1k8e","🆙#ESMO26 快速口头报告 I：#LCSM 转移\n🔥COCOON：改善接受一线(1L)皮下注射(SC) Amivantamab + Lazertinib治疗的EGFR突变晚期NSCLC中重度皮肤科不良事件的预防：新COCOON队列的首批结果\n🎙️ @cbcbc1971\n🔢2700RO\n🎯通过补充锌优化皮肤科管理\n🎯截至第12周，≥2级DAEIs占34%\n🎯头皮5%，甲周炎18%；剂量下调11%，停药3%\n☑️NCT06120140\n🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255\n@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters","https://x.com/HHorinouchi/status/2112891661244346767","e3ea20cd-8f33-4f3d-9253-6808491017a1","🆙#ESMO26 Rapid Oral I: #LCSM Mets 🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adve",{"_270":2596,"_246":2597},"tag:#cancerdata","#CANCERDATA","@myESMO 2026：Day 1 预览\n\n探索 #ESMO26 见解：https://clin.larvol.com/conference/abstract/ESMO%202026\n\n#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC","2026-10-21T15:44:21.000Z","2026-10-24T16:13:43.000Z",[],{"_262":2592,"_264":2593,"_265":297,"_267":2594,"_269":2595},"vrtno13sqlvbn1p6it588dsdh","@myESMO 2026：Day 1 预览\n\n探索 #ESMO26 见解：https://clin.larvol.com/conference/abstract/ESMO%202026\n\n#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @PTarantinoMD | @ErikaHamilton9 | @stolaney1 | @pashtoonkasi | @ArndtVogel | @Erman_Akkus | @DrChoueiri | @DrYukselUrun | @neerajaiims","https://x.com/Larvol/status/2113313616455958933","Larvol","30e78a4e-2826-4ae9-97aa-eb5e68dff3aa","@myESMO 2026: Day 1 Preview @myESMO 2026: Day 1 Preview Explore #ESMO26 insights here: https://clin",{"_270":2615,"_246":2616},"tag:#pdac","#PDAC","AMPLIFY-7P 随机 ph2\n✅7价（camupepimut）mKRAS 淋巴结靶向两亲性分子\n➡️以治愈为目标 & <6mth 无复发 #PDAC\n✅T 细胞应答，主要终点阴性\n➡️在 ctDNA 阴性且未接受放疗者中获益？\n➡️6个月时 DFS 获益 14%，p=0.056\n✅计划开展 ph3\n@myESMO @OncoAlert #ESMO26","2026-10-23T13:08:20.000Z","2026-10-23T15:31:19.000Z",[2608,2609],{"_262":2606,"_264":2601,"_265":297,"_267":2607,"_269":1289},"swu8eov57ymfx5cuxqkk9vk6e","https://x.com/graokane/status/2113618528251314320",{"_382":1281,"_17":384,"_246":2614,"_386":2612,"_388":-5,"_389":-5,"_390":2613},{"_382":2610,"_17":384,"_246":2611,"_386":2612,"_388":-5,"_389":-5,"_390":2613},"LBA83","Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 study","https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/241","Proffered paper 1: Gastrointestinal tumour, upper digestive","Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study","f533b6bd-7791-413c-9c57-f95596e78523","AMPLIFY-7P randomised ph2 AMPLIFY-7P randomised ph2 ✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile ➡️curative intent & no r",{"_270":2638,"_246":2639},"code:KRASCENDO","KRASCENDO","1/ 我为 #ESMO26（马德里，10月23–27日）挑选的 7 大胸部肿瘤研究，按排名排列。 @myESMO \n\n其中 5 项 III 期研究已公布积极的主要终点结果。ESMO 是我们最终看到效应量的地方。\n\n每项研究回答的问题 🧵 #LCSM\n@LungCancerRx @OncoAlert @oncodaily","2026-10-19T18:04:30.000Z","2026-10-23T02:15:25.000Z",[2628,2629,2630],{"_262":2625,"_264":2620,"_265":297,"_267":2626,"_269":2627},"e2wn2yec3xdsy4zanqqytwatk","https://x.com/ADesaiMD/status/2113454214810591712","ADesaiMD",{"_382":2059,"_17":393,"_246":2060,"_386":395,"_388":-5,"_389":2637,"_390":2062},{"_382":2635,"_17":384,"_246":2632,"_386":2633,"_388":-5,"_389":2636,"_390":2632},{"_382":2631,"_17":393,"_246":2632,"_386":2633,"_388":-5,"_389":2634,"_390":2632},"NCT06497556","KRASCENDO-1","https://clinicaltrials.gov/study/NCT06497556",[2631],"LBA5",[2631],[2063,2063,2063],"edad0c79-a6c9-4e49-9a11-ad865870de28","1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked",{"_270":2651,"_246":2652},"code:4736O","4736O","🧬 #ESMO26 | 摘要 4736O\nOncoAlert🚨 #Podium2Screen 系列\n\nIII期 CA017-078 试验揭示了围手术期免疫治疗在肌层浸润性膀胱癌（MIBC）中的哪些结果？\n\n📊 主要结果 🔹 无事件生存期：围手术期 nivolumab + gemcitabine/cisplatin (GC) 与单独 GC 之间无统计学显著差异（HR 0.94; P = 0.67）。 🔹 病理学完全缓解：分别为","2026-10-23T11:57:00.000Z","2026-10-23T14:11:00.000Z",[],{"_262":2648,"_264":2649,"_265":297,"_267":2650,"_269":999},"jl7ri8c5sd886htct845fvhm6","🧬 #ESMO26 | 摘要 4736O\nOncoAlert🚨 #Podium2Screen 系列\n\nIII期 CA017-078 试验揭示了围手术期免疫治疗在肌层浸润性膀胱癌（MIBC）中的哪些结果？\n\n📊 主要结果 🔹 无事件生存期：围手术期 nivolumab + gemcitabine/cisplatin (GC) 与单独 GC 之间无统计学显著差异（HR 0.94; P = 0.67）。 🔹 病理学完全缓解：分别为 39.1% 和 29.6%；差异无统计学意义。 🔹 总生存期：数据仍不成熟。 🔹 安全性：≥3级治疗相关不良事件发生率分别为 45.9% 和 49.5%。\n\n🎤 摘要 4736O 👨‍⚕️ 演讲者：@AndreaNecchi 🇮🇹，意大利米兰 🕐 报告时间：13:40–13:50\n\n@shilpaonc, @MattGalsky\n\n尽管主要终点差异无统计学意义，但这些发现有助于持续探讨如何优化 MIBC 的围手术期治疗策略。\n\n💬 未来的生物标志物分析（包括 ctDNA）可能如何帮助进一步精准选择治疗？\n\n呼叫我们的专家教授\n@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3","https://x.com/OncoAlert/status/2113633344088907958","0a607ed5-cca9-4e8b-bc80-2fb7b797721f","🧬 #ESMO26 | Abstract 4736O 🧬 #ESMO26 | Abstract 4736O OncoAlert🚨 #Podium2Screen Series What did the phase III CA017-078 trial reveal abou",{"_270":2663,"_246":2664},"tag:#bladdercancer","#BLADDERCANCER","这是否意味着在 #bladdercancer 中铂类化疗 + 免疫治疗的时代结束了？🤔 我们现在该如何处理 NIAGARA？😬\n@OncoAlert @myESMO @OncoDailyGU \n#ESMO26","2026-10-23T11:58:44.000Z","2026-10-23T21:15:08.000Z",[],{"_262":2661,"_264":2656,"_265":297,"_267":2662,"_269":1888},"p0lyhfcj1zmqr6ddmx8e8p8cq","https://x.com/drenriquegrande/status/2113601012510716106","38009290-5ec7-49f1-b984-59b1ff92fd76","Is this the end of platinum-based chemo + immunotherapy in #bladdercancer",{"_270":2678,"_246":2679},"code:NADINA","NADINA","我预计今天会有多家卖方分析师围着 $MRNA 疲于应对，但 Evercore ISI 的 Cory Kasimov 提出了一个非常审慎的看法。很高兴看到！#Esmo26","2026-10-22T22:56:17.000Z","2026-10-23T14:46:19.000Z",[2676],{"_262":2673,"_264":2668,"_265":297,"_267":2674,"_269":2675},"so7jmydr371i4g9xv14eqsw6q","https://x.com/JacobPlieth/status/2113643183993450941","JacobPlieth",{"_382":2223,"_17":393,"_246":2224,"_386":395,"_388":-5,"_389":2677,"_390":2226},[2227,2227,2227],"9a772238-6a7a-4537-bfa5-38eed6dfedaa","Kicking off #ESMO26 with the best colleagues and friends at the INMC meeting",{"_270":2691,"_246":2692},"code:LITESPARK-012","LITESPARK-012","OncoAlert 4Sight 摘要将在 #ESMO26 发布 \n 一线帕博利珠单抗 + 仑伐替尼 + 贝鲁替凡或 MK-1308A + 仑伐替尼治疗晚期 RCC：随机开放标签 III 期 LITESPARK-012 研究\n\n @DrChoueiri\n @tompowles1\n @MVossMD\n @ERPlimackMD\n @HowardGurney\n @brian_rini \n\n 🔬 III 期 (n=1688)，未治疗的晚期","2026-10-21T12:00:58.000Z","2026-10-22T16:06:02.000Z",[],{"_262":2688,"_264":2689,"_265":297,"_267":2690,"_269":999},"mmg7dina7xcuig60p0dkp5vwj","OncoAlert 4Sight 摘要将在 #ESMO26 发布 \n 一线帕博利珠单抗 + 仑伐替尼 + 贝鲁替凡或 MK-1308A + 仑伐替尼治疗晚期 RCC：随机开放标签 III 期 LITESPARK-012 研究\n\n @DrChoueiri\n @tompowles1\n @MVossMD\n @ERPlimackMD\n @HowardGurney\n @brian_rini \n\n 🔬 III 期 (n=1688)，未治疗的晚期 ccRCC：帕博利珠单抗 + 仑伐替尼 + 贝鲁替凡 (A 组) 或 MK-1308A + 仑伐替尼 (B 组) 对比帕博利珠单抗 + 仑伐替尼。双主要终点：BICR 评估的 PFS 和 OS。\n\n ➡️ A 组：PFS HR 1.08 (0.93–1.26)；OS HR 1.04 (0.87–1.25)\n ➡️ B 组：PFS HR 1.07 (0.92–1.25)；OS HR 1.12 (0.94–1.35)\n ➡️ 因不良事件停药：51.6% (A)，51.4% (B)，36.2% (对照)\n ✅ 无论是贝鲁替凡还是 CTLA-4 阻断加在帕博利珠单抗 + 仑伐替尼上均未提高疗效；帕博利珠单抗 + 仑伐替尼仍为一线标准治疗 (1L SOC)。#KidneyCancer\n\n 🎙️ Toni Choueiri\n 👥 Thomas Powles · Martin Voss · Elizabeth Plimack · Howard Gurney · Yue Song · Rodolfo Perini · Karla Rodriguez-Lopez · Brian Rini \n\n(4Sight 仅基于 ESMO 网站公开的摘要制作)\nPinging Our Faculty\n @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper","https://x.com/OncoAlert/status/2112876795540148541","87f0a315-bcc4-4060-8446-e8d311061285","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 First-Line Pembrolizumab + Lenva",{"_270":2704,"_246":2705},"code:AVA6103","AVA6103","我们很高兴在 #ESMO26 上展示 2 组数据集 - #AVCT 进行中的试验中，AVA6103 展示了一些关键平台数据，显示了成纤维细胞招募的机制证据、快速且深度的肿瘤渗透，以及优于传统 ADC 的增强载药暴露\n\n#LetsDoThis","2026-10-23T06:05:32.000Z","2026-10-24T11:23:52.000Z",[],{"_262":2701,"_264":2696,"_265":297,"_267":2702,"_269":2703},"f8698sec9zsqz2kfwarziepvo","https://x.com/coughlin582/status/2113605727269146860","coughlin582","7a95e0a1-5ff2-4c0b-a5aa-ede5eedf6e37","We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechani",{"_270":2718,"_246":2719},"code:STARBOARD","STARBOARD","我的最佳🥈💎 #Melanoma #ESMO26 STARBOARD——BRAF V600 黑色素瘤三联疗法：enco + bini + pembro 对比 pembro 单药，用于 1L。\n\n💥 ORR：70% vs 32.7% || mPFS：33.0 vs 3.4 mo\n▪️G3/4 TEAEs：70% vs 39%\n\nOS：呈积极趋势，但试验提前关闭后数据尚不成熟。\n\nPFS 表现令人印象深刻！但 STARBOARD 尚未","2026-10-23T14:26:52.000Z","2026-10-23T22:28:46.000Z",[2717],{"_262":2714,"_264":2715,"_265":297,"_267":2716,"_269":599},"juqug7dowgmhcxhxdsqr388nf","我的最佳🥈💎 #Melanoma #ESMO26 STARBOARD——BRAF V600 黑色素瘤三联疗法：enco + bini + pembro 对比 pembro 单药，用于 1L。\n\n💥 ORR：70% vs 32.7% || mPFS：33.0 vs 3.4 mo\n▪️G3/4 TEAEs：70% vs 39%\n\nOS：呈积极趋势，但试验提前关闭后数据尚不成熟。\n\nPFS 表现令人印象深刻！但 STARBOARD 尚未抵达 OS 的彼岸⚓\n\n@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma","https://x.com/MarioBalsaMD/status/2113651822715949170",{"_382":2033,"_17":393,"_246":2034,"_386":2035,"_388":-5,"_389":-5,"_390":2036},"eabdb807-62f2-4e02-b1f4-a451e386a7f7","My top 🥈💎 #Melanoma #ESMO26 STARBOARD - Triplet therapy in BRAF V600 melanoma: enco + bini + pembro vs pembro alone in 1L",{"_270":2732,"_246":2733},"code:TROFUSE-005","TROFUSE-005","🚨 ESMO 2026 | 值得关注的妇科肿瘤学 TOP 10 试验！\n\n从无化疗免疫治疗到新一代ADC，#ESMO26可能重塑妇科肿瘤学！\n\n🔥 我的十大重点试验，按癌症亚型分类：\n\n🔴 子宫内膜癌\n\nTroFuse-005 (LBA11) | Sacituzumab tirumotecan vs 医生选择方案，用于复发/晚期疾病。\nKEYNOTE-C93 (LBA12) | Pembrolizumab单药 vs 化疗，用于1L","2026-10-22T06:38:47.000Z","2026-10-24T11:07:28.000Z",[],{"_262":2728,"_264":2729,"_265":297,"_267":2730,"_269":2731},"ngj3p9g1jcfjmgj1odvxjw4w9","🚨 ESMO 2026 | 值得关注的妇科肿瘤学 TOP 10 试验！\n\n从无化疗免疫治疗到新一代ADC，#ESMO26可能重塑妇科肿瘤学！\n\n🔥 我的十大重点试验，按癌症亚型分类：\n\n🔴 子宫内膜癌\n\nTroFuse-005 (LBA11) | Sacituzumab tirumotecan vs 医生选择方案，用于复发/晚期疾病。\nKEYNOTE-C93 (LBA12) | Pembrolizumab单药 vs 化疗，用于1L dMMR疾病。能否免用化疗？\nNRG-GY020 (1239O) | 辅助放疗 ± pembrolizumab，用于早期dMMR疾病。\nSacituzumab tirumotecan + pembrolizumab (1259P) | ADC + 免疫治疗，用于铂类治疗后pMMR疾病。\n\n🔵 卵巢癌\n\nBEHOLD-1 (LBA41) | Mocertatug rezetecan，一款B7-H4 ADC，用于铂类耐药疾病。\nREJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab，用于铂类耐药疾病。\nREJOICE-Ovarian01 (1331P) | Raludotatug deruxtecan更新后的疗效和安全性。\nBEHOLD-1生物标志物分析 (1248RO) | 哪些生物标志物可预测对B7-H4 ADC治疗的应答？\n\n🟣 宫颈癌\n\nCALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs 化疗，用于复发/转移性疾病。\nEMPOWER-Cervical 1 (1250O) | 基于cemiplimab的策略及长期结局。\n\n⭐ 我的三大重点关注试验：\nKEYNOTE-C93 | TroFuse-005 | BEHOLD-1\n\n哪项试验最有可能改变你的临床实践？\n@ESMO_open @myesmo @ASCO @oncoalert\n\n#ESMO26 #GynOnc #Oncology","https://x.com/DrRishabhOnco/status/2113566049102889208","DrRishabhOnco","893b0fd5-84e2-4e0e-bd5e-8962ed8e3da5","🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH",{"_270":2758,"_246":2759},"code:UNION","UNION","会场（3530O）：UNION III 期。局部晚期直肠癌 n=231。短程放疗 → CAPOX + 卡瑞利珠单抗 → TME，对比长程放化疗 → CAPOX → TME。3 年 EFS 91.3% vs 77.4%，HR 0.33（0.15–0.71），P=0.0029。放疗日程和 IO 同时改了，这条读数不能单独归因于其中一项。","2026-10-18T23:00:37.000Z","2026-10-23T12:17:00.000Z",[2751,2752],{"_2747":2748,"_2749":-5},{"_262":2743,"_264":2744,"_265":297,"_267":2745,"_269":2746},"q55pt2c1ljyq3tfp457qtm58y","🚨UNION 试验🚨\n\n局部晚期直肠癌\nN=231\n\n🔍随机分组\n🔵同步放化疗➡️2周期 CAPOX➡️TME➡️6周期 CAPOX\n🟢短程放疗➡️2周期 CAPOX + 卡瑞利珠单抗 ➡️TME➡️6周期 CAPOX + 卡瑞利珠单抗\n\n🔥短程放疗 + 化疗-免疫在 EFS 上显示出巨大差异，91% 对 77%！！！\n\n#ESMO26","https://x.com/KrishanJethwa/status/2113390661793677605","KrishanJethwa","paragraphs",[2737,2750],"directionLabel","期刊骨架：UNION 更早的 pCR 读数在 Ann Oncol 2024。会上是预设的 EFS 分析。",{"_382":2756,"_17":393,"_246":2736,"_386":2754,"_388":-5,"_389":2757,"_390":2736},{"_382":2753,"_17":393,"_246":2736,"_386":2754,"_388":-5,"_389":2755,"_390":2736},"NCT04928807","https://clinicaltrials.gov/study/NCT04928807",[2753],"3530O",[2753],"892e8d5e-1d74-4380-842f-96ffe3827f63","🚨UNION Trial🚨 🚨UNION Trial🚨 Locally advanced rectal cancer N=231 🔍Randomized 🔵Chemoradiation➡️2c CAPOX➡️TME➡️6c CAPOX 🟢SCRT➡️2c CAPOX",{"_270":2774,"_246":2775},"code:ARION","ARION","会场（2879RO）：ARION 随机 II 期。局部晚期食管癌（77% 鳞癌）根治性放化疗加减 durvalumab。n=112。中心评审 PFS HR 0.91（0.55–1.49），P=0.351；OS HR 0.99（0.59–1.68），P=0.489。阴性。","2026-10-22T21:50:53.000Z","2026-10-23T15:24:31.000Z",[2773],{"_2747":2772,"_2749":-5},{"_262":2769,"_264":2770,"_265":297,"_267":2771,"_269":2746},"g16jovcizzp286wz631jpogh0","🚨ARION PRODIGE 67🚨\n\n局部晚期食管癌（腺癌或鳞癌）\nn=112\n\n随机\nCRT（50 Gy/25 Fx + FOLFOX）+/- 同步及辅助 durvalumab（共 12 个月）\n\n以下指标无统计学显著差异：\nPFS：48% vs. 50%\nOS：68% vs. 75%\n\n#ESMO26","https://x.com/KrishanJethwa/status/2113387641013936310",[2763],{"_382":2535,"_17":393,"_246":2536,"_386":387,"_388":-5,"_389":-5,"_390":391},"e52b0dc5-7685-4abe-bd7c-a037d0b19341","🚨ARION PRODIGE 67🚨 🚨ARION PRODIGE 67🚨 Locally Advanced Esophagus Cancer (adeno or squam) n=112 Randomized CRT (50 Gy/25 Fx + FOLFOX) +/-",{"_270":2788,"_246":2789},"code:GY020","GY020","GY020 未达到其主要终点：3年成功率为 pembro+RT 组 70%，RT 单独组 73%。退出研究按失败计。\n\nKM RFS 在数值上有利于 pembro，但 CI 跨过了 1。G3/4 毒性为 43% vs 15%。在这里，RT 单独治疗仍是我的默认选择。\n#ESMO26 #radonc\n\nhttps://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/presentat","2026-10-22T23:04:05.000Z","2026-10-24T20:09:05.000Z",[2787],{"_262":2784,"_264":2785,"_265":297,"_267":2786,"_269":1390},"jfe170t9t9tr86jlv5cl0pa1w","GY020 未达到其主要终点：3年成功率为 pembro+RT 组 70%，RT 单独组 73%。退出研究按失败计。\n\nKM RFS 在数值上有利于 pembro，但 CI 跨过了 1。G3/4 毒性为 43% vs 15%。在这里，RT 单独治疗仍是我的默认选择。\n#ESMO26 #radonc\n\nhttps://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/presentation/list?q=1239O","https://x.com/jryckman3/status/2113406063185658168",{"_382":1275,"_17":393,"_246":1276,"_386":1256,"_388":-5,"_389":-5,"_390":1257},"aacf0bd7-f5d5-4edb-982b-71d0aae6cd66","GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone",{"_270":2801,"_246":2802},"drug:deuderuxtecan","deuderuxtecan","APEX Breast01\nTQB2102（针对 HER2 的双特异性 ADC，搭载 topo1 有效载荷）\nRolditamig Deuderuxtecan (TQB2102) 对比 TPC 化疗，用于 HER2 低表达 MBC，既往未接受化疗（461 例 HR+，81 例 TNBC）\nPFS HER2 低表达：16.4 对 5.5 个月，HR 0.29\nILD 1.1%\n\n@OncoAlert #ESMO2026","2026-10-20T10:57:00.000Z","2026-10-23T18:09:01.000Z",[],{"_262":2798,"_264":2793,"_265":297,"_267":2799,"_269":2800},"ckixaekd5wjq31g3m9hh0rbvg","https://x.com/stolaney1/status/2113603452353798538","stolaney1","3cc428ae-905d-427b-8812-4847fba4a2ce","APEX Breast01 APEX Breast01 TQB2102 (biapotropic ADC against HER2 with topo1 payload) Rolditamig Deuderuxtecan (TQB2102) vs TPC Chemo in HER",{"_270":2818,"_246":2819},"code:KEYNOTE-365","KEYNOTE-365","#ESMO26 上神经endocrine前列腺癌的 OS 结果令人鼓舞！\n\n#KEYNOTE-365 评估了 pembrolizumab + carboplatin/etoposide 与单用化疗的对比。\n\n• mOS：10.2 对 7.1 个月（HR 0.33）\n• rPFS：5.1 对 4.0 个月（HR 0.66）\n• PD-L1 CPS ≥1：mOS 11.0 对 4.8 个月（HR 0.16）\n\n未观察到新的安全性信号。\n\n@","2026-10-23T11:46:45.000Z","2026-10-24T13:30:07.000Z",[2814],{"_262":2811,"_264":2812,"_265":297,"_267":2813,"_269":299},"hlux2lrn8oz0jgzqstyo8vh2d","#ESMO26 上神经endocrine前列腺癌的 OS 结果令人鼓舞！\n\n#KEYNOTE-365 评估了 pembrolizumab + carboplatin/etoposide 与单用化疗的对比。\n\n• mOS：10.2 对 7.1 个月（HR 0.33）\n• rPFS：5.1 对 4.0 个月（HR 0.66）\n• PD-L1 CPS ≥1：mOS 11.0 对 4.8 个月（HR 0.16）\n\n未观察到新的安全性信号。\n\n@myESMO @oncoalert","https://x.com/DrChoueiri/status/2113601390496915517",{"_382":2815,"_17":393,"_246":2816,"_386":1173,"_388":-5,"_389":2817,"_390":1175},"2217RO","Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)",[1176],"242467e2-4577-4b74-8815-198b3f1337d0","Encouraging OS results in neuroendocrine prostate cancer at #ESMO26",{"_270":2832,"_246":2833},"drug:tucatinib","tucatinib","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\nBRIDGET：一项 II 期试验，评估在晚期 HER2 阳性乳腺癌患者出现孤立性颅内进展后，加用 Tucatinib 至 Trastuzumab/Pertuzumab 或 Ado-Trastuzumab Emtansine 的疗效\n\n@drsarahsam\n@DrVanSwearingen\n@rashmikmurthy\n@CareyAnders1\n\n🔬 单臂 II ","2026-10-10T00:40:00.000Z","2026-10-24T13:34:00.000Z",[2831],{"_262":2828,"_264":2829,"_265":297,"_267":2830,"_269":999},"zge51i0wavyusj7cr0dfwvjy9","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\nBRIDGET：一项 II 期试验，评估在晚期 HER2 阳性乳腺癌患者出现孤立性颅内进展后，加用 Tucatinib 至 Trastuzumab/Pertuzumab 或 Ado-Trastuzumab Emtansine 的疗效\n\n@drsarahsam\n@DrVanSwearingen\n@rashmikmurthy\n@CareyAnders1\n\n🔬 单臂 II 期（47 例可评估）：在 HER2+ 转移性乳腺癌患者接受 SRS 治疗孤立性颅内进展后，将 tucatinib 加入正在进行的 HP 或 T-DM1 方案。主要终点：iPFS（RANO-BM）。\n➡️ 中位 iPFS 未达；p<0.0001，优于历史中位 5 个月\n➡️ 6 个月 iPFS 91%，12 个月 64%，18 个月 59%\n➡️ ≥3 级不良事件 15%；颅外进展 4.3%\n✅ 放疗后在 HP 方案中加用 tucatinib 达到主要终点，超过一半患者在 18 个月内无颅内进展。#BreastCancer\n\n🎙️ Sarah Sammons\n👥 Amanda Van Swearingen · Laura Noteware · Nusayba Bagegni · Kelly Moulton · Stevie Threatt · Denise Jaggers · Shannon Shea · Eric Lipp · Erin Riley · Sin-Ho Jung · Gloria Broadwater · Masey Ross · Kimberly Strickland · Sasha Beyer · Alison Conlin · Aki Morikawa · Rashmi Murthy · Carey Anders\n\n(4Sight 由 ESMO 网站公开的摘要制作)\n\n通知 OncoAlert 乳腺癌专家组\n@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc\n@Lucarecco @Dr_Oncologista @guiandri76","https://x.com/OncoAlert/status/2113208953446232179",{"_382":1214,"_17":393,"_246":1215,"_386":1216,"_388":-5,"_389":-5,"_390":1217},"0a014b45-87c9-463e-8f9b-9fe0b54dd076","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 BRIDGET: A Phase II Trial of Tuc",{"_270":2845,"_246":2846},"code:DELLPHI-304","DELLPHI-304","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\nTarlatamab 在既往治疗的 SCLC 中：来自 III 期 DeLLphi-304 试验的总生存期延长随访\n\n@charlesrudin\n @g_mountzios\n @cbcbc1971\n @JulienMazieres\n @teekayowo\n @LuisPaz_Ares \n\n 🫁 III 期（n=509）：tarlatamab 对比化疗（托泊替康、鲁比替","2026-10-22T13:01:24.000Z","2026-10-24T07:07:49.000Z",[],{"_262":2842,"_264":2843,"_265":297,"_267":2844,"_269":999},"kn869jm7og55m9pw1nnwzit8h","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\nTarlatamab 在既往治疗的 SCLC 中：来自 III 期 DeLLphi-304 试验的总生存期延长随访\n\n@charlesrudin\n @g_mountzios\n @cbcbc1971\n @JulienMazieres\n @teekayowo\n @LuisPaz_Ares \n\n 🫁 III 期（n=509）：tarlatamab 对比化疗（托泊替康、鲁比替康或阿霉素）用于一线铂类化疗后的 SCLC。主要终点：OS；中位随访 23 个月。\n ➡️ 中位 OS 13.6 对比 8.4 个月；HR 0.62 (0.51–0.76)；18 个月 OS 42% 对比 24%\n ➡️ 基线脑转移亚组：OS HR 0.52 (0.38–0.70)\n ➡️ ≥3 级 TRAEs 28% 对比 63%\n ✅ 持久的生存获益，安全性可控且无新安全信号，巩固了 tarlatamab 作为一线铂类化疗后标准治疗的地位。 #LungCancer #SCLC\n\n 🎙️ Charles Rudin\n 👥 Giannis Mountzios · Longhua Sun · Byoung Chul Cho · Umut Demirci · Sofia Baka · Mahmut Gümüş · Antonio Lugini · Bo Zhu · Yan Yu · Ippokratis Korantzis · Ji-Youn Han · Tudor-Eliade Ciuleanu · Myung-Ju Ahn · Pedro Rocha · Julien Mazières · Sally Lau · Martin Schuler · Fiona Blackhall · Tatsuya Yoshida · Taofeek Owonikoko · Luis Paz-Ares · Tony Jiang · Ali Hamidi · Diana Gauto · Gonzalo Recondo \n\n(4Sight 由 ESMO 网站公开的摘要制作)\n\n通知我们的师资团队\n@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD \n\n@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers","https://x.com/OncoAlert/status/2113254395777327329","9fae653c-545c-41ad-a90c-7196984bd3cf","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Tarlatamab in Previously Treated",{"_270":2860,"_246":2861},"code:DESTINY-BREAST11","DESTINY-BREAST11","#ESMO26 | DESTINY-Breast11 MRI分析在第4个周期时，T-DXd→THP组的ORR为77.3%，而ddAC→THP组为50.8%。在接受4个周期T-DXd后，MRI评估达到CR、PR或无客观缓解的患者中，完成THP后达到pCR的比例分别为90%、67%和54%。这些数据显示，早期MRI缓解无法可靠预测pCR。摘要未纳入T-DXd单药组的连续MRI缓解数据。我希望这些数据能在分会期间公布。这些数据对于根据缓解","2026-10-14T11:13:00.000Z","2026-10-24T14:12:42.000Z",[2859],{"_262":2855,"_264":2856,"_265":297,"_267":2857,"_269":2858},"zp9rors4s4jjlvz9pqzpj579q","#ESMO26 | DESTINY-Breast11 MRI分析在第4个周期时，T-DXd→THP组的ORR为77.3%，而ddAC→THP组为50.8%。在接受4个周期T-DXd后，MRI评估达到CR、PR或无客观缓解的患者中，完成THP后达到pCR的比例分别为90%、67%和54%。这些数据显示，早期MRI缓解无法可靠预测pCR。摘要未纳入T-DXd单药组的连续MRI缓解数据。我希望这些数据能在分会期间公布。这些数据对于根据缓解情况个体化确定新辅助治疗持续时间至关重要。","https://x.com/dr_yakupergun/status/2112097446469767592","dr_yakupergun",{"_382":1209,"_17":393,"_246":1210,"_386":1156,"_388":-5,"_389":-5,"_390":1157},"071f4219-afe0-4454-a62b-15bdd235a848","#ESMO26 | DESTINY-Breast11 MRI Analysis At cycle 4, ORR was 77",{"_270":2873,"_246":2874},"code:ELI-002","ELI-002","$ELTX：我们 #ESMO2026 观察名单中的催化剂之一刚刚公布了结果。\n\nELI-002 7P 胰腺癌 2 期更新：\n• 主要 DFS 终点 misse 早在 6 月就已披露。\n• 新亚组数据：ctDNA 阴性患者的 DFS HR 为 0.51；ctDNA 阳性患者为 0.57。\n\n📊股价收窄此前跌幅，降至 −1.5%\n\n我们此前的 ESMO Prob/Mag 情景如下 👇\n\n下一步关注：3 期开发计划。","2026-10-23T13:03:27.000Z","2026-10-24T15:25:54.000Z",[],{"_262":2870,"_264":2865,"_265":297,"_267":2871,"_269":2872},"uymukguincf71f9o3m004z125","https://x.com/BiopharmIQ/status/2113666444835651691","BiopharmIQ","940c1779-6273-4726-bef5-2a2247971326","$ELTX: One of our #ESMO2026 watchlist catalysts just reported",{"_270":2888,"_246":2889},"drug:tavatecan","tavatecan","G-HOPE-001 phs-3: Arcotatug tavatecan 对比 TPC 在既往治疗过的 G/GEJA：首次中期分析\n#ESMO26 #ESMOAmbassadors\n 🇨🇳🇯🇵，2600 例预筛选，430 例入组\n👉ORR：37% 对 7.7%\n👉 mPFS：7.1 对 3.1 个月\n👉 mOS：10.2 对 6.9 个月\n🧐CLDN-2 ADC，显示强效疗效信号，安全性可接受\n@myESMO @ASC","2026-10-23T11:39:36.000Z","2026-10-24T06:59:07.000Z",[2886],{"_262":2883,"_264":2884,"_265":297,"_267":2885,"_269":2019},"dqe0qcebhr0obgt600luxd32a","G-HOPE-001 phs-3: Arcotatug tavatecan 对比 TPC 在既往治疗过的 G/GEJA：首次中期分析\n#ESMO26 #ESMOAmbassadors\n 🇨🇳🇯🇵，2600 例预筛选，430 例入组\n👉ORR：37% 对 7.7%\n👉 mPFS：7.1 对 3.1 个月\n👉 mOS：10.2 对 6.9 个月\n🧐CLDN-2 ADC，显示强效疗效信号，安全性可接受\n@myESMO @ASCO","https://x.com/ArndtVogel/status/2113596197877195234",{"_382":247,"_17":384,"_246":2887,"_386":2612,"_388":-5,"_389":-5,"_390":2613},"Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G","1a98dc0d-0e15-4687-b8d2-323a92544fa2","G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis G-HOPE-001 phs-3: Arcotatug tavatecan vs T",{"_270":2903,"_246":2904},"code:DESTINY-BREAST05","DESTINY-BREAST05","DESTINY-Breast05：#ESMO26 的 PROs\n\n对于伴残留浸润性疾病的高危 HER2+ 早期乳腺癌患者，T-DXd 和 T-DM1 均基本维持了 HRQoL。\n\n@OncoAlert #BCSM #BreastCancer","2026-10-09T09:40:00.000Z","2026-10-24T17:03:29.000Z",[2900],{"_262":2898,"_264":2893,"_265":297,"_267":2899,"_269":1979},"rvfqu8i0o4201vz90ulyjqcdg","https://x.com/Dr_Oncologista/status/2113649521402015942",{"_382":2901,"_17":393,"_246":2902,"_386":1156,"_388":-5,"_389":-5,"_390":1157},"539RO","Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)","94e6e5e6-9d1c-4949-9002-1720d8ddd282","DESTINY-Breast05: PROs at #ESMO26 DESTINY-Breast05: PROs at #ESMO26 HRQoL was largely maintained with both T-DXd and T-DM1 in high-risk HER2",{"_270":2917,"_246":2918},"drug:talazoparib","talazoparib","欢迎来到马德里参加 #ESMO26 \n🎥 新教育胶囊 | @GuardConsortium \n🇪🇸 TALAPRO-3：PARP 抑制剂在激素敏感性前列腺癌中的新进展？\n\nDr. Joaquín Mateo (@quimmateo) 来自巴塞罗那的 @VHIO 解读了 TALAPRO-3 试验，该试验在 ASCO 2026 上展示并发表于《新英格兰医学杂志》，与 @AzadOncology、@neerajaiims 及同事共同完成","2026-10-24T14:00:33.000Z",[2915],{"_262":2912,"_264":2913,"_265":297,"_267":2914,"_269":999},"u1ls36pwnn9gqbag86m4qgwh4","欢迎来到马德里参加 #ESMO26 \n🎥 新教育胶囊 | @GuardConsortium \n🇪🇸 TALAPRO-3：PARP 抑制剂在激素敏感性前列腺癌中的新进展？\n\nDr. Joaquín Mateo (@quimmateo) 来自巴塞罗那的 @VHIO 解读了 TALAPRO-3 试验，该试验在 ASCO 2026 上展示并发表于《新英格兰医学杂志》，与 @AzadOncology、@neerajaiims 及同事共同完成。\n\n🧬 TALAPRO-3 显示了什么？\n\n这项 III 期试验评估了 talazoparib 联合 enzalutamide 与安慰剂联合 enzalutamide 在 HRR 突变的转移性激素敏感性前列腺癌 (mHSPC) 患者中的疗效。\n\n🔹 两个治疗组共入组 599 例患者。\n\n🔹 3 年影像学无进展生存期 (rPFS)：77% 对 56%（HR 0.48；95% CI 0.36–0.65；p<0.001）。\n\n🔹 中期分析中 3 年总生存期 (OS)：78% 对 72%（HR 0.77；95% CI 0.56–1.04）。OS 数据尚不成熟。\n\n🔹 安全性：接受 talazoparib 治疗的患者中，51% 出现 ≥3 级贫血。\n\n💡 关键问题：PARP 抑制剂的角色是否将发生转变，提前用于激素敏感阶段？\n\n观看 Dr. Mateo 的分析并参与讨论。👇\n\n🔗 https://nejm.org/doi/full/10.1056/NEJMoa2604126?referrer=https%3A%2F%2Fwww.google.com%2F\n\n#GuardConsortium #TALAPRO3 #ProstateCancer #ASCO2026\n\nGU Oncology colleagues: @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @OncBrothers @Helena_de_Palma @DrIacovelli @mjuanfi81\n\nOncoALert faculty: @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @AndreaNecchi @scocmem","https://x.com/OncoAlert/status/2113564356210245960",{"_382":1177,"_17":393,"_246":1178,"_386":1173,"_388":-5,"_389":2916,"_390":1175},[1176],"4e1738f5-f82c-4a60-b721-6d8fdd71411e","Bienvenidos a Madrid para #ESMO26 Bienvenidos a Madrid para #ESMO26 🎥 Nueva Educational Capsule | @GuardConsortium 🇪🇸 TALAPRO-3: ¿Un nuev",{"_270":2940,"_246":2941},"code:KEYNOTE-975","KEYNOTE-975","会场（2875O）：KEYNOTE-975 IA2。不能手术的局部晚期食管/胃食管结合部癌，pembro 加入根治性放化疗。CPS≥10 的 EFS：15.2 vs 14.7 个月，HR 0.97（0.77–1.23），P=0.3994，阴性。层级在此停止，OS 未正式检验。n=703。","2026-10-18T22:36:10.000Z","2026-10-24T22:55:20.000Z",[2932,2933],{"_2747":2931,"_2749":-5},{"_262":2928,"_264":2929,"_265":297,"_267":2930,"_269":2019},"uysa97zwjqp7jasxwqgbk7ivi","KEYNOTE-975 phs-3 研究：Pembrolizumab 或安慰剂联合同步根治性放化疗，用于 E/GEJ 癌\n#ESMO26 #ESMOAmbassadors\n👉 mEFS：15.2 vs 14.7 个月\n👉 mOS：32 vs 35 个月\n🧐令人失望的是，所有患者及 & CPS>10 患者均无获益\n@myESMO @ASCO","https://x.com/ArndtVogel/status/2113600912883146920",[2922],{"_382":2938,"_17":393,"_246":2939,"_386":2612,"_388":-5,"_389":-5,"_390":2613},{"_382":2934,"_17":393,"_246":2935,"_386":2936,"_388":-5,"_389":2937,"_390":2935},"NCT04210115","- **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","https://clinicaltrials.gov/study/NCT04210115",[2934],"2875O","Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: The phase 3 randomized KEYNOTE-975 study","ce5373e3-ce15-480e-a89a-0ed4c42937b8","KEYNOTE-975 phs-3 study: Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in E/GEJ cancer KEYNOTE-975 phs-3 study: Pemb",{"_270":2959,"_246":2960},"code:KEYNOTE-905","KEYNOTE-905","#DrAndersUllen 在针对顺铂不适用型 MIBC 的 KEYNOTE-905 III 期探索性分析中报告了围手术期 EV + Pembro 的积极势头。\n2 年 EFS：EV/Pembro 组为 75.8%，Pembro 组为 55.8%，单纯手术组为 41.0%。\nEFS HR 分别为 0.40 和 0.71（各与对照组相比）。\npCR 分别为 58.8%、25.3% 和 10.3%。\n\n#ESMO26 #BladderCa","2026-10-22T16:04:17.000Z","2026-10-23T21:13:56.000Z",[2953,2954],{"_262":2950,"_264":2951,"_265":297,"_267":2952,"_269":299},"i089ge7cftiubrk05p458u235","#DrAndersUllen 在针对顺铂不适用型 MIBC 的 KEYNOTE-905 III 期探索性分析中报告了围手术期 EV + Pembro 的积极势头。\n2 年 EFS：EV/Pembro 组为 75.8%，Pembro 组为 55.8%，单纯手术组为 41.0%。\nEFS HR 分别为 0.40 和 0.71（各与对照组相比）。\npCR 分别为 58.8%、25.3% 和 10.3%。\n\n#ESMO26 #BladderCancer @myESMO @OncoAlert","https://x.com/DrChoueiri/status/2113611550653022558",{"_382":1637,"_17":393,"_246":1638,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":2955,"_17":393,"_246":2956,"_386":2957,"_388":-5,"_389":2958,"_390":2956},"NCT03924895","- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","https://clinicaltrials.gov/study/NCT03924895",[2955],"cffe56eb-7123-4c1e-8ee6-aaddbee6d033","Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph",{"_270":2974,"_246":2975},"tag:#lcsm","#LCSM","准备好参加 @myesmo #ESMO26 了吗？\n以下是 @oncoalert 评选出的十大 #LCSM 演讲\n\n@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManoch",26,"2026-10-21T11:08:49.000Z","2026-10-24T15:53:33.000Z",[],{"_262":2970,"_264":2971,"_265":297,"_267":2972,"_269":2973},"zsf69sjmia098gcvejfoeww4f","准备好参加 @myesmo #ESMO26 了吗？\n以下是 @oncoalert 评选出的十大 #LCSM 演讲\n\n@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen","https://x.com/GlopesMd/status/2112863672980619411","GlopesMd","5511de82-01d8-4fc0-bdb8-05408eb8f1ab","Getting ready for @myesmo #ESMO26",{"_270":2994,"_246":2995},"code:MASTERPLAN","MASTERPLAN","会场：MASTERPLAN II 期。高危可切除 / 交界 / 局部晚期胰腺癌，化疗 ± 胰腺 SBRT 40 Gy/5 次。n=74。12 个月局部区域复发 52.0% vs 20.2%（P=0.022）；mPFS 6.3 vs 11.9 个月（P=0.002）；OS 14 vs 22 个月（P=0.006）。HR 未报。次要终点，不能当成明确的 OS 证据。",11,"2026-10-22T21:55:49.000Z","2026-10-24T10:59:20.000Z",[2991],{"_2747":2990,"_2749":-5},{"_262":2986,"_264":2987,"_265":297,"_267":2988,"_269":2989},"m8fbwsgyc023y4fitddnoyzew","🚨📣 #ESMO26 重磅消息：🧵1/MASTERPLAN RCT 表明，对于高危局限性 #pancreatic cancer，在围手术期化疗基础上加用 SABR，可将中位总生存期提高至 22.0 个月，而对照组为 14.0 个月（HR 0.45）。#PancreaticCancer #RadOnc @TROGfightcancer 新闻稿 @TheLancetOncol - https://www.thelancet.com/journals/lanonc/article/S1470-2045(26)00532-2/fulltext","https://x.com/_ShankarSiva/status/2113653564354539854","_ShankarSiva",[2979],{"_382":2992,"_17":393,"_246":2993,"_386":387,"_388":-5,"_389":-5,"_390":391},"3136RO","Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial","e4cf20d6-7d15-46c3-804c-7769ce5c4021","🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️",{"_270":3008,"_246":3009},"code:HERIZON-GEA","HERIZON-GEA","🚀上消化道口头报告 #ESMO26 第1天结果汇总\n\n1) Arcotatug tavatecan在3L+治疗的CLDN18.2+ G/GEJA患者中改善了PFS\n\n2) SANO试验：食管癌患者在接受nCR后达到完全临床缓解时，主动监测与手术的5年OS相似，尽管远处转移更多\n\n3) 在既往未接受治疗、不可切除的食管癌或GEJ癌且PD-L1 CPS ≥10的患者中，dCRT加用pembrolizumab未改善EFS\n\n4) 在RASo","2026-10-23T03:16:15.000Z",[3007],{"_262":3003,"_264":3004,"_265":297,"_267":3005,"_269":3006},"j8lest4uk0olbn6sct2soaein","🚀上消化道口头报告 #ESMO26 第1天结果汇总\n\n1) Arcotatug tavatecan在3L+治疗的CLDN18.2+ G/GEJA患者中改善了PFS\n\n2) SANO试验：食管癌患者在接受nCR后达到完全临床缓解时，主动监测与手术的5年OS相似，尽管远处转移更多\n\n3) 在既往未接受治疗、不可切除的食管癌或GEJ癌且PD-L1 CPS ≥10的患者中，dCRT加用pembrolizumab未改善EFS\n\n4) 在RASolute-302试验中，daraxonrasib在不同RAS突变亚组中均显示一致的OS获益\n\n5) mKRAS特异性、淋巴结靶向的两亲性免疫治疗在PDAC中未达到主要DFS终点\n\n6) 在HERIZON-GEA-01的IA2中，Zani + CT +/- tisle保持了OS获益\n\n7) 在既往接受过trastuzumab治疗的HER2阳性GC/GEJC腺癌患者中，Anbenitamab联合ChT改善了OS\n\n8) TQB2102（HER2双特异性抗体偶联药物）联合bemotrizumab和capecitabine在晚期GC/GEJC的1L治疗中显示出令人鼓舞的抗肿瘤活性\n\n9) 在局部dMMR/MSI-H GEA患者中，Dostarlimab在首次中期分析时使1y-cCR率达到62.5%，从而可实现器官保留\n\n10) 在既往接受过紫杉类治疗的GEA患者中，FOLFIRI和Ram对比paclitaxel改善了PFS，但未改善OS\n\n11) 在D2切除术后的II–IIIB期胃癌患者中，4个月辅助XELOX治疗在3年DFS方面不劣于6个月治疗\n\n12) 在局部晚期食管癌中，dCRT加用durvalumab未改善PFS\n\n13) 在高危、临界可切除或局部晚期胰腺癌患者中，MFOLFIRINOX加用SBRT改善了LRR和PFS\n\n14) 表达FGFR2b且同时存在FGFR2扩增的GC/GEJ可能构成一个生物学特征不同的亚群，或对bemarituzumab具有潜在敏感性\n\n#cancer #oncology #MedX #GI #gastrointestinal @OncoAlert","https://x.com/Erman_Akkus/status/2113505152879546834","Erman_Akkus",{"_382":383,"_17":384,"_246":385,"_386":387,"_388":-5,"_389":-5,"_390":391},"693d12ff-5290-4d92-816d-c45fe2da647f","🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 1) Arcotatug tavatecan impro",{"_270":3028,"_246":3029},"gene:MET","MET","太棒了 @AndreaNecchi，在 @myESMO #ESMO26 上精彩展示 ENERGIZE 试验！👏\nPh3，n=653 顺铂适用 MIBC：新辅助 GC + nivo → 辅助 nivo 对比单用 GC。\n中位随访 54.5 个月。\n🔹 pCR 39.1% 对 29.6%：未达显著差异\n🔹 EFS HR 0.94：共同主要终点未达标\n🔹 OS HR 0.88\n👉 试验结果为阴性，但 ctDNA 数据是关键信息：基线","2026-10-22T13:46:00.000Z","2026-10-24T15:32:43.000Z",[3022,3023],{"_262":3018,"_264":3019,"_265":297,"_267":3020,"_269":3021},"y2bjwcxrnyfuu1eteicr9v6ol","太棒了 @AndreaNecchi，在 @myESMO #ESMO26 上精彩展示 ENERGIZE 试验！👏\nPh3，n=653 顺铂适用 MIBC：新辅助 GC + nivo → 辅助 nivo 对比单用 GC。\n中位随访 54.5 个月。\n🔹 pCR 39.1% 对 29.6%：未达显著差异\n🔹 EFS HR 0.94：共同主要终点未达标\n🔹 OS HR 0.88\n👉 试验结果为阴性，但 ctDNA 数据是关键信息：基线及新辅助化疗后可检测到的 ctDNA 强烈预示更差的 EFS 与 OS。\n按 ctDNA 选择患者，而非对所有患者添加免疫治疗，是该领域的发展方向！\n很高兴看到这建立在我们的 Ph2 BLASST-1 研究之上。尽管结果为阴性，但对临床实践极具指导意义。\n\n为能参与这项工作感到自豪！\n@CleClinicMD @caseccc @CleClinicUro @sonpavde @MattGalsky @MichvdHeijden @Uromigos @Annals_Oncology @tompowles1","https://x.com/shilpaonc/status/2113611608068874349","shilpaonc",{"_382":3025,"_17":393,"_246":3026,"_386":395,"_388":-5,"_389":-5,"_390":3027},{"_382":2367,"_17":393,"_246":2368,"_386":2369,"_388":-5,"_389":3024,"_390":2368},[2367],"1017P","Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","Developmental therapeutics","0c236e06-f08f-4e9b-bed3-4d1ddc39e2f2","Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26",{"_270":3050,"_246":3051},"gene:BRAF","BRAF","#ESMO26 摘要已发布！\n在我们与 @OncBrothers（Rohit 和 Rahul）共同完成的荟萃分析中，我们比较了一线 BRAF/MEK 抑制剂与基于 ICI 的方案在 BRAF V600E 突变型 aNSCLC 中的疗效。\n在 589 例患者中，BRAF/MEKis 获得了更高的缓解率（61% 对比 48%），而 PFS 或 OS 无显著差异👇","2026-10-18T22:59:41.000Z","2026-10-24T19:01:40.000Z",[3040,3041,3042,3043,3044,3045],{"_262":3038,"_264":3033,"_265":297,"_267":3039,"_269":2858},"ytqloaoageyk7v3r8jsb6ywg8","https://x.com/dr_yakupergun/status/2111955405093872029",{"_382":2033,"_17":393,"_246":2034,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":2223,"_17":393,"_246":2224,"_386":395,"_388":-5,"_389":3049,"_390":2226},{"_382":1694,"_17":393,"_246":2032,"_386":1906,"_388":-5,"_389":-5,"_390":1907},{"_382":1149,"_17":393,"_246":1150,"_386":395,"_388":-5,"_389":3048,"_390":1152},{"_382":2028,"_17":393,"_246":2029,"_386":2030,"_388":-5,"_389":3047,"_390":2029},{"_382":2024,"_17":393,"_246":2025,"_386":2026,"_388":-5,"_389":3046,"_390":2025},[2024],[2028],[1153,1153,1153],[2227,2227,2227],"49d62ca0-d986-4026-9c3c-17f432799aac","#ESMO26 Abstracts Are Out",{"_270":3071,"_246":3072},"gene:KRAS","KRAS","根据一项由 MSK 研究人员共同牵头开展的研究，一种新型疫苗持续显现出作为胰腺癌现成疗法的潜力。\n\nMSK 的 @EileenMOReilly 在 #ESMO26 上公布了 AMPLIFY-7P 的 2 期结果。该疫苗靶向 KRAS 突变，而超过 90% 的胰腺癌都存在这种突变。\n\n99% 接受疫苗治疗的患者产生了抗癌免疫 T 细胞。免疫反应最强的患者复发率最低。\n\nO’Reilly 博士表示：“拥有一种‘现成可用’的疫苗，将让更多患者","2026-10-21T13:48:56.000Z","2026-10-24T21:19:29.000Z",[3063,3064,3065],{"_262":3060,"_264":3061,"_265":297,"_267":3062,"_269":2210},"apsmt9u4axjmbblq0cvyfhb4b","根据一项由 MSK 研究人员共同牵头开展的研究，一种新型疫苗持续显现出作为胰腺癌现成疗法的潜力。\n\nMSK 的 @EileenMOReilly 在 #ESMO26 上公布了 AMPLIFY-7P 的 2 期结果。该疫苗靶向 KRAS 突变，而超过 90% 的胰腺癌都存在这种突变。\n\n99% 接受疫苗治疗的患者产生了抗癌免疫 T 细胞。免疫反应最强的患者复发率最低。\n\nO’Reilly 博士表示：“拥有一种‘现成可用’的疫苗，将让更多患者更容易、更快速且成本更低地接受治疗。这为那些疾病复发后已无有效治疗手段的胰腺癌患者带来了希望。”了解更多：https://bit.ly/3VSsO3h","https://x.com/MSKCancerCenter/status/2113699507502281212",{"_382":3067,"_17":393,"_246":3068,"_386":395,"_388":-5,"_389":3069,"_390":3027},{"_382":2059,"_17":393,"_246":2060,"_386":395,"_388":-5,"_389":3066,"_390":2062},{"_382":1455,"_17":393,"_246":1456,"_386":395,"_388":-5,"_389":-5,"_390":607},[2063,2063,2063],"1039P","Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study",[3070,3070,3070],"NCT05067283","39cfb6e5-9810-44ad-86b0-5235b829a9e4","#ESMO26 Our trial of the #KRAS vaccine 💉presented today alongside concurrent publication in @NatureMedicine",{"_270":3083,"_246":3084},"tag:#breastcancer","#BREASTCANCER","NSABP B-42（15年数据）：#ESMO26\n\n延长来曲唑治疗可降低远处复发，但未带来显著的总生存（OS）获益。\n\n🔹 淋巴结阳性：绝对获益 4.4%\n\n🔹 淋巴结阴性：1.6%（无统计学意义）\n\n@OncoAlert #BreastCancer #bcsm","2026-10-21T09:00:31.000Z","2026-10-24T08:35:39.000Z",[],{"_262":3081,"_264":3076,"_265":297,"_267":3082,"_269":1979},"x3bevzk62e3yyop0796fw9fbq","https://x.com/Dr_Oncologista/status/2113618945060073853","a55ef582-e9d7-4c6f-a932-9125a06b6ff5","NSABP B-42 (15-year data): #ESMO26 NSABP B-42 (15-year data): #ESMO26 Extended letrozole reduces distant recurrence, but without a significa",{"_270":3098,"_246":3099},"code:APEX-BREAST01","APEX-BREAST01","APEX-Breast01：#ESMO26\n\nTQB2102 在 HER2 低表达转移性乳腺癌中带来显著的 PFS 获益，而 OS 和长期安全性仍有待成熟\n\n@OncoAlert #BreastCancer #Bcsm","2026-10-20T12:40:00.000Z","2026-10-24T09:34:00.000Z",[3095],{"_262":3093,"_264":3088,"_265":297,"_267":3094,"_269":1979},"v11l76obv4xc8of0rszf3a2p9","https://x.com/Dr_Oncologista/status/2113607208344727916",{"_382":3096,"_17":384,"_246":3097,"_386":685,"_388":-5,"_389":-5,"_390":686},"LBA27","APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study","57906bb7-3f25-41f7-bb0c-bc8c03a249dd","APEX-Breast01: #ESMO26 APEX-Breast01: #ESMO26 TQB2102 Delivers a Substantial PFS Benefit in HER2-Low Metastatic Breast Cancer, With OS and L",{"_270":3114,"_246":3115},"code:SANO","SANO","🚨SANO 5年：临床完全缓解（cCR）后采用监测还是手术\n\nOS 50% vs 54%（NS）\n\n远处转移 46% vs 29%（P<.01）\n\n提醒：仅有41.4 Gy/23 fx，这是术前剂量，可以说并非根治性剂量，尤其是约75%为腺癌时。\n\nOS无统计学意义并不能证明非劣效。\n#ESMO26 #RadOnc #OncTwitter",16,"2026-10-22T22:42:42.000Z","2026-10-24T17:14:02.000Z",[3111],{"_262":3109,"_264":3103,"_265":297,"_267":3110,"_269":1390},"ilyta7tipxm6cng879fi8mtwv","https://x.com/jryckman3/status/2113400682065891547",{"_382":3112,"_17":384,"_246":3113,"_386":2612,"_388":-5,"_389":-5,"_390":2613},"LBA78","Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: Long-term results of a cluster-randomised controlled trial (SANO)","e067b758-4d3d-49c5-b626-bb6a7f204d1c","🚨SANO 5y: surveillance vs surgery after cCR 🚨SANO 5y: surveillance vs surgery after cCR OS 50% vs 54% (NS) Distant mets 46% vs 29% (P<",{"_270":3135,"_246":3136},"drug:docetaxel","docetaxel","ABBV-969 dual-targeting ADC #ESMO26 \n MOA = PSMA/STEAP1— TOPO1 \n\n在转移性去势抵抗性前列腺癌中出现深度缓解\n这款药肯定能击败多西他赛？","2026-10-22T11:00:33.000Z","2026-10-24T20:19:45.000Z",[3127,3128,3129],{"_262":3124,"_264":3119,"_265":297,"_267":3125,"_269":3126},"wm7w1bm9epny83cslvjvj7r4x","https://x.com/tompowles1/status/2113682217134080012","tompowles1",{"_382":1317,"_17":393,"_246":1318,"_386":395,"_388":-5,"_389":3134,"_390":484},{"_382":2405,"_17":384,"_246":2406,"_386":1072,"_388":-5,"_389":-5,"_390":1073},{"_382":3130,"_17":393,"_246":3131,"_386":3132,"_388":-5,"_389":3133,"_390":3131},"NCT04884282","- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","https://clinicaltrials.gov/study/NCT04884282",[3130],[1320,1320,1320],"8129e33d-8f84-44ed-b5f7-1959e20f76bd","ABBV-969 dual-targeting ADC #ESMO26 ABBV-969 dual-targeting ADC #ESMO26 MOA = PSMA/STEAP1— TOPO1 Deep responses in metastatic castration-res",{"_270":3151,"_246":3152},"code:HORIZON-BREAST06","HORIZON-BREAST06","HORIZON-Breast06：\n\nTrastuzumab Rezetecan 治疗 HER2 低表达转移性 #BreastCancer——带来显著的 PFS 获益，但 OS 和长期安全性仍需进一步随访\n\n@OncoAlert #ESMO26 @myESMO #Bcsm",17,"2026-10-23T06:06:56.000Z","2026-10-24T08:40:00.000Z",[3148],{"_262":3146,"_264":3140,"_265":297,"_267":3147,"_269":1979},"yzwgwq4y4uxuwkw2y19vp0so6","https://x.com/Dr_Oncologista/status/2113603145678888996",{"_382":3149,"_17":384,"_246":3150,"_386":685,"_388":-5,"_389":-5,"_390":686},"LBA13","Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)","7a641e6b-afd6-47e2-b1bb-c773bf4a33aa","HORIZON-Breast06: HORIZON-Breast06: Trastuzumab Rezetecan in HER2-Low Metastatic #BreastCancer — A Major PFS Benefit, With OS and Long-Term ",{"_270":3170,"_246":3171},"code:KEYNOTE-B15","KEYNOTE-B15","来自 KEYNOTE-B15 的 ctDNA 洞察（#DrJonathanChatzkel）：在顺铂适用的 MIBC 中，对比围手术期 EV + Pembro 与 Gem/Cis。ctDNA 清除率为 82.1% vs 66.7%。\n术后 ctDNA+ 比例为 4.8% vs 13.5%。\n在各基线 ctDNA 分层中，EV/Pembro 均显示 EFS 获益；探索性分析中，ctDNA+ 的 HR 为 0.54。\n\n#ESMO26 #B","2026-10-22T12:25:02.000Z","2026-10-24T22:56:08.000Z",[3164,3165],{"_262":3161,"_264":3162,"_265":297,"_267":3163,"_269":299},"n3362ftkwg37bq2lph383j4gy","来自 KEYNOTE-B15 的 ctDNA 洞察（#DrJonathanChatzkel）：在顺铂适用的 MIBC 中，对比围手术期 EV + Pembro 与 Gem/Cis。ctDNA 清除率为 82.1% vs 66.7%。\n术后 ctDNA+ 比例为 4.8% vs 13.5%。\n在各基线 ctDNA 分层中，EV/Pembro 均显示 EFS 获益；探索性分析中，ctDNA+ 的 HR 为 0.54。\n\n#ESMO26 #BladderCancer @myESMO @OncoAlert","https://x.com/DrChoueiri/status/2113615213631058231",{"_382":1160,"_17":393,"_246":1161,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":3166,"_17":393,"_246":3167,"_386":3168,"_388":-5,"_389":3169,"_390":3167},"NCT04700124","- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","https://clinicaltrials.gov/study/NCT04700124",[3166],"366a571b-8033-4300-8f8c-abbcc746ff22","ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC",{"_270":3186,"_246":3187},"code:DASL-HICAP","DASL-HICAP","会场（LBA4）：DASL-HiCaP。极高危局限期前列腺癌，darolutamide + ADT + 放疗。中期读数。NCT04136353。数字以会上幻灯为准，背景里还没有完整终点表。",22,"2026-10-17T21:42:01.000Z","2026-10-24T23:03:14.000Z",[],{"_2747":3185,"_2749":-5},{"_262":3182,"_264":3183,"_265":297,"_267":3184,"_269":2731},"cedyqubqvllu2kg5s7foli1mo","🚨 ESMO 2026｜值得关注的十大 GU 癌症试验！\n\n从围手术期免疫治疗和 AR 通路强化，到 HIF-2α 抑制和长期生存数据更新，GU 肿瘤学将在 #ESMO26 上迎来多项重磅报告。\n\n以下是我的十大研究，按亚专科分组。👇\n\n🔵 前列腺癌\n\n1️⃣ DASL-HiCaP (LBA4)\n在极高危局限性前列腺癌中，ADT + 放疗基础上加用 darolutamide 能否改善结局？\n\n2️⃣ PROTEUS (LBA53)\n高危局限性前列腺癌的围手术期 apalutamide + ADT。PROTEUS 项目的又一重要数据。\n\n3️⃣ CAPItello-281 (LBA56)\nPTEN 缺失 mHSPC 中 capivasertib + abiraterone 的更新总生存数据。AKT 抑制能否重新定义生物标志物驱动的治疗？\n\n4️⃣ PEACE-1 (2215O)\n在新诊断的转移性去势敏感性前列腺癌中，以 abiraterone 为基础强化治疗的长期生存结局。\n\n🟢 膀胱癌／尿路上皮癌\n\n5️⃣ VOLGA (LBA2)\nESMO 2026 最重要的报告之一！\n在顺铂不适用的肌层浸润性膀胱癌中，围手术期 durvalumab ± tremelimumab 联合新辅助 enfortumab vedotin 能否改善结局？\n\n6️⃣ KEYNOTE-866 (4735O)\n在顺铂适用的 MIBC 中采用围手术期 pembrolizumab + gemcitabine/cisplatin。详细结果能否明确在传统围手术期化疗中加入免疫治疗的作用？\n\n7️⃣ ENERGIZE / CA017-078 (4736O)\n在 MIBC 中，在基于顺铂的化疗基础上加用围手术期 nivolumab 能否改善结局？\n\n🟠 肾细胞癌\n\n8️⃣ LITESPARK-011 (3587O)\n在既往接受过 PD-(L)1 治疗的晚期 RCC 中，belzutifan + lenvatinib 对比 cabozantinib。HIF-2α 抑制剂联合方案能否改善治疗结局？\n\n9️⃣ LITESPARK-012 (3586O)\n在晚期 RCC 一线治疗中，含 belzutifan 或 quavonlimab 的方案联合 pembrolizumab + lenvatinib。下一代联合方案的重要疗效和安全性数据。\n\n🔟 KEYNOTE-564 (3589RO)\n透明细胞 RCC 中辅助 pembrolizumab 的最终预设分析。随着随访时间延长，其获益能持久多久？\n\n🔬 我的其他关注研究\n\n• PE-PE：寡转移性 RCC 的围手术期免疫治疗\n• KEYNOTE-B15：MIBC 的 ctDNA 分析\n• TALAPRO-3：分子和患者报告结局\n• NIAGARA：分子亚型分析\n• SWOG S2200：乳头状 RCC\n\n🔥 ESMO 2026 的三大关键问题\n\n🔹 围手术期治疗策略能否重新定义 MIBC 的管理？\n🔹 治疗强化和生物标志物筛选能否改善前列腺癌结局？\n🔹 HIF-2α 联合方案能否重塑晚期 RCC 的治疗序贯策略？\n\n📌 会前关注清单。并非所有试验都预计会报告阳性结果。\n\n哪项 GU 试验最有可能改变您的临床实践？👇\n\n@myesmo @ESMO_open @ASCO @oncoalert\n#ESMO26 #GUOncology #ClinicalTrials #Oncology","https://x.com/DrRishabhOnco/status/2112521101825986695",[3175],"eaab3b14-d205-4901-a120-6f2390f26e44","🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH",{"_270":3204,"_246":3205},"code:PANKU-BREAST01","PANKU-BREAST01","会场（LBA50，乳腺癌 Proffered paper 1，10/23 14:35）：PANKU-Breast01。既往治疗过的不可切除局部晚期/转移 HR+/HER2− 乳腺癌，iza-bren（EGFR/HER3 双抗 ADC）对比医生选择化疗。mPFS 8.18 vs 4.01 个月，HR 0.41（0.33–0.53；P<0.0001）；ORR 40.5% vs 20.2%；mDoR 6.93 vs 4.21 个月；ILD 1.1%（均为 1–2 级）；OS 不成熟。","2026-10-20T10:12:54.000Z","2026-10-24T16:00:11.000Z",[3201],{"_2747":3200,"_2749":-5},{"_262":3197,"_264":3198,"_265":297,"_267":3199,"_269":999},"nx9y5onuy5q7g57femtq54b9z","🚨 #ESMO26 乳腺癌：由 @OncoAlert 评选的十大重点🎗️ 我们的专家团从马德里🇪🇸筛选并标记为必读的摘要 👇 1️⃣ PANKU-Breast01 (LBA50)：iza-bren 用于 HR+/HER2− mBC 2️⃣ FOURLIGHT-1 (1842O)：CDK4/6i 治疗后使用 atirmociclib + fulvestrant 3️⃣ NATALEE (LBA25)：辅助使用 ribociclib 的 6 年 OS 4️⃣ APEX-Breast01 (LBA27)：TQB2102 用于 HER2-low 5️⃣ KEYNOTE-B49 (LBA51)：pembro + 化疗用于 HR+/HER2− 6️⃣ HORIZON-Breast06 (LBA13)：SHR-A1811 用于 HER2-low 7️⃣ POP-DURVA (LBA26)：术前使用 durvalumab 治疗 I 期 TNBC 8️⃣ SWITCH (4RO)：既往接受 ADC 治疗后进行 ADC 靶点切换 9️⃣ postMONARCH (1RO)：abemaciclib + fulvestrant 的 OS 🔟 DESTINY-Breast09 (LBA49)：基线存在脑转移时使用 T-DXD + P #BreastCancer @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @double_whammied @maryam_lustberg @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @SirohiBhawna @jamecancerdoc @nataliagandur @acampsmalea @FernandoOnco @realbowtiedoc @Lucarecco @AmandaNizamMD @scocmem @MarioBalsaMD @Dr_Oncologista","https://x.com/OncoAlert/status/2112487214869295477",[3191],{"_382":3202,"_17":384,"_246":3203,"_386":685,"_388":-5,"_389":-5,"_390":686},"LBA50","PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)","40bceb8e-4726-4a32-8fdf-4c5af8f6cb96","🚨 #ESMO26 Breast Cancer: Top Ten by @OncoAlert 🎗️ The abstracts our faculty flagged as must-know from MADRID🇪🇸 👇 1️⃣ PANKU-Breast01 (LB",{"_270":3218,"_246":3219},"code:POSTMONARCH","POSTMONARCH","OncoAlert 4Sight 摘要将于 #ESMO26 展示\n1RO：postMONARCH 最终总生存期分析：既往 CDK4/6 抑制剂治疗后进展的 HR+、HER2– 晚期乳腺癌患者中，abemaciclib 联合 fulvestrant\n\n @KalinskyKevin\n @BianchiniGP\n @ErikaHamilton9\n @DrSGraff\n @drsarahsam\n @MuozMateu \n\n 🔬 3 期双盲试","2026-10-21T11:00:32.000Z","2026-10-24T21:39:36.000Z",[3217],{"_262":3214,"_264":3215,"_265":297,"_267":3216,"_269":999},"cdpg9l08rfng9kntkvsoiokph","OncoAlert 4Sight 摘要将于 #ESMO26 展示\n1RO：postMONARCH 最终总生存期分析：既往 CDK4/6 抑制剂治疗后进展的 HR+、HER2– 晚期乳腺癌患者中，abemaciclib 联合 fulvestrant\n\n @KalinskyKevin\n @BianchiniGP\n @ErikaHamilton9\n @DrSGraff\n @drsarahsam\n @MuozMateu \n\n 🔬 3 期双盲试验（n=368）：在既往 CDK4/6i + ET 治疗后进展的 HR+、HER2– ABC 患者中，采用 abemaciclib 或安慰剂联合 fulvestrant。最终 OS 分析。\n ➡️ 中位 OS 为 32.1 vs 24.6 个月；HR 0.80（0.60–1.06）；p=0.1145，尚未达到统计学显著性\n ➡️ 更新后的 PFS：HR 0.78（0.62–0.99）；名义 p=0.0390\n ➡️ 安全性与已确立的 abemaciclib 特征一致；未发现新信号\n ✅ 中位 OS 数值上更长，但未达到统计学显著性。尽管 PFS 绝对获益较小，但总体证据支持考虑在既往 CDK4/6i + ET 治疗后疾病进展时采用以 abemaciclib 为基础的治疗。#BreastCancer\n\n 🎙️ Kevin Kalinsky\n 👥 Giampaolo Bianchini · Erika Hamilton · Stephanie Graff · Kyong Hwa Park · Rinath Jeselsohn · Umut Demirci · Miguel Martin · Rachel Layman · Sara Hurvitz · Sarah Sammons · Peter Kaufman · Montserrat Muñoz · Jiun-I Lai · Holly Knoderer · Cynthia Sandoval · Aarti Chawla · Bastien Nguyen · Yanhong Zhou · Elizabeth Ravenberg · Lacey Litchfield · Lillian Smyth · Seth Wander \n\n（4Sight 根据 ESMO 网站公开的摘要制作） \n\n提醒 OncoAlert 乳腺癌专家组成员\n@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc \n@Lucarecco @Dr_Oncologista","https://x.com/OncoAlert/status/2112861589820891194",{"_382":1734,"_17":393,"_246":1735,"_386":1216,"_388":-5,"_389":-5,"_390":1217},"0fbd2577-0c77-4437-9ef1-b24ca091945f","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 1RO: Final Overall Survival Anal",{"_270":3243,"_246":3244},"drug:trastuzumab","trastuzumab","🧵 在 #ESMO26 上展示：\n\n在低 erythroblastic oncogene B 2 (ERBB2) 晚期 #BreastCancer 患者中，trastuzumab rezetecan 相比医生选择的化疗改善了无进展生存期。获益在化疗初治患者和总体人群中均有观察到，支持 trastuzumab rezetecan 作为该设置下的潜在治疗选择。\n\nhttps://ja.ma/3Ub9qxU\n\n@myESMO",27,"2026-10-24T07:12:02.000Z",[3231,3232,3233,3234,3235,3236,3237,3238],{"_262":3228,"_264":3223,"_265":297,"_267":3229,"_269":3230},"ruzdtlwzx9wx3r916a2fsk0ed","https://x.com/JAMA_current/status/2113631529142235384","JAMA_current",{"_382":1214,"_17":393,"_246":1215,"_386":1216,"_388":-5,"_389":-5,"_390":1217},{"_382":1211,"_17":393,"_246":1212,"_386":395,"_388":-5,"_389":-5,"_390":1213},{"_382":3241,"_17":393,"_246":3242,"_386":395,"_388":-5,"_389":-5,"_390":1213},{"_382":2427,"_17":393,"_246":2428,"_386":395,"_388":-5,"_389":-5,"_390":2429},{"_382":2901,"_17":393,"_246":2902,"_386":1156,"_388":-5,"_389":-5,"_390":1157},{"_382":1209,"_17":393,"_246":1210,"_386":1156,"_388":-5,"_389":-5,"_390":1157},{"_382":3149,"_17":384,"_246":3150,"_386":685,"_388":-5,"_389":-5,"_390":686},{"_382":3239,"_17":384,"_246":3240,"_386":1216,"_388":-5,"_389":-5,"_390":1217},"LBA17","HER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trial","1795TIP","A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide","a68accf4-c263-4977-9157-59cf9e4dfa7a","China keeps delivering new assets and studies, now in HER2+ gastric 🇨🇳 China keeps delivering new assets and studies, now in HER2+ gastric",{"_270":3261,"_246":3262},"code:FOURLIGHT-1","FOURLIGHT-1","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\n Atirmociclib + Fulvestrant 在既往 CDK4/6 抑制剂治疗后进展的 HR+/HER2– 晚期/转移性乳腺癌患者中的疗效和安全性：一项随机 II 期研究（FOURLIGHT-1）\n @antgiorda \n\n 🔬 随机 II 期（n=263）：atirmociclib + fulvestrant vs 研究者选择（fulvestrant 或","2026-10-21T14:01:40.000Z","2026-10-24T22:51:48.000Z",[3256,3257],{"_262":3253,"_264":3254,"_265":297,"_267":3255,"_269":999},"wjms5nz0nsmlpl6l7ajh6vxcu","OncoAlert 4Sight 摘要将在 #ESMO26 上展示\n Atirmociclib + Fulvestrant 在既往 CDK4/6 抑制剂治疗后进展的 HR+/HER2– 晚期/转移性乳腺癌患者中的疗效和安全性：一项随机 II 期研究（FOURLIGHT-1）\n @antgiorda \n\n 🔬 随机 II 期（n=263）：atirmociclib + fulvestrant vs 研究者选择（fulvestrant 或 everolimus + exemestane），用于既往 CDK4/6i 治疗后进展的 HR+/HER2– mBC。主要终点：研究者评估的 PFS。\n ➡️ 中位 PFS 9.4 vs 6.6 个月；HR 0.60（0.440–0.825）；单侧 p=0.0007\n ➡️ 可测量疾病患者中的 ORR：19.3% vs 11.3%；CBR：61.9% vs 46.0%\n ➡️ 因 TRAEs 导致 atirmociclib 停药：4.0%；最常见的 TRAE 为中性粒细胞减少（46.4%）\n ✅ 首个在既往 CDK4/6i 治疗后显示具有统计学显著性及临床意义的 PFS 改善的下一代 CDKi，且安全性可控。#BreastCancer\n 🎙️ Antonio Giordano \n\n（4Sight 由 ESMO 网站公开提供的摘要制作而成）\n\n@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc \n@Lucarecco @Dr_Oncologista @guiandri76","https://x.com/OncoAlert/status/2112907173822972062",{"_382":2296,"_17":393,"_246":2297,"_386":1072,"_388":-5,"_389":-5,"_390":1073},{"_382":3258,"_17":393,"_246":3247,"_386":3259,"_388":-5,"_389":3260,"_390":3247},"NCT06105632","https://clinicaltrials.gov/study/NCT06105632",[3258],"9f61581b-d428-44c0-bbd1-f78a22ccba7b","OncoAlert 4Sight Abstracts to be Presented at #ESMO26 OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Efficacy and Safety of Atirmocic",{"_270":3277,"_246":3278},"code:KEYNOTE-866","KEYNOTE-866","KEYNOTE-866 未显示 EFS，也未显示 OS。Jens Bedke 教授的精彩演讲 👏🏼 #ESMO26 @OncoAlert @Uromigos @urotoday @Uroweb @DGUrologie @high5md","2026-10-21T15:01:30.000Z","2026-10-24T19:11:53.000Z",[3274],{"_262":3271,"_264":3266,"_265":297,"_267":3272,"_269":3273},"n5gnol8m1igwfd8oik82erqln","https://x.com/amerseburger/status/2113598642334691643","amerseburger",{"_382":3275,"_17":393,"_246":3276,"_386":1162,"_388":-5,"_389":-5,"_390":1163},"4735O","Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study","479512a1-1eab-4c58-bbe8-57e74617006f","KEYNOTE-866 did not show EFS not OS",{"_270":3293,"_246":3294},"drug:daraxonrasib","daraxonrasib","Tango 报告在 #ESMO26 上针对晚期 #PancreaticCancer 的联合疗法（Daraxonrasib 加 vopimetostat）试验中肿瘤缓解率达 82%\nhttps://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/\n降低毒性数据尤",31,34,"2026-10-24T11:38:59.000Z",[3292],{"_262":3288,"_264":3289,"_265":297,"_267":3290,"_269":3291},"mdw1gkd38xyfvcs4may7gq6x6","Tango 报告在 #ESMO26 上针对晚期 #PancreaticCancer 的联合疗法（Daraxonrasib 加 vopimetostat）试验中肿瘤缓解率达 82%\nhttps://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/\n降低毒性数据尤为重要，因为可以使用更低剂量的 Daraxonrasib。","https://x.com/Aiims1742/status/2113594963795836982","Aiims1742",{"_382":1281,"_17":384,"_246":2614,"_386":2612,"_388":-5,"_389":-5,"_390":2613},"8a4a3564-0004-4148-bb6f-c97626ab30b0","Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 T",{"_270":3316,"_246":3317},"drug:nivolumab","nivolumab","临近 #ESMO26，热点成果层出不穷。\n\n不甘示弱于 AZUR-1、CheckMate 8HW 或其他令人惊叹的 IO 突破，Chalabi 发布了 NICHE-2 的长期随访结果。\n\n一言以蔽之？完美。\n\n111 例局部晚期 dMMR 结肠癌患者。仅接受 6 周新辅助纳武利尤单抗/伊匹单抗治疗后行手术。\n\n零复发。5 年总生存率 100%。\n\n请记住，这些并非全是低风险肿瘤。许多属于高风险 III 期疾病。\n\n我们仅用几周免疫治疗就",37,"2026-10-13T17:40:14.000Z","2026-10-24T17:21:49.000Z",[3308,3309,3310,3311,3312],{"_262":3304,"_264":3305,"_265":297,"_267":3306,"_269":3307},"zbv2671mqbvn3uj5tn11krzzs","临近 #ESMO26，热点成果层出不穷。\n\n不甘示弱于 AZUR-1、CheckMate 8HW 或其他令人惊叹的 IO 突破，Chalabi 发布了 NICHE-2 的长期随访结果。\n\n一言以蔽之？完美。\n\n111 例局部晚期 dMMR 结肠癌患者。仅接受 6 周新辅助纳武利尤单抗/伊匹单抗治疗后行手术。\n\n零复发。5 年总生存率 100%。\n\n请记住，这些并非全是低风险肿瘤。许多属于高风险 III 期疾病。\n\n我们仅用几周免疫治疗就治愈了患者。\n\n现在，能否完全避免手术？\n\n治疗胃肠癌的时代真好。\n\n@TheGutOncLab @OncoAlert @Onco_Nexus \n\nhttps://www.sciencedirect.com/science/article/pii/S0140673626016028","https://x.com/GIMedOnc/status/2113153087284097401","GIMedOnc",{"_382":2228,"_17":393,"_246":2229,"_386":395,"_388":-5,"_389":3315,"_390":2226},{"_382":2642,"_17":393,"_246":3314,"_386":1162,"_388":-5,"_389":-5,"_390":1163},{"_382":1837,"_17":393,"_246":1838,"_386":971,"_388":-5,"_389":-5,"_390":972},{"_382":2221,"_17":384,"_246":2222,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":3130,"_17":393,"_246":3131,"_386":3132,"_388":-5,"_389":3313,"_390":3131},[3130],"Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)",[2227,2227,2227],"ec738536-313b-47bb-9f6d-230df6c62dfa","So many hot drops leading up to #ESMO26",{"_270":3333,"_246":3334},"code:TALENT","TALENT","#ESMO26 | TALENT \n\n新辅助 T-DXd 在 HR+/HER2-low 早期乳腺癌中显示出非常低的 pCR 率：\n\n- T-DXd：7%\n- T-DXd + anastrozole：3%\n- T-DXd → 化疗：9%\n\n我们应当记住，pCR 是 HR+ 疾病中有限的替代终点。然而，这些结果并不支持将 T-DXd 作为标准新辅助化疗的替代方案。\n\n此外，鉴于 HER2-low 疾病的异质性，T-DXd 在转移性治疗中的成",33,36,"2026-10-24T15:45:29.000Z",[3330],{"_262":3327,"_264":3328,"_265":297,"_267":3329,"_269":2858},"l8cmilenf6mhdm9kqkn9m855b","#ESMO26 | TALENT \n\n新辅助 T-DXd 在 HR+/HER2-low 早期乳腺癌中显示出非常低的 pCR 率：\n\n- T-DXd：7%\n- T-DXd + anastrozole：3%\n- T-DXd → 化疗：9%\n\n我们应当记住，pCR 是 HR+ 疾病中有限的替代终点。然而，这些结果并不支持将 T-DXd 作为标准新辅助化疗的替代方案。\n\n此外，鉴于 HER2-low 疾病的异质性，T-DXd 在转移性治疗中的成功未能在早期疾病中转化为相似的结果，这并不令人意外，尽管早期疾病的肿瘤负荷更低。","https://x.com/dr_yakupergun/status/2113491790409990418",{"_382":3331,"_17":384,"_246":3332,"_386":685,"_388":-5,"_389":-5,"_390":686},"LBA23","Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer","3be53e72-4395-46d6-b9c7-4834f5d6f67f","#ESMO26 | TALENT #ESMO26 | TALENT Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer: - T-DXd: 7% - T-DXd + ana",{"_270":3353,"_246":3354},"code:NATALEE","NATALEE","NATALEE 是手术之后的辅助治疗：激素受体阳性、HER2 阴性的早期乳腺癌，在内分泌治疗上加 CDK4/6 抑制剂 ribociclib（挡住细胞分裂 G1→S 的关卡），对比单用内分泌。入组比 monarchE 更宽，含一部分淋巴结阴性。本届 LBA25 报的是六年总生存，不是那篇 NEJM 的无侵袭性疾病生存。",42,51,"2026-10-18T19:20:11.000Z","2026-10-24T16:15:46.000Z",[3352],{"_2747":3349,"_2749":-5},{"_262":3346,"_264":3347,"_265":297,"_267":3348,"_269":2858},"omgibiwl7fcyzhlc06gaz9req","今天，在 #ESMO26 上将展示 NATALEE 的 6 年结果。在此次报告之前，我个人对辅助 CDK4/6 抑制剂带来的生存获益的看法……\n\nNATALEE 中的 6 年 OS 率为 91.86% vs 89.73%：绝对获益为 2.1 个百分点（HR 0.809；95% CI 0.661–0.989；名义单侧 p=0.019）。\n\nmonarchE 中 7 年 OS 的绝对获益为 1.8 个百分点（HR 0.842；p=0.027）。我认为，不应将这些获益轻视为“仅 2%”。\n\n在 EBCTCG 分析中，在以蒽环类药物为基础的化疗中加入紫杉烷类药物——这是多年来我们一直认可的标准治疗——带来的 5 年 OS 绝对获益约为 1.9 个百分点。研究人群和随访时间存在差异，因此无法直接比较治疗疗效。然而，我们用来判断几个百分点生存获益的标准应当保持一致。\n\n此外，monarchE 中 95.4% 的患者此前已经接受过化疗。这一生存获益是在化疗和内分泌治疗基础上带来的额外获益。\n\n患者筛选、毒性、治疗时长和成本当然值得讨论。然而，对于经过适当筛选的患者，辅助 CDK4/6 抑制剂的生存获益不应被低估。","https://x.com/dr_yakupergun/status/2113551328672616726",[3338,3350,3351],"现场帖给出的六年总生存：91.86% vs 89.73%，绝对差 2.1 个百分点（风险比 0.809；95% 置信区间 0.661–0.989；名义单侧 P=0.019）。完整幻灯和分层以会上为准。","期刊骨架（当时总生存不成熟）：NEJM 2024（PMID 38507751）；Annals of Oncology 终分析无侵袭性疾病生存风险比 0.749，3 年率 90.7% vs 87.6%（PMID 39442617）。会上总生存与期刊无侵袭性疾病生存分开读，不把 2024 年的无病生存写成这次的六年总生存。",{"_382":1584,"_17":384,"_246":1585,"_386":685,"_388":-5,"_389":-5,"_390":686},"39a7bb41-f12c-442c-9945-2d6ae302ba7a","Today at #ESMO26, the 6-year results of NATALEE will be presented",{"_270":3378,"_246":3379},"gene:HER2","HER2","视角：新型 HER2 ADC 不断提高 HER2 低表达乳腺癌的治疗标准。 @FraSchettMDPhD #ESMO26",69,"2026-10-18T23:04:52.000Z","2026-10-24T22:52:59.000Z",[3366,3367,3368,3369,3370,3371,3372,3373],{"_262":3364,"_264":3358,"_265":297,"_267":3365,"_269":641},"qbdjx868blq4nt3a4dfq9h2ec","https://x.com/PTarantinoMD/status/2113604009848144365",{"_382":3374,"_17":393,"_246":3375,"_386":395,"_388":-5,"_389":3376,"_390":3027},{"_382":1214,"_17":393,"_246":1215,"_386":1216,"_388":-5,"_389":-5,"_390":1217},{"_382":1211,"_17":393,"_246":1212,"_386":395,"_388":-5,"_389":-5,"_390":1213},{"_382":3241,"_17":393,"_246":3242,"_386":395,"_388":-5,"_389":-5,"_390":1213},{"_382":2296,"_17":393,"_246":2297,"_386":1072,"_388":-5,"_389":-5,"_390":1073},{"_382":1258,"_17":393,"_246":1259,"_386":395,"_388":-5,"_389":-5,"_390":1260},{"_382":1734,"_17":393,"_246":1735,"_386":1216,"_388":-5,"_389":-5,"_390":1217},{"_382":1350,"_17":393,"_246":1351,"_386":387,"_388":-5,"_389":-5,"_390":391},"1067P","Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors",[3377,3377,3377],"NCT06806982","04533835-3dda-47d8-8c2c-6158a5db3e07","POV: novel HER2 ADCs keep raising the bar in HER2-low breast cancer",{"_270":3403,"_246":3404},"drug:pembrolizumab","pembrolizumab","#ESMO26 | PERSEE——III期\n\n在晚期 NSCLC 且 PD-L1 ≥50% 的患者中，在 pembrolizumab 基础上加用化疗，将中位 PFS 从 6.9 个月延长至 16.1 个月（HR 0.56）。OS 的数值差异引人注目（50.2 vs 29.9 个月；HR 0.77），但未达到统计学显著性。不过，我们应记住，OS 并非主要终点！\n\n≥3 级毒性：53.8% vs 19.3%。\n\n我认为，加用化疗能够带来获",48,52,"2026-10-08T12:00:00.000Z","2026-10-24T18:01:33.000Z",[3393,3394,3395,3396,3397,3398,3399,3400],{"_262":3390,"_264":3391,"_265":297,"_267":3392,"_269":2858},"gy0ecvm5o94appijh43b5bspz","#ESMO26 | PERSEE——III期\n\n在晚期 NSCLC 且 PD-L1 ≥50% 的患者中，在 pembrolizumab 基础上加用化疗，将中位 PFS 从 6.9 个月延长至 16.1 个月（HR 0.56）。OS 的数值差异引人注目（50.2 vs 29.9 个月；HR 0.77），但未达到统计学显著性。不过，我们应记住，OS 并非主要终点！\n\n≥3 级毒性：53.8% vs 19.3%。\n\n我认为，加用化疗能够带来获益，但代价是毒性增加。我们需要更好地识别哪些患者值得承受这种毒性。","https://x.com/dr_yakupergun/status/2112439291502559300",{"_382":1275,"_17":393,"_246":1276,"_386":1256,"_388":-5,"_389":-5,"_390":1257},{"_382":1269,"_17":393,"_246":1270,"_386":395,"_388":-5,"_389":3402,"_390":628},{"_382":2033,"_17":393,"_246":2034,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":2233,"_17":393,"_246":2234,"_386":2035,"_388":-5,"_389":-5,"_390":2036},{"_382":2815,"_17":393,"_246":2816,"_386":1173,"_388":-5,"_389":3401,"_390":1175},{"_382":1455,"_17":393,"_246":1456,"_386":395,"_388":-5,"_389":-5,"_390":607},{"_382":2938,"_17":393,"_246":2939,"_386":2612,"_388":-5,"_389":-5,"_390":2613},{"_382":392,"_17":393,"_246":394,"_386":395,"_388":-5,"_389":-5,"_390":396},[1176],[1272,1272,1272],"43b94cf9-789c-4bf4-9b19-8a3b0930bc53","Final Phase 2, lifileucel + pembrolizumab, data explore earlier use of #TILtherapy in frontline melanoma at #ESMO26",{"_270":3424,"_246":3425},"code:VOLGA","VOLGA","会场预告（LBA2，Presidential I，10/24）：VOLGA，肌层浸润性膀胱癌，围手术期 durvalumab + tremelimumab + 新辅助 enfortumab vedotin。中期 EFS/OS 阳性；FDA 优先审评。NCT04960709。正式幻灯数字以会上披露为准。",73,"2026-10-15T00:02:52.000Z","2026-10-25T00:08:03.000Z",[3419,3420],{"_2747":3418,"_2749":-5},{"_262":3415,"_264":3416,"_265":297,"_267":3417,"_269":999},"un6lx8e3yjoealrnspczy15l5","🚨 #ESMO26 GU肿瘤学——OncoAlert 重点精选 🎯 #BladderCancer：VOLGA、KEYNOTE-B15、ENERGIZE、KEYNOTE-866 #ProstateCancer：DASL-HiCaP、CAPItello-281、PROTEUS #KidneyCancer：LITESPARK-011 & -012、ivonescimab、PE-PE、SWOG S2200、XmAb819 我们的参会专家 @DrChoueiri、@tompowles1、@apolo_andrea、@neerajaiims、@montypal、@Silke_Gillessen、@AOmlin、@brian_rini、@PGrivasMDPhD、@TiansterZhang、@amerseburger、@DrDanielHeng、@HHammersMD、@scocmem、@AndreaNecchi、@AmandaNizamMD、@drenriquegrande、@nataliagandur、@AlbigesL、@cdanicas、@declangmurphy、@seanmmcbride、@shilpaonc、@DrRanaMcKay、@scserendipity1、@DrYukselUrun、@ravikanesvaran、@BraunMDPhD、@EfstathiouEleni、@mzugman、@crisbergerot、@ElisaAgostinett、@to_be_elizabeth、@MarioBalsaMD、@BRicciutiMD、@HHorinouchi、@UOzkerim、@p_ciracimd、@DrMirallas、@sonpavde、@Dr_Oncologista","https://x.com/OncoAlert/status/2112114051333439580",[3408],{"_382":1624,"_17":384,"_246":1625,"_386":516,"_388":-5,"_389":-5,"_390":517},{"_382":3421,"_17":393,"_246":3407,"_386":3422,"_388":-5,"_389":3423,"_390":3407},"NCT04960709","https://clinicaltrials.gov/study/NCT04960709",[3421],"a9576461-5a68-47a9-aa0b-3abe00e5fba7","🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯 #BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 #ProstateCancer: DASL-HiCaP, C",{"_270":3446,"_246":3447},"code:INTERPATH-001","INTERPATH-001","会场/解除 embargo（LBA1，Presidential I，10/24）：INTerpath-001，切除后 IIB–IV 期黑色素瘤，n=1137。intismeran autogene + pembrolizumab 对比 pembrolizumab。RFS HR 0.58；2 年 RFS 82.2% vs 70.0%。DMFS 同步达到；OS 随访未成熟。无新的安全性信号。NCT05933577。",54,72,"2026-10-15T09:26:07.000Z","2026-10-24T21:03:47.000Z",[3443,3444],{"_2747":3441,"_2749":-5},{"_262":3437,"_264":3438,"_265":297,"_267":3439,"_269":3440},"pgim7zf5vle5v6ouzsvt7mx58","#ESMO26 因信息泄露而解除发布禁令。\n\n详细数据证实，Moderna $MRNA 与 Merck $MRK 的癌症疫苗在黑色素瘤试验中达到关键终点\n\n与标准治疗相比，个体化 mRNA 疗法将疾病复发率降低了 42%\n\n https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/","https://x.com/adamfeuerstein/status/2113346013167489222","adamfeuerstein",[3429,3442],"期刊骨架（不是这次会上的数字）：前身 KEYNOTE-942，Lancet 2024，PMID 38246194。会上数字与期刊数字分开读。",{"_382":514,"_17":384,"_246":515,"_386":516,"_388":-5,"_389":-5,"_390":517},{"_382":767,"_17":393,"_246":777,"_386":778,"_388":-5,"_389":3445,"_390":777},[767],"4b0f0283-5d60-4c1b-ab0c-fc4e142afcce","#ESMO26 embargo lifted following breach",{"_270":3465,"_246":3466},"code:DELLPHI-305","DELLPHI-305","会场预告（LBA3，Presidential）：DeLLphi-305，广泛期 SCLC 一线维持，tarlatamab + durvalumab 对比 durvalumab。预告写中期 OS 阳性。走廊里的 KM 投影不是官方读数，等会上数字。",65,88,"2026-10-15T21:07:08.000Z","2026-10-24T23:36:13.000Z",[3464],{"_2747":3462,"_2749":-5},{"_262":3459,"_264":3460,"_265":297,"_267":3461,"_269":2731},"oc4xhm97bknoxf14djn70osjm","ESMO 2026｜值得关注的十大肺癌试验！\n\n从 DLL3 双特异性抗体到下一代 KRAS 抑制剂，再到新型 ADC，重磅肺癌数据即将在 #ESMO26 公布。\n\n🔥 我关注的十大试验\n\n1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC\n2.SAFFRON | Osimertinib + savolitinib | MET 改变的 EGFR+ NSCLC\n3.Krascendo 1 | Divarasib 对比已获批的 KRAS G12C 抑制剂\n4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC\n5.OptiTROP-Lung04 | EGFR-TKI 进展后的 TROP2 ADC\n6.SigVie-002 | 整合素 αvβ6 ADC 对比 docetaxel\n7.SARON | 寡转移性 NSCLC 的巩固治疗 RT\n8.PERSEE | Pembrolizumab ± 化疗 | PD-L1 ≥50%\n9.DeLLphi-304 | 使用 tarlatamab 的长期生存\n10.ASTRIDE | Serplulimab 对比 atezolizumab + 化疗 | ES-SCLC\n\n三场主席报告尤其值得关注：DeLLphi-305、SAFFRON 和 Krascendo 1。\n\n哪项试验可能对肺癌治疗产生最大影响？\n@myesmo @ESMO_open @ASCO @oncoalert\n\n#ESMO26 #LungCancer #Oncology","https://x.com/DrRishabhOnco/status/2112902318580752451",[3451,3463],"期刊/已完成骨架：DeLLphi-301、DeLLphi-304 是已经公开的 DLL3 双抗读数，用来对照，不替代 305。",{"_382":2531,"_17":384,"_246":2532,"_386":516,"_388":-5,"_389":-5,"_390":517},"dd4a3a39-59af-42c1-a3ba-78db92a07714","ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH",{"_270":3469,"_246":3468},"#HEALTHCARE","",0,[],"2026-10-23","2026-10-24","2026-10-25","2026-10-26","2026-10-27",{"_3481":3493,"_3483":3494,"_3485":3495},{"_3481":3490,"_3483":3491,"_3485":3492},{"_3481":3487,"_3483":3488,"_3485":3489},{"_3481":3482,"_3483":3484,"_3485":3486},"key","day3","label","Day 3 · 10/25","count",177,"day2","Day 2 · 10/24",1263,"day1","Day 1 · 10/23",1051,"prelude","会前",349,"slug","esmo-2026","name","startsOn","endsOn","venue","Madrid","blurb","马德里现场。一条会场帖是一条资讯；同一试验、同一药的多人讨论聚成热度探针。会中按天铺现场，会前讨论进会前榜。不转摘要正文，不贴别人的幻灯片。","itemCount",2840,"changelogVersion","2026-10-24T20:30","enEditionEnabled"]